A Behavioral and Molecular Approach for Understanding Angelman Syndrome by Mandel-Brehm, Caleigh
A Behavioral and Molecular Approach
for Understanding Angelman Syndrome
The Harvard community has made this
article openly available.  Please share  how
this access benefits you. Your story matters
Citation Mandel-Brehm, Caleigh. 2016. A Behavioral and Molecular
Approach for Understanding Angelman Syndrome. Doctoral
dissertation, Harvard University, Graduate School of Arts &
Sciences.
Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:26718736
Terms of Use This article was downloaded from Harvard University’s DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at http://
nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAA
!"#$%&'()*&+"&,-".)+$/0+&*"!11*)&/%"2)*"3,-$*45&,-(,6"!,6$+7&,"89,-*)7$!
!
"!#$%%&'()($*+!,'&%&+(&#!
-.!
/)0&$12!3)+#&045'&26!
(*!
72&!8$9$%$*+!*:!3&#$;)0!<;$&+;&%!
!
$+!,)'($)0!:=0:$006&+(!*:!(2&!'&>=$'&6&+(%!
:*'!(2&!#&1'&&!*:!
8*;(*'!*:!?2$0*%*,2.!
$+!(2&!%=-@&;(!*:!
A&='*%;$&+;&!
!
B)'9)'#!C+$9&'%$(.!
/)6-'$#1&D!3)%%);2=%&((%!
!
E;(*-&'D!FGHI!
!
J!FGHI!K!/)0&$12!3)+#&045'&26!
"00!'$12(%!'&%&'9&#L!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!!!"
"
8$%%&'()($*+!"#9$%*'M!3$;2)&0!NL!O'&&+-&'1!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!/)0&$12!3)+#&045'&26!! ! !!!!!!!!!!!!!!!
!"#$%&'()*&+"&,-".)+$/0+&*"!11*)&/%"2)*"3,-$*45&,-(,6"!,6$+7&,"89,-*)7$!
"
!:45*&/5"
"=($%6!<,&;('=6!8$%*'#&'!P"<8Q!$%!)!%&(!*:!2=6)+!#&9&0*,6&+()0!#$%*'#&'%!(2)(!)::&;(%!RH!$+!ST!;2$0#'&+L!!72&!;0$+$;)0!:&)(='&%!*:!"<8!$+;0=#&!#&:$;$(%!$+!%*;$)0!-&2)9$*'!)+#!:'&>=&+(!;*46*'-$#$(.!*:!6*(*'D!&6*($*+)0!)+#!%&+%*'.!$6,)$'6&+(L!/=''&+(0.D!(2&'&!)'&!+*!&::&;($9&!('&)(6&+(%!:*'!"<8L!!"!6)@*'!*-%();0&!:*'!('&)($+1!"<8!$%!(2&!0$6$(&#!U+*V0&#1&!*:!(2&!+&='*+)0!;$';=$(%!(2)(!#'$9&!(2&%&!;*6,0&W!-&2)9$*'%L!

A&='*+)0!%=-%(')(&%!*:!C5NY"!2)9&!-&&+!$#&+($:$&#!)+#!(2&$'!&W,'&%%$*+!2)%!-&&+!%2*V+!(*!-&!=,4'&1=0)(&#!$+!"<!+&='*+%L!!Z!+*V!(&%(!(2&!2.,*(2&%$%!(2)(!(2$%!#&'&1=0)($*+!;*+('$-=(&%!(*!%,&;$:$;!,)(2*0*1.!*:!"<L!![$'%(D!Z!#&%;'$-&#!;0$+$;)00.!'&0&9)+(!-&2)9$*')0!,2&+*(.,&%!$+!)+!"<!6*=%&!6*#&0L!!A&W(D!Z!1&+&($;)00.!'&#=;&#!(2&!&W,'&%%$*+!0&9&0!*:!(V*!C5NY"!%=-%(')(&%D!"\/!P";($9$(.4\&1=0)(&#!/.(*%U&0&(*+4"%%*;$)(&#!?'*(&$+Q!)+#!
!#"
"
N?BN]ZAI&P\2*!O=)+$+&!A=;0&*($#&!NW;2)+1&![);(*'!HIQ!$+!(2&!"<!6*=%&!)+#!)%%).&#!:*'!'&9&'%)0!*:!-&2)9$*')0!)-+*'6)0$($&%L!

"
"
"
"
"
"
"
"
#"
"
;&:+$")2"<),5$,54"
"-%(');(LLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLL$$$!^$%(!*:![$1='&%LLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLL9$!";U+*V0&#16&+(%LLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLL9$$!"(('$-=($*+%LLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLL9$$$!
=""">,5*)-0/5(),""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""" """""""""""HLH!!!"+1&06)+!<.+#'*6&M!/0$+$;)0!?2&+*(.,&LLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLS!HLF!!!"+1&06)+!<.+#'*6&M!O&+*(.,&4?2&+*(.,&!/*''&0)($*+__LLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLHF!HLY!!!C5NY"!<('=;(='&!)+#![=+;($*+!____LLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLH`!HLa!!!72&!C5NY"!<=-%(')(&!B.,*(2&%$%__LLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLFI!HLI!!!^$6$()($*+%!*:!)!6*=%&!6*#&0!*:!"+1&06)+!<.+#'*6&LLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLYH!\&:&'&+;&%______________________________LLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLYI!
?"""8$(@0*$A+(B$"&/5('(59"(,"&"C0'$,(+$"!,6$+7&,"89,-*)7$"7)04$"7)-$+"(4""
"""""&55$,50&5$-":9"*$-0/(,6"!*/"$D1*$44(),""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""E="!FLH!!!!"-%(');(LLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLaa!FLF!!!!5);U1'*=+#!)+#!<$1+$:$;)+;&LLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLaI!FLY!!!!3)(&'$)0%!)+#!3&(2*#%LLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLaT!FLa!!!!\&%=0(%!_LLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLIS!\&:&'&+;&%_______LLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLbS!
F"""G(4/044()," " " " " " " " " " "
" " " " " " """""""""""""""""""""""""""""""" " " """""""""""""""""""""HI"""""""""YLH!!!!<=66)'.!*:!:$+#$+1%________________________________LL___TG"YLF!!!!Z6,0$;)($*+%!:*'!(2&'),&=($;!),,'*);2&%!________________L_____L__LLLT`!YLY!!!!C5NY"D!"+1&06)+!<.+#'*6&!)+#!"<8____________________LL__L___`H!\&:&'&+;&%____________________________________________`a!
EJ"!11$,-(D"!K"L)*B"*$40+5(,6"2*)7"/)++&:)*&5(),4___________________LL`I!
"
#!"
"
J(45")2"K(60*$4"
HLH!!!!5&2)9$*')0!(')$(%!*:!"+1&06)+!<.+#'*6&LLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLT!HLF!!!!\&,'&%&+()($9&!N0&;('*&+;&,2)0*1')6!:'*6!)+!$+#$9$#=)0!V$(2!"<___L__LLLLLLLLLLLLLLLLLLHH!HLY!!!!<;2&6)($;!*:!*'1)+$X)($*+!*:!(2&!HI>HHLF4HF!1&+*6$;!0*;=%LLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLHY!HLa!!!!<;2&6)($;!*:!C5NY"!$6,'$+($+1!6&;2)+$%6!$+!+&='*+%LLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLHb!HLI!!!!72'&&!6)$+!(.,&%!*:!NY!=-$>=$($+!0$1)%&%__LLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLL!LLLFG"HLS!!!!?'&#$;(&#!%('=;(='&!*:!C5NY"!V$(2!"<4;)=%$+1!6=()($*+%__LLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLFY!cFa"HLb!!!!5$*0*1$;)0!,'*;&%%&%!*:!C5NY"!%=-%(')(&%LLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLFb"HLT!!!!3*#&0!:*'!(2&!C5NY"!2.,*(2&%$%_____LLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLYG"HL`!!!!d)'$)-$0$(.!$+!(2&!-&2)9$*')0!,2&+*(.,&!*:!"<!6$;&LLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLYF"HLHG!!<;2&6)($;!*:!-&2)9$*')0!(&%($+1LL!_________LLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLYa"FLH!!!!3&(2*#M!C0(')%*+$;!d*;)0$X)($*+!"+)0.%$%LLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLIG!FLF!!!!d)0$#)($*+!*:!%,$U$+1!&9&+(!)+)0.%$%__LLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLIa!FLY!!!![&)(='&%!*:!e7!)+#!"<!=0(')%*+$;!9*;)0$X)($*+%LLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLIb!FLa!!!!?'*0*+1&#!C<d!,'*#=;($*+!$+!@=9&+$0&!"<!6$;&!LLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLI`!FLI!!!!e&$12(!)+)0.%$%!)+#!2)+#0$+1!;*+('*0!C<d!)%%).LLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLSG!c!SH!FLS!!!!3*(*'!,2&+*(.,&%!$+!@=9&+$0&!"<!6$;&!LLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLSY!FLb!!!!B$+#0$6-!;0)%,!*:!"<!6$;&!$+!&)'0.!,*%(+)()0!#&9&0*,6&+(L!LLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLSa!FLT!!!!"=#$*1&+$;!<($6=0=%!"%%).!_________________L!LLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLSb!FL`!!!!d)0$#)($*+!*:!1&+&($;!$+(&');($*+!),,'*);2!LLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLS`!FLHG!!O&+&($;!$+(&');($*+M!C<d%D!6*(*'!,2&+*(.,&%LLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLbG4bF!FLHH!!O&+&($;!$+(&');($*+M!NNO!)+#!%,$U$+1!)+)0.%$%LLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLbacbI!YLH!!!!E9&'9$&V!*:!-&2)9$*')0!,2&+*(.,&!$+!)!@=9&+$0&!"<!6*=%&!!LLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLTF!YLF!!!!3*0&;=0)'!)+)0.%$%!*:!"\/!$+!9)'$*=%!;*+(&W(%!LLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLTIcTS!YLY!!!!?'*,*%&#!6*#&0%!:*'!"\/!6&#$)(&#!-&2)9$*')0!'&%;=&!LLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLTT!
"
! "##!
!"#$%&'()*(+($,-.

!"#$#%&'($"()%*"()$*%*"(+",-".%/01/%$2#*3"!7-/#+((+!D#&<-/#6!P(#C-;+,3!$,*&%4*26!7#-/+!$"2!-/)!Q&;+5,-!A.#-4.#-6!!
4)+")'5$"2+("()$"*0%.)($*("&06$")+7",6&)"()$%/"0+5$3"*688+/("'2#"7%0#"'2(%&*")'5$")$08$#",$"
()/+6.)9"!"',"1+/$5$/"./'($160"(+")'5$"()$*$"*(/+2.3"',':%2."7+,$2"%2",-"0%1$9"
"
;<%2.0%1$"
#!!!"
"
!55*(:05(),4"!
<%&15$*"=M""
K(60*$"=N=!$%!:'*6!e$00$)6%!/"!&(!)0LD!FGHGh!K(60*$"=N?!$%!:'*6!5*V&+!)+#!f&)9*+%D!H`Sbh!
K(60*$"=NF!$%!:'*6!e$00$)6%!/"!&(!)0LD!FGHGh!K(60*$"=NE!$%!:'*6!3)--!"3!&(!)0LD!FGHHh!!
K(60*$"=NO!$%!:'*6!2((,MiiVVVL2=;;L2*U=#)$L);L@,iR#FGIGIi&+i'&%&)';2ih!K(60*$"=NP!$%!:'*6!<)#$U*9$;!&(!)0LD!FGHah!K(60*$"=NH!$%!:'*6!j2*=!]!&(!)0LDFGHIh!K(60*$"=NQ!$%!:'*6!?&(&'!<;2&$::$0&!)+#!"%$6!"L!5&1D!FGHGh!K(60*$"=NI!$%!:'*6!B=)+1!B!&(!)0LD!FGHY!)+#!f$)+1!B!&(!)0LD!H```!h!K(60*$"=N=R!V)%!1&+&')(&#!-.!6.%&0:L!!
<%&15$*"?M"/2),(&'!F!$%!'&4:*'6)((&#!:'*6!k.&,-$+A#*$%7"<S"<)0*1$)++$%!fD!82)6+&!<D!\*(&+-&'1!"D!O'&&+-&'1!3NL!PFGHIQ!<&$X='&40$U&!);($9$(.!$+!)!@=9&+$0&!"+1&06)+!<.+#'*6&!6*=%&!6*#&0!$%!)((&+=)(&#!-.!'&#=;$+1!%4+&&W,'&%%$*+L!?A"<!HHFPHSQMIHF`4Yak!!N,2&W$+I!U+*;U*=(!6$;&!V&'&!1&+&')(&#!-.!3=%():)!<)2$+!)+#!7)6!72*6,%*+!$+!(2&!/2$0#'&+l%!B*%,$()0!5*%(*+!;*'&!:);$0$(.L!"';!U+*;U*=(!6$;&!V&'&!,'*9$#&#!)%!)!1$:(!:'*6!8'L!3)';!5&)'m%!0)-*')(*'.!)(!3)%%);2=%&((%!Z+%($(=(&!*:!7&;2+*0*1.L!N,2&W$+I!)+($-*#$&%!V&'&!1&+&')(&#!,'&9$*=%0.!-.!<&(2!3)'1*0$%D!f*2+!<)0*1$)++$%!)+#!^$+#)!B=L!!Z!,&':*'6&#!)00!*(2&'!-&2)9$*')0!)+#!6*0&;=0)'!)%%).%!=+#&'!(2&!%=,&'9$%$*+!*:!3$;2)&0!O'&&+-&'1!!
<%&15$*"FM"![$1='&!YLH!c!YLY!V)%!1&+&')(&#!-.!6.%&0:!!![$1='&!YLF!$%!#)()!1&+&')(&#!-.!6.%&0:!)+#!$%!:'*6!(2&!,'&9$*=%0.!,=-0$%2&#!V*'U!n.&,-$+A
#*$%7"<S"<)0*1$)++$%!fD!82)6+&!<D!\*(&+-&'1!"D!O'&&+-&'1!3NL!PFGHIQ!<&$X='&40$U&!);($9$(.!$+!)!@=9&+$0&!"+1&06)+!<.+#'*6&!6*=%&!6*#&0!$%!)((&+=)(&#!-.!'&#=;$+1!%4+&&W,'&%%$*+L!?A"<!HHFPHSQMIHF`4Yak!
!$"
"
!
"
"!!!k72&!2$%(*'.!*:!6&#$;$+&!$%! :=00!*:! $+(&'&%($+1!%(*'$&%!)-*=(!(2&!#$%;*9&'.!*:! $00+&%%&%L!72&!%)1)!*:!"+1&06)+m%!%.+#'*6&!$%!*+&!%=;2!%(*'.L!Z(!V)%!,='&0.!-.!;2)+;&!(2)(!+&)'0.!(2$'(.!.&)'%!)1*!P&L1LD!;$';)!H`SaQ!(2'&&!2)+#$;),,&#!;2$0#'&+!V&'&!)#6$((&#!)(!9)'$*=%!($6&%!(*!6.!;2$0#'&+md&'*+)!;)00&#!L!L! L!)!5*.!V$(2!)!?=,,&(L!72&!-*.m%!0)=12$+1!:);&!)+#!(2&!:);(!(2)(!6.!,)($&+(%!&W2$-$(&#!@&'U.!6*9&6&+(%!1)9&!6&!(2&!$#&)!*:!V'$($+1!)+!)'($;0&!)-*=(!(2&!(2'&&!;2$0#'&+!V$(2!)!($(0&!*:!?=,,&(!/2$0#'&+L!Z(!V)%!+*(!)!+)6&!(2)(!,0&)%&#! )00! ,)'&+(%! -=(! $(! %&'9&#! )%! )!6&)+%!*:! ;*6-$+$+1! (2&! (2'&&! 0$((0&! ,)($&+(%! $+(*! )!%$+10&! 1'*=,L! ^)(&'! (2&! +)6&! V)%! ;2)+1&#! (*! "+1&06)+! %.+#'*6&L! 72$%! )'($;0&! V)%!,=-0$%2&#! $+! H`SI! )+#! ):(&'! %*6&! $+$($)0! $+(&'&%(! 0).! )06*%(! :*'1*((&+! =+($0! (2&! &)'0.!&$12($&%Lk!! 4!8'L!B)''.!"+1&06)+H! !!
!!!
"""""""""""""""""""""""""""""""""""""""" """"""""""""""""""""
%"&'()*+,'-"H., Personal "Communication" (letter)" to Dr. Charles Williams. 1991. 
"
 1 
!
!
!
!
!
!
!
!
!
"#$%&'(!)!
*+,-./01,2.+!
 2 

 3 


 4 

 5 
)=(/#.(+22%/1&+'/,F#V(#'0/#/L+92"/#=-#R/''#;4(,%=9/A#"=**#=-#6X5^I#"/+,*#'=#+#*2/1&-&1#,4*-.(1'&=(#&(#3='0#9='=%#+(,#1=99.(&1+'&@/#1=('/L'*A#*.))/*'&()#'0/*/#3/0+@&=%*#+%/#"&(H/,#'0%=.)0#*=9/#1=99=(A#.(H(=$(#3&="=)4#'0+'#=11.%*#&(#(=%9+"#,/@/"=29/('F#_&'0#+#)/(/'&1#+(,#9="/1."+%#9+%H/%#&(#0+(,A#=(/#1+(#/".1&,+'/#'0/#3&="=)&1+"#2+'0$+4*#'0+'#+%/#1=99=(#'=#'0/*/#,&*1%/'/#3/0+@&=%+"#'%+&'*F###`a='+3"4A#1=24#(.93/%#@+%&+'&=(*#&(#'0/#b8XN!#)/(/#+%/#+#*&)(&-&1+('#-&(,&()#>E7NP?#+9=()#&(,&@&,.+"*#$&'0#!;<IUF##G0.*A#'0/#*'.,4#=-#b8XN!7,/2/(,/('#2+'0$+4*#&(#'0/#1=('/L'#=-#!;#&*#.*/-."#-=%#+,,%/**&()#'0/#S./*'&=(#=-#0=$#9="/1."/*#&(-"./(1/#'0/#,/@/"=29/('#=-#1=92"/L#3/0+@&=%+"#1&%1.&'*A#+(,#-=%#)/(/%+'&()#042='0/*/*#+3=.'#0=$#'0/*/#1&%1.&'*#)=#+$%4#&(#1=92"/L#,&*=%,/%*A#*.10#+*#!;<*F## ##
 6 
)3)!$+45678+!9:+/-.75;!"62+2186!%<5+.,:=5!#
&<5!>5<8?2.-86!%<5+.,:=5!.@!$+45678+!9:+/-.75!! !!()/"9+(#;4(,%=9/#>!;A#6V6#EOUDNO?#&*#+#(/.%="=)&1+"#,&*=%,/%#'0+'#/L2%/**/*#+#.(&S./#3/0+@&=%+"#20/(='42/#&(#/+%"4#,/@/"=29/('F##G0/#1"&(&1+"#20/(='42/#=-#!;#$+*#-&%*'#,/*1%&3/,#+*#cd+224#^.22/'#;4(,%=9/e#&(#EWCUA#$0/(#<%F#df
 7 
+(,#1=92"/'/#"=**#=-#3+"+(1/NQANUF##!"'0=.)0#/2&"/2*4#&*#(='#2%/*/('#+9=()#+""#&(,&@&,.+"*#&'#&*#=(/#=-#'0/#9=*'#,/3&"&'+'&()#*492'=9*#=-#'0&*#,&*=%,/%F#G0/#2+'0=)/(/*&*#=-#!;A#&(1".,&()#3='0#'0/#2%&9+%4#+(,#*/1=(,+%4#-/+'.%/*A#&*#0&)0"4#%/*'%&1'/,#'=#'0/#(/%@=.*#*4*'/9F##;=9/#,4*9=%20&1#-/+'.%/*#0+@/#3//(#,/*1%&3/,A#*.10#+*#9&,7-+1/#042=2"+*&+A#$&,/"4#*2+1/,#'//'0A#,//27*/'#/4/*A#2%=)(+'0&*9#+(,#10+()/*#&(#*H&(#+(,#0+&%#1="=%NCF##d
 8 
###########
!
!
!
A240-5!)3)#>5<8?2.-86!,-82,B!.@!$+45678+!9:+/-.753#M%/S./('#*9&"&()A#+3(=%9+"#)+&'#+(,#0+(,7-"+22&()#3/0+@&=%*#+%/#,/2&1'/,F#!'#'&9/*#'0/#-+1&+"#+22/+%+(1/#1+(#*.))/*'#*4(,%=9&1#,&+)(=*&*#3.'#.*.+""4#'0/%/#&*#(=#*&)(&-&1+('#-+1&+"#,&9=%20&*9#>V9+)/#'+H/(#-%=9#_&""&+9*#5!#/'#+"FA#IOEO?F#####
 9 

 10 
%<:B2.6.42186!1.--568,5B!.@!$+45678+!9:+/-.75!!(#+3(=%9+"#/"/1'%=/(1/20+"=)%+9#>XXg?#&*#+#%=3.*'#204*&="=)&1+"#9+%H/%#=-#!;A#=3*/%@/,#&(#EOOP#=-#'0/#&(,&@&,.+"*#$0=#0+@/#3//(#1"&(&1+""4#,&+)(=*/,#$&'0#!;#'0%=.)0#3/0+@&=%+"#+**/**9/('I[F##G0/#+3(=%9+"&'&/*#&(#1=%'&1+"#+1'&@&'4#&(1".,/#%04'09&1#Q7C#dT#3.%*'*#=-#+1'&@&'4#'0+'#2/%*&*'*#$&'0#/4/#1"=*.%/#+(,#0&)07@="'+)/A#*"=$#>I7N#dT?#,/"'+#+1'&@&'4#$&'0#*2=H/*#+(,#*0+%2#$+@/*IQAI[ANQ#>M&).%/#EFI?F##<./#'=#+#,/"+4#&(#*492'=9#2%/*/('+'&=(#+(,#"&9&'+'&=(*#&(#1"&(&1+"#,&+)(=*&*A#+#2%/1&*/#=(*/'#-=%#'0/#XXg#20/(='42/#0+*#(='#3//(#,/'/%9&(/,A#3.'#0+*#3//(#=3*/%@/,#+*#/+%"4#+*#D#9=('0*#=-#+)/NQF#G0/%/#&*#"&''"/#.(,/%*'+(,&()#=-#0=$#'0/#+3(=%9+"#XXge*#+%/+#+(,#_/&%(/H/e*#+%/+F#6&",#1=%'&1+"#+'%=204#+(,#,/94/"&(+'&=(#$&'0&(#'0/#1=%'/L#0+@/#+"*=#3//(#=3*/%@/,NOF##G0/#1=('%&3.'&=(#=-#'0/*/#204*&="=)&1+"#,/-&1&'*#'=#'0/#3/0+@&=%+"#+3(=%9+"&'&/*#(='#4/'#.(,/%*'==,F####V(#*.9A#'0/#3/0+@&=%+"#20/(='42/#=-#!;#&*#1=92"/L#+(,#&*#10+%+1'/%&T/,#34#*/@/%/#&92+&%9/('#=-#*=1&+"#1=99.(&1+'&=(#+(,#9='=%#3/0+@&=%*F#;=9/#=-#'0/*/#-/+'.%/*A#*.10#+*#(=(@/%3+"#3/0+@&=%*A#*/&T.%/*A#+3(=%9+"#)+&'#+(,#0+(,7-"+22&()#*'/%/='42&/*#+%/#
 11 
=@/%"+22&()#-/+'.%/*#$&'0#3%=+,/%#!;<*A#*.10#+*#!.'&*9[F##G0/#*2/1&-&1#,4*-.(1'&=(#=-#'0/#(/%@=.*#*4*'/9#+(,#'0/#2%=)%/**&=(#=-#*492'=9*A#&(1".,&()#'0/#=(*/'#&(#/+%"4#,/@/"=29/('#+(,#2/%*&*'/(1/#'0%=.)0#+,."'0==,A#+%/#+"*=#0&)0"4#%/9&(&*1/('#=-#$0+'#&*#=3*/%@/,#&(#!;<*F#G0.*A#'0/#*'.,4#=-#!;#=--/%*#+#1=92/""&()#1=('/L'#'=#3/)&(#,&**/1'&=(#=-#'0/#1=92"/L#20/(='42/#&(#!;<F#### #
!
!
!
!
!
!
!
!
!
!
!
A240-5!)3C#(5=-5B5+,8,2?5!'651,-.5+15=<86.4-87!@-.7!8+!2+/2?2/086!D2,<!$93!50+%+1'/%&*'&1#0&)0#+92"&'.,/A#I7N#dT#*2&H&()#/@/('*#+%/#=3*/%@/,#&(#+#10&",#$&'0#!;A#+'#,&--/%/('#+)/*#,.%&()#,/@/"=29/('!>V9+)/#'+H/(#-%=9#8=$/(#+(,#h/+@=(*A#EWC[?F#
!
 12 
)3C!$+45678+!9:+/-.75;!E5+.,:=5F%<5+.,:=5!".--568,2.+!#
92+465!45+5!70,8,2.+G!1.7=65H!I5<8?2.-86!=<5+.,:=5!G0/#1"&(&1+"#20/(='42/#=-#!;#+%&*/*#-%=9#9.'+'&=(#=-#'0/#9+'/%(+""4#&(0/%&'/,A#10%=9=*=9+"#"=1.*#EUSEEFI7ENIDANOAINF#!22%=L&9+'/"4#[U7DUP#=-#&(,&@&,.+"*#0+@/#+#"+%)/##>BC#63?#10%=9=*=9+"#9&1%=,/"/'&=(#*2+((&()#*/@/%+"#1=99=("4#&,/('&-&/,#3%/+H2=&('*#>M&).%/#EFI?F##V(#B#EO7EUP#=-#'0/#1+*/*A#+#9.'+'&=(#=11.%*#&(#+#*&()"/#)/(/A#b8XN!INF#R+%/#9.'+'&=(*#&(1".,/#&(0/%&'+(1/#=-#'$=#1=2&/*#=-#'0/#2+'/%(+"#EUSEE7EN#"=1.*#>.(&2+%/('+"#,&*=94#=%#b^<?A#=%#9.'+'&=(*#&(#+#<a!#*/S./(1/#.2*'%/+9#=-#'0/#b8XN!#)/(/A#H(=$(#+*#'0/#&92%&('&()#1/('/%#>V5?F#G0/#=("4#-/+'.%/#'0+'#&*#*0+%/,#+9=()#+""#9="/1."+%#*.3'42/*#&*#'0/#,&*%.2'&=(#=-#'0/#9+'/%(+"#b8XN!#)/(/#>M&).%/#EFI?NOANCF#!""#9="/1."+%#*.3'42/*#%/*."'#&(#+#*=9/$0+'#.(&-=%9#1"&(&1+"#2&1'.%/#=-#,/@/"=29/('+"#,/"+4A#+3*/(1/#=-#*2//10A#9=@/9/('#,&*=%,/%A#042/%7/L1&'+3"/#'%+&'*#+(,#+(#+3(=%9+"#XXgQEF#a='+3"4A#'0/#(=(@/%3+"#3/0+@&=%#+(,#+3(=%9+"#XXg#+%/#2%/*/('#+9=()#'0/#EUSEEFI7EN#,/"/'&=(#+(,#b8XN!#)/(='42/*F##G0/*/#,+'+#*.))/*'#'0+'#9.'+'&=(#=-#b8XN!#+"=(/#&*#*.--&1&/('#'=#)&@/#%&*/#'=#'0/#(/.%=3/0+@&=%+"#20/(='42/#=-#!;A#'0.*#9='&@+'&()#'0/#1"+**&-&1+'&=(#=-#!()/"9+(#;4(,%=9/#+*#+#9=(=)/(&1A#=%#*&()"/7)/(/A#(/.%=,/@/"=29/('+"#,&*=%,/%F###G0/#&(,&@&,.+"*#$&'0#EUSEEFI7EN#9&1%=,/"/'&=(*#+(,#2+'/%(+"#b^<#0+@/#9=%/#*/@/%/#=-#*492'=9*#1=92+%/,#'=#b8XN!#9.'+'&=(*A#$0&"/#'0/#V5#9.'+'&=(*#+%/#'0/#"/+*'#*/@/%/#=-#+""#*.3'42/*NQAQEF##</"/'&=(#+(,#b^<#9.'+'&=(*#%/*."'#&(#+#9=%/#%=3.*'#9=@/9/('#,&*=%,/%#>+'+L&+A#-//,&()#,&--&1."'&/*?A#&(1%/+*/,#-%/S./(14#+(,#/+%"&/%#=(*/'#=-#*/&T.%/*A###
 13 
####
!
!
A240-5!)3J!91<578,21!.-48+2K8,2.+!.@!,<5!)LM))3CF)C!45+.721!6.10B3!`=1+'&=(#=-#'0/#!;#)/(/A#4+/*'A#&*#&(,&1+'/,#34#'0/#+%%=$F#5=99=(#8%/+H#^=&('*#>8^*?#+%/#&(,&1+'/,#34#'0/#@/%'&1+"#+%%=$*#+(,#Y+))/,#"&(/*Z#'0/#9=*'#1=99=(#5"+**#V#+(,#5"+**#VV#,/"/'&=(*#+%/#(='/,#34#'0/#,+*0/,#"&(/*F#G0/#V5#&*#,/2&1'/,A#"=1+'/,#+22%=L&9+'/"4#UOO#i3#1/('%=9/%&1#'=#
4+/*'F#>M&).%/#-%=9#_&""&+9*#5!#/'#+"FA#IOEO?F######
 14 
#9=%/#2%=(=.(1/,#9&1%=1/20+"4A#+(,#'0/%/#&*#+#0&)0/%#"&H/"&0==,#=-#/L2%/**&()#042=2&)9/('+'&=(#=-#'0/#*H&(#+(,#0+&%NIAQEF##`=**#=-#+,,&'&=(+"#)/(/*#$&'0&(#'0/#EUSEEFI7EN#,/"/'&=(#%/)&=(#+%/#'0=.)0'#'=#1=('%&3.'/#'=#'0/*/#,&--/%/(1/*Z#`=**#=-#+(#&(0&3&'=%4#g!8!#%/1/2'=%#1".*'/%#+(,#'0/#j5!7I#)/(/#"&H/"4#&(1%/+*/#'0/#*/@/%&'4#&(#*/&T.%/*#+(,#042=2&)9/('+'&=(A#%/*2/1'&@/"4F#!#)/(='42/720/(='42/#+(+"4*&*#1+((='#3/#2/%-=%9/,#-=%#'0/#204*&="=)&1+"#,/-&1&'*#'0+'#0+@/#3//(#,&*1=@/%/,A#+*#'0/#6RV#+(,#<GV#*'.,&/*#0+@/#3//(#%/*'%&1'/,#'=#&(,&@&,.+"*#$&'0#+#EUSEEFI7EN#,/"/'&=(ECAQOF##G0/#9.'+'&=(*#'0+'#=11.%#&(#'0/#9+'/%(+"#b8XN!#)/(/#&(1".,/#*&()"/#(.1"/='&,/#2="49=%20&*9*#>;a^?A#+(,#*9+""#&(*/%'&=(*#+(,#,.2"&1+'&=(*#=-#*0=%'#<a!#*/S./(1/*INAQIF##a=@/"#*2"&1/#*&'/*#+(,#'%+(*"+'&=(+"#/%%=%#@+%&+('*#+%/#+#%/*."'#-%=9#'0/*/#9.'+'&=(*#+(,#+%/#2%/,&1'/,#'=#,&*%.2'#'0/#(=%9+"#2%=1/**&()#=-#b8XN!#9Ra!F#V(#+,,&'&=(A#*=9/#2+'0=)/(&1#@+%&+('*#+%/#2%/,&1'/,#'=#,&*%.2'#'0/#'%+(*"+'&=(#=-#b8XN!#2%='/&(#'0%=.)0#9.'+'&=(#&(#*'=2#1=,=(*#=%#&('%=,.1'&=(#=-#(=@/"A#2%/9+'.%/#*'=2#1=,=(*#$&'0&(#'0/#'%+(*1%&2'F##;/@/%+"#9.'+'&=(*#,=#(='#&92+&%#'%+(*1%&2'&=(#=%#'%+(*"+'&=(#=-#'0/#b8XN!#)/(/A#3.'#&(*'/+,A#,&*%.2'#'0/#*2/1&-&1#-.(1'&=(#=-#b8XN!#2%='/&(#k,&*1.**/,#&(#*/1'&=(#EFNlQIF#G0.*A#'0/#9+Y=%&'4#=-#b8XN!#9.'+'&=(*#+%/#2%/,&1'/,#'=#1+.*/#"=**#=-#2%='/&(#=%#*2/1&-&1#,&*%.2'&=(#'=#b8XN!#-.(1'&=(F###!9=()#&(,&@&,.+"*#$&'0#b8XN!#9.'+'&=(*#'0/%/#&*#@+%&+3&"&'4#&(#'0/#"/@/"#=-#*2//10#&92+&%9/('A#*/&T.%/*A#042/%7/L1&'+3"/#'%+&'*#+(,#9=@/9/('#,&*=%,/%F#!"'0=.)0#9+(4#&(,&@&,.+"*#$&'0#b8XN!#9.'+'&=(*#+%/#(=(7@/%3+"A#*=9/#9+4#0+@/#&(*'/+,A#+#*/@/%/#,/@/"=29/('+"#,/"+4#=-#*2//10F#V(#=(/#1+*/#=-#!;A#+(#&(,&@&,.+"#1=.",#,&*2"+4#+#9&(&9+"#.*/#=-#$=%,*#+(,#0+%3=%/,#+#;a^#&(#'0/#*/1=(,#(.1"/='&,/#=-#'0/#b8XN!#)/(/F#V'#&*#"&H/"4#'0+'#
 15 
'0&*#9.'+'&=(A#+*#$/""#+*#='0/%*A#1+.*/#+#%/,.1'&=(#&(#b8XN!#/L2%/**&=(#&(*'/+,#=-#'='+"#"=**#=-#/L2%/**&=(F#V-#'0/#"/@/"#=-#*2//10#&92+&%9/('#@+%&/*#$&'0#'0/#"/@/"#=-#b8XN!#/L2%/**&=(#&'#$=.",#-.%'0/%#*.22=%'#'0/#&,/+#'0+'#b8XN!#&*#+#1%&'&1+"#2"+4/%#&(#'0/#,/@/"=29/('#=-#"+().+)/#1&%1.&'*F#!(+"4*&*#=-#b8XN!#/L2%/**&=(#&(#1/""#"&(/*#-%=9#2+'&/('*#$&'0#b8XN!#9.'+'&=(*#&*#+(#+1'&@/#-&/",#=-#%/*/+%10#$&'0&(#'0/#!;#-&/",F####
N>'J$!/0=6218,2.+!8+/!/2B58B5!G0/#1=((/1'&=(#=-#b8XN!#'=#'0/#&92+&%9/('#=-#*=1&+"#+(,#9='=%#3/0+@&=%*#&*#%/2"&1+'/,#&(#1"&(&1+"#-&(,&()*#-%=9#&(,&@&,.+"*#'0+'#2=**/**#,.2"&1+'&=(*#=-#'0/#EUSEEFI7EN#"=1.*IUAQNAQQF##G0&*#)/(=9&1#"=1.*#&*#0&)0"4#.(*'+3"/#+(,#,.2"&1+'&=(*#=%#'%&2"&1+'&=(*#0+@/#3//(#&,/('&-&/,#+*#=(/#=-#'0/#9=*'#1=99=(#1=247(.93/%#@+%&+('*#>5am?#&(#2+'&/('*#$&'0#!;<#>.2#'=#NP?F##V('/%*'&'&+"#,.2"&1+'&=(#=-#'0&*#9+'/%(+"#"=1.*#*0=$*#&(1=92"/'/#2/(/'%+(1/#+(,#%/*."'*#+#@+%&+3"/#20/(='42/#'0+'#&(1".,/*#,/@/"=29/('+"#,/"+4#+(,#,&*+3&"&'4#=-#"+().+)/#+(,#*=1&+"#1=99.(&1+'&=(#*H&""*F##G0/#,.2"&1+'&=(#=-'/(#1=('+&(*#9."'&2"/#)/(/*#*.10#'0+'#'0/#,&%/1'#%="/#=-#b8XN!#,4*-.(1'&=(#0+*#3//(#,&--&1."'#'=#'/+*/#+2+%'F##d=$/@/%A#+#%/1/('#%/2=%'#,/*1%&3/*#'0/#-&%*'#-/9+"/#2+'&/('#$&'0#+#9+'/%(+"#EUSEEFI7EN#,.2"&1+'&=(#'0+'#1=('+&(*#=("4#'0/#b8XN!#)/(/#QUF##G0&*#2+'&/('#0+*#)"=3+"#,/@/"=29/('+"#,/"+4#&(#9='=%#3/0+@&=%#>1%+$"&()#+'#EC#9=('0*A#$+"H&()#+'#ED#9=('0*?#+(,#$+*#(=(7@/%3+"#.('&"#'0/#+)/#=-#'0%//F##_&'0#&('/(*/#3/0+@&=%+"#'0/%+24A#'0&*#&(,&@&,.+"#$+*#+3"/#'=#"/+%(#(/$#9='=%#+(,#*=1&+"#1=99.(&1+'&=(#*H&""*#*.10#+*#*&)(#"+().+)/A#+"'0=.)0#'0/4#%/9+&(/,#0&)0"4#(=(7@/%3+"F##G0/#*2/1&-&1#,/"+4#=-#9='=%#,/@/"=29/('A#(=(@/%3+"#3/0+@&=%#+(,#*2+%&()#=-#"/+%(&()#+(,#9/9=%4#'0+'#%/*."'*#-%=9#,.2"&1+'&=(#=-#'0/#b8XN!#)/(/#+%/#%/9&(&*1/('#=-#-/+'.%/*#'0+'#=11.%#&(#!;F##
 16 
!
*7=-2+,2+4!.@!N>'J$!2+!,<5!+5-?.0B!B:B,57#;/@/%+"#)/(/*#$&'0&(#'0/#!;71+.*&()#"=1.*#EUSEEFI7EN#+%/#&92%&('/,A#=%#/L2%/**/,#&(#+#2+%/('7=-7=%&)&(#,/2/(,/('#9+((/%F#G0/#&92%&('&()#9/10+(&*9#&(@="@/*#2%/-/%/('&+"#52g#9/'04"+'&=(#+'#*/@/%+"#"=1+'&=(*#$&'0&(#9+'/%(+"#10%=9=*=9/#EUSEEFI7EN#>M&).%/#EFN?QCF#G0/#9+'/%(+"#*2/1&-&1#9/'04"+'&=(#2+''/%(#"/+,*#'=#'0/#*&"/(1&()#=-#*/@/%+"#9+'/%(+""4#&(0/%&'/,#)/(/*#>6iRaNA#6!gX`IA#a<aA#;abRM7;aR^a?#%/*."'&()#&(#/L1".*&@/#/L2%/**&=(#-%=9#'0/#2+'/%(+"#+""/"/F#G0/#%/9+&(&()#)/(/*#+%/#/L2%/**/,#3&7+""/"&1+""4A#-%=9#3='0#'0/#2+'/%(+"#+(,#9+'/%(+"#1=24F#G0&*#,&--/%/('&+"#9/'04"+'&=(#2+''/%(#&*#/*'+3"&*0/,#&(#==14'/*A#/*1+2/*#/%+*.%/#+(,#&*#*'+3"/#'0%=.)0=.'#2=*'(+'+"#,/@/"=29/('F##M=%#9=*'#=-#'0/#)/(/*#&(#"=1.*#EUSEEFI7ENA#'0/#&92%&('&()#*'+'.*#&*#*'+3"/#+(,#(='#1/""7'42/#*2/1&-&1F##d=$/@/%A#&(#,&--/%/('&+'/,#(/.%=(*A#'0/#b8XN!#)/(/#*$&'10/*#-%=9#3&7+""/"&1#/L2%/**&=(#'=#3/&()#/L2%/**/,#/L1".*&@/"4#-%=9#'0/#9+'/%(+"#10%=9=*=9/QCF#G0/#2%/-/%/('&+"#/L2%/**&=(#=-#b8XN!#-%=9#'0/#9+'/%(+"#+""/"/#&*#+(#&(,&%/1'#%/*."'#-%=9#'0/#&92%&('&()A#=%#*&"/(1&()A#=-#'0/#2+'/%(+"#b8XN!#1=24F#G0/#&92%&('&()#9/10+(&*9#&(@="@/*#'0/#'%+(*1%&2'&=(#=-#+#I#i3#+('&*/(*/#Ra!#'%+(*1%&2'#>b8XN!7!G;?#'0+'#&*#&(&'&+'/,#=(#'0/#2+'/%(+"#10%=9=*=9/A#+'#+#*&'/#$0/%/#'0/#9+'/%(+"#+""/"/#&*#2%/-/%/('&+""4#9/'04"+'/,Q[F#G0/#+('&*/(*/#'%+(*1%&2'#+1'*#&(#+#ABC#%/)."+'=%4#9+((/%#'=#&92/,/#/L2%/**&=(#=-#'0/#2+'/%(+"#b8XN!#)/(/F#i(=1H,=$(#=%#'%.(1+'&=(#=-#'0/#b8XN!7!G;#0+*#3//(#*0=$(#'=#+""/@&+'/#%/2%/**&=(#=-#'0/#2+'/%(+"#b8XN!#)/(/#B?3@B@>8728;28DF#G0/#+('&*/(*/#'%+(*1%&2'#&*#(='#-=.(,#&(#='0/%#1/""7'42/*#+(,#'0/#3&="=)&1+"#9/10+(&*9#'0+'#,&1'+'/*#(/.%=(+"#*2/1&-&1&'4#&*#(='#H(=$(UO7UIF###
 17 
# #
!
!
!
!
!
A240-5!)3O!91<578,21!.@!N>'J$!27=-2+,2+4!751<8+2B7!2+!+50-.+BF#R/,#&(,&1+'/*#)/(/*#'0+'#+%/#/L2%/**/,#/L1".*&@/"4#-%=9#'0/#9+'/%(+"#1=24#>2+'/%(+""4#&92%&('/,?A#g%//(#%/2%/*/('*#)/(/*#'0+'#,&*2"+4#3&7+""/"&1#/L2%/**&=(#+(,#8"./#%/2%/*/('*#)/(/*#+%/#/L2%/**/,#/L1".*&@/"4#-%=9#'0/#2+'/%(+"#+""/"/#>9+'/%(+""4#&92%&('/,?F##G0/#b8XN!7!G;#&*#=("4#-=.(,#&(#'0/#(/%@=.*#*4*'/9F#>V9+)/#'+H/(#-%=9#6+33#!6#/'#+"FA#IOEE?F######
 18 
M&(,&()*#-%=9#'0/*/#/L2%/**&=(#*'.,&/*#=--/%#+#9="/1."+%#9/10+(&*9#'=#/L2"+&(#'0/#2.%/"4#(/.%="=)&1+"#20/(='42/#=-#!;F##V(#(=(7(/.%="=)&1+"#'&**./*A#9.'+'&=(*#&(#9+'/%(+"#b8XN!#%/*."'#&(#=("4#2+%'&+"#"=**#=-#-.(1'&=(A#+*#'0/#2+'/%(+"#+""/"/#1+(#1=92/(*+'/F#d=$/@/%#&(#(/.%=(*A#+#9.'+'&=(#&(#'0/#9+'/%(+"#b8XN!#)/(/#%/*."'*#&(#1=92"/'/#"=**#=-#b8XN!#/L2%/**&=(F#G0.*A#+"'0=.)0#b8XN!#&*#.3&S.&'=.*"4#/L2%/**/,#&(#+""#1/""7'42/*A#'0/#(/%@=.*#*4*'/9#&*#.(&S./"4#@."(/%+3"/#'=#!;#1+.*&()#9.'+'&=(*F##!#-+@=%/,#+22%=+10#-=%#'%/+'&()#!;#&(@="@/*#,/7%/2%/**&()#'0/#(=(79.'+'/,#2+'/%(+"#1=24#=-#b8XN!#&(#'0/#(/%@=.*#*4*'/9UIAUNF##!#1"+**#=-#'=2=&*=9/%+*/#&(0&3&'=%*A#$0&10#2%/-/%/('&+""4#,=$(7%/)."+'/#"=()#'%+(*1%&2'*A#0+@/#3//(#*0=$(#'=#,=$(7%/)."+'/#'0/#b8XN!7!G;#&(@="@/,#&(#'0/#*&"/(1&()#=-#2+'/%(+"#b8XN!QWF##G0&*#0+*#+"*=#3//(#+10&/@/,#'0%=.)0#20+%9+1="=)&1+"#9/+(*#@&+#,/"&@/%4#=-#+('&*/(*/#="&)=(.1"/='&,/*#>!;j?#'0+'#'+%)/'#'0/#b8XN!7!G;#&(#(/.%=(*UNF##G0/#'+%)/'&()#34#!;j*#&*#0&)0"4#*2/1&-&1#+(,#%/*."'#&(#,/)%+,+'&=(#=-#'0/#b8XN!7!G;F##6="/1."+%#+(,#)/(/'&1#'0/%+2&/*#'0+'#%/,.1/#'0/#b8XN!7!G;#0+@/#3//(#/--&1+1&=.*#&(#%/1=@/%&()#/L2%/**&=(#-%=9#'0/#2+'/%(+"#b8XN!#+""/"/A#+(,#'0/*/#+22%=+10/*#+%/#1.%%/('"4#3/&()#'/*'/,#&(#9=.*/#9=,/"*#=-#!;F##
!
! G=#*.99+%&T/A#9.'+'&=(#&(#+#*&()"/7)/(/A#b8XN!A#&*#*.--&1&/('#'=#2%=,.1/#+""#=-#'0/#1=%/#3/0+@&=%#+(,#204*&="=)&1+"#-/+'.%/*#&(#!;F#G0/#!;71+.*&()#9.'+'&=(*#&(#b8XN!#=11.%#*2/1&-&1+""4#=(#'0/#9+'/%(+"#+""/"/A#$0&10#&*#'0/#=("4#*=.%1/#b8XN!#/L2%/**&=(#&(#(/.%=(*#,./#'=#'0/#(/.%=(+"#*2/1&-&1#&92%&('&()#=-#'0/#2+'/%(+"#1=24F#G0.*A#"=**#=-#b8XN!#*2/1&-&1+""4#&(#(/.%=(*#&*#'0=.)0'#'=#2%=,.1/#'0/#,&*1%/'/#*/'#=-#3/0+@&=%+"#+3(=%9+"&'&/*#=3*/%@/,#&(#!;F#!
!
 19 
)3J!N>'J$!9,-01,0-5!8+/!A0+1,2.+!#
N>'J$!2B!8+!'JF0I2M02,2+!6248B5!!b8XN!#&*#+(#XN#.3&S.&'&(#"&)+*/#'0+'#-.(1'&=(*#$&'0&(#+#3&="=)&1+"#1+*1+,/#H(=$(#+*#'0/#.3&S.&'&(72%='/+*=9/#2+'0$+4#>b^^?UQ7UCF#G0/#b^^#&*#+#0&)0"4#%/)."+'/,#+(,#*2/1&-&1#2+'0$+4#'0+'#&*#&92=%'+('#-=%#1=('%=""&()#'0/#,/)%+,+'&=(#=-#2%='/&(*#&(#+#1/""F#G0/#b^^#&*#1=92%&*/,#=-#'0%//#/(T49/*#>XEA#XIA#+(,#XN?#'0+'#-.(1'&=(#*/S./('&+""4#'=#*0.''"/#-%//"4#+@+&"+3"/#.3&S.&'&(#9="/1."/*#=('=#+#*2/1&-&1#2%='/&(#'+%)/'A#=%#*.3*'%+'/F##</2/(,&()#=(#'0/#'42/#=-#2="4.3&S.&'&(#10+&(#'0+'#&*#+''+10/,A#'0/#*.3*'%+'/*#$&""#/(,=$#,&--/%/('#-.(1'&=(*#=%#-+'/*F#G0/#9+Y=%&'4#=-#.3&S.&'&(+'&=(#/@/('*#-=%9#`fCOO?#=-#XN#.3&S.&'&(#"&)+*/*UDF#G0.*A#'0/#XN#.3&S.&'&(#"&)+*/*#+%/#2%/,&1'/,#'=#3/#'0/#H/4#2"+4/%*#$&'0&(#'0/#b^^#'0+'#9/,&+'/#'0/#*2/1&-&1#%/1=)(&'&=(#=-#2%='/&(#*.3*'%+'/*F######
 20 
####
!
A240-5!)3L#&<-55!782+!,:=5B!.@!'J!0I2M02,2+!6248B5B3!#;10/9+'&1#=-#b^^#1=('+&(&()#>-%=9#"/-'#'=#%&)0'?n#dX5G#>d=9="=)=.*#'=#XC!^75+%3=L4#'/%9&(.*?#,=9+&(#"&)+*/*A#RVag#>R/+""4#V('/%/*'&()#a/$#g/(/?#'42/#XN#"&)+*/*#+(,#b73=L#'42/#XN#"&)+*/*#>M&).%/#EF[?F#a='/n#dX5G#,=9+&(#"&)+*/*#+%/#'0/#=("4#'42/#=-#XN#"&)+*/#'0+'#+1'&@/"4#2+%'&1&2+'/*#&(#'0/#'%+(*-/%#=-#'0/#.3&S.&'&(#-%=9#'0/#XI#/(T49/#=('=#'0/#2%='/&(#*.3*'%+'/#>V9+)/#'+H/(#-%=9#0''2n::$$$F0.11F0=H.,+&F+1FY2:B,IOUOU:/(:%/*/+%10:?F###
!
!
!
!
 21 
!
N>'J$;!&<5!2+8040-86!'J!#'"&!/.782+!6248B5!G0/#XN#"&)+*/#+1'&@&'4#=-#b8XN!#>.(,/%#'0/#+"&+*#XC!^?#$+*#-&%*'#,/9=(*'%+'/,#&(#1+(1/%#%/"+'/,#*'.,&/*#.*&()#1/""*#&(-/1'/,#$&'0#'0/#d.9+(#^+2&""=9+#m&%.*UQAUWF#<.%&()#&(-/1'&=(A#b8XN!#$+*#&,/('&-&/,#+*#'0/#1/""."+%#-+1'=%#'0+'#9/,&+'/,#'0/#&('/%+1'&=(#3/'$//(#'0/#@&%+""4#/L2%/**/,#2%='/&(#XC#+(,#'0/#/(,=)/(=.*#'.9=%#*.22%/**=%#2%='/&(A#2UNF##G0/#3&(,&()#=-#b8XN!#'=#XC#2%='/&(A#+(,#*.3*/S./('#3&(,&()#+(,#.3&S.&'&(+'&=(#=-#2UN#34#b8XN!A#%/@/+"/,#b8XN!e*#-.(1'&=(#+*#+(#XN#.3&S.&'&(#"&)+*/F#;.3*/S./('#,/)%+,+'&=(#=-#2UN#-=""=$&()#.3&S.&'&(+'&=(#2%=@&,/,#-.%'0/%#/@&,/(1/#'0+'#'0/#b8XN!7XC#1=92"/L#-.(1'&=(*#$&'0&(#'0/#.3&S.&'&(72%='/+*=9/#2+'0$+4#>b^^?F###V(#"+'/%#*'.,&/*A#&'#$+*#,&*1=@/%/,#'0+'#b8XN!#1=.",#.3&S.&'&(+'/#+#,&--/%/('#*.3*'%+'/A#ddRIN!A#/@/(#&(#'0/#+3*/(1/#=-#XC#2%='/&(COF#b8XN!#$+*#+"*=#*0=$(#'=#2=**/**#*'%=()#+.'=7.3&S.&'&(+'&()#2%=2/%'&/*A#&F/F#&'#1=.",#'+%)/'#&'*/"-#-=%#.3&S.&'&(+'&=(#+(,#,/)%+,+'&=(CEF#M&(,&()*#-%=9#'0/*/#"+'/%#*'.,&/*#*.))/*'/,#b8XN!#0+,#/(,=)/(=.*#XN#"&)+*/#+1'&@&'4#'0+'#"&H/"4#2"+4/,#+(#&92=%'+('#3&="=)&1+"#%="/#&(#1/""*F##G0/#1+'+"4'&1#,=9+&(#=-#b8XN!#'0+'#9/,&+'/,#.3&S.&'&(+'&=(#=-#2UN#*.3*/S./('"4#10+%+1'/%&T/,#+(,#'/%9/,#+#JdX5GK#,=9+&(#-=%#d=9="=)=.*#'=#XC!^75+%3=L4e*#G/%9&(.*#>XC!^?F##b8XN!#&*#+#EOO#H<+#2%='/&(#>DCU#++#%/*&,./*?#+(,#'0/#-=.(,&()#9/93/%#=-#'0/#-+9&"4#=-#XN#"&)+*/*#H(=$(#+*#dX5G#,=9+&(#"&)+*/*F#G0/#dX5G#,=9+&(#&(#b8XN!#&*#"=1+'/,#$&'0&(#+#NUO#++#%/*&,./#&(#'0/#5+%3=L47'/%9&(+"#=-#'0/#2%='/&(F#G0/#dX5G#,=9+&(#&*#10+%+1'/%&T/,#34#+#0&)0"4#1=(*/%@/,#a7'/%9&(+"#XI7/(T49/#3&(,&()#"=3/A#+(,#+#57'/%9&(+"#1+'+"4'&1#,=9+&(#'0+'#0+%3=%*#+(#+1'&@/#14*'/&(/#>54*?#%/*&,./UDAUWF#G0&*#54*#%/*&,./#-=%9*#'0/#*'%=()#'0&=/*'/%#3=(,#$&'0#.3&S.&'&(#,.%&()#'0/#'%+(*-/%#=('=#'0/#2%='/&(#*.3*'%+'/#
 22 
>M&).%/#EFU?F#G0/#9+Y=%&'4#=-#.3&S.&'&(+'&()#/@/('*#34#b8XN!#&(@="@/#'0/#+,,&'&=(#=-#+#`4*7QD#.3&S.'&(#10+&(A#'0.*#*.3*'%+'/*#=-#b8XN!#+%/#*.3*/S./('"4#,/)%+,/,#34#'0/#2%='/+*=9/F#6.'+'&=(*#&(#'0/#1+'+"4'&1#*&'/#=-#'0/#dX5G#,=9+&(#0+@/#3//(#&,/('&-&/,#+9=()#&(,&@&,.+"*#$&'0#!;A#+(,#,/9=(*'%+'/,#'=#,&*%.2'#b8XN!#c*#"&)+*/#+1'&@&'4#&(#/L2/%&9/('+"#1=('/L'*F##^%='/&(#9=,/"&()#+22%=+10/*#1+(#+"*=#3/#.*/,#'=#2%/,&1'#'0/#"&H/"&0==,#=-#+#)&@/(#9.'+'&=(#&(#'0/#dX5G#,=9+&(#'=#,&*%.2'#b8XN!#"&)+*/#+1'&@&'4F#G$=#*.10#9.'+'&=(*A#;/%&(/UDI#+(,#6DOI#-%+9/7*0&-'#,/"/'&=(*#+%/#9=,/"/,#&(#M&).%/#EFCF##V(#+,,&'&=(#'=#'0/#dX5G#,=9+&(A#b8XN!#0+*#*/@/%+"#%/1/2'=%#&('/%+1'&()#`]]``#9='&-*QIACOACIF#G0/*/#9='&-*#0+@/#3//(#-=.(,#'=#9/,&+'/#3&(,&()#=-#b8XN!#'=#XC#2%='/&(A#XC7,/2/(,/('#3&(,&()#'=#2UNA#+(,#3&(,&()#=-#b8XN!#'=#*'/%=&,#%/1/2'=%*F#G0/#*'/%=&,#%/1/2'=%#%/*2=(*&@/#/"/9/('#&*#1=('+&(/,#$&'0&(#'0%//#1=(*/(*.*7%/1/2'=%#&('/%+1'&()#`]]``#9='&-*A#'$=#=-#$0&10#+%/#1=('+&(/,#$&'0&(#'0/#a#'/%9&(.*A#+(,#+#'0&%,#"=1+'/,#&(#'0/#1+%3=L4#'/%9&(.*#=-#'0/#2%='/&(F#m&+#'0/*/#9='&-*#b8XN!#0+*#3//(#*0=$(#'=#&('/%+1'#$&'0#'0/#2%=)/*'/%=(/#%/1/2'=%#>^R?A#+(,%=)/(#%/1/2'=%#>!R?#+(,#/*'%=)/(#%/1/2'=%#>XR?F#G0/#-&-'0#,=9+&(#>+9&(=#+1&,#%/*&,./*#E[O7CDO?#&*#+(#+1'&@+'&=(#,=9+&(#'0+'#&*#1%&'&1+"#-=%#;'/%=&,7d=%9=(/#R/1/2'=%#'%+(*1%&2'&=(+"#1=7+1'&@+'&=(F#V(#+,,&'&=(#'=#'0/#"&)+*/#+1'&@&'4A#b8XN!#0+*#3//(#*0=$(#'=#+1'#+*#+#'%+(*1%&2'&=(+"#1=7+1'&@+'=%#=-#*'/%=&,#0=%9=(/#%/1/2'=%*COF##G0/#1=7+1'&@+'=%#'%+(*1%&2'&=(+"#+1'&@&'4#=-#b8XN!#&*#(='#1=.2"/,#'=#'0/#"&)+*/#+1'&@&'4#$&'0&(#'0/#dX5G#,=9+&(#+(,#1+(#-.(1'&=(#&(#&'*#+3*/(1/F##G0.*A#"=**#=-#'0/#'%+(*1%&2'&=(+"#-.(1'&=(#=-#b8XN!#&*#(='#1=(*&,/%/,#+#1=('%&3.'&()#-+1'=%#'0/#2+'0="=)4#=-#!;F### #
 23 
# ##
A240-5!)3P!!%-5/21,5/!B,-01,0-5!.@!N>'J$!D2,<!$9F180B2+4!70,8,2.+BF#!;#1+.*&()#9.'+'&=(*#;UDI#+(,#6DOI#+%/#&(1=%2=%+'/,#&('=#'0/#2%='/&(#*'%.1'.%/#=-#b8XN!F#G0/#3"./#*'%.1'.%/#%/2%/*/('*#'0/#XI7/(T49/A#'0/#=%+()/#+(,#)%//(#*'%.1'.%/*#+%/#'0/#a#+(,#57'/%9&(+"#=-#b8XN!A#%/*2/1'&@/"4F#G0/#4/""=$#1&%1"/*#9+%H#1+'+"4'&1#*&'/*#=(#'0/#XI#+(,#XN#/(T49/F#8='0#9.'+'&=(*#+%/#2%/*/('#&(#+#*&()"/#9=,/" >V9+)/#-%=9#;+,&H=@&1#/'#+"FA#IOEQ?F#>!? </2&1'*#'0/#XI7XN#1=92"/LA#'0/#;UDI#+(,#6DOI#9.'+'&=(*#+%/#0&)0"&)0'/,#&(#2&(H#'/L'F#a='/#'0/#2%=L&9&'4#=-#6DOI#'=#'0/#XN7DIO#*&'/A#$0&10#&*#'0/#1+'+"4'&1#*&'/#%/S.&%/,#-=%#'0/#'%+(*-/%#=-#.3&S.&'&(#'=#+#*.3*'%+'/F##!"*=#(='/#'0+'#'0/#;UDI#&*#"=1+'/,#&(#'0/#%/)&=(#$0/%/#b8XN!#H&(H*#,.%&()#'0/#&('/%+1'&=(#$&'0#'0/#XI#/(T49/#>*//#2+(/"#<?F#>8? ;&,/@&/$#=-#>!?F#>5? 50/9&1+"#&('/%+1'&=(*#*.%%=.(,&()#'0/#;UDI#9.'+'&=(F##><? </2&1'*#'0/#XI7XN7.3&S.&'&(#1=92"/L#>b3&S.&'&(#&(#2.%2"/?F##
 24 
!
!
!
!
!
!
!
!
"#$%&'!()*!+,-./0!!"# $%&'(%')*+,*!-#*!.#* /++0'&*%1*(%')*+,*23'*4567*08292%+1*%1*23'*:+12';2*+,*23'*"7<"=<8>%?8%2%1*:+0@A';B*C+2'*2392*23'*4567*08292%+1*%1,A8'1:'D*23'*E'+0'2F%:*D39@'*+,*23'*G576*:929AH2%:*:A',2I*91&*23%D*%1,A8'1:'D*23'*>%1&%1E*+,*23%D*@+:J'2*2+*23'*8>%?8%2%1*!A+)'F*A',2*:+F1'F*+,*23%D*@91'A#B************
 25 
G=#*.99+%&T/A#b8XN!#&*#+(#XN#`&)+*/#'0+'#1+'+"4T/*#'0/#.3&S.&'&(+'&=(#=-#+#*2/1&-&1#*/'#=-#2%='/&(*#&(#'0/#1/""F#6.'+'&=(*#&(#b8XN!#-=.(,#&(#!;#1+.*/#,&*%.2'&=(#=-#b8XN!#"&)+*/#+1'&@&'4#/&'0/%#,&%/1'"4#'0%=.)0#*2/1&-&1#9.'+'&=(A#=%#&(,&%/1'"4#'0%=.)0#,/*'+3&"&T+'&=(#=-#b8XN!#2%='/&(#=%#'%+(*1%&2'F##G0/%/#&*#+#*'%=()#1=%%/"+'&=(#3/'$//(#'0/#=11.%%/(1/#=-#!()/"9+(#*4(,%=9/#+(,#'0/#"=**#=-#b8XN!#1+'+"4'&1#+1'&@&'4A#*.))/*'&()#'0+'#'0/#,4*%/)."+'&=(#=-#b8XN!#*.3*'%+'/*#&*#+(#&92=%'+('#-+1'=%#&(#!;F###
)3O!&<5!N>'J$!90IB,-8,5!#:=.,<5B2B!# #
#EF34+/*'3%GHCIJKIF3&LM>IEFCBC3MJF=BAIC3IEKI3=FJFNGOKIB>?3>P3K3CMFABPBA3CFI3>P34+/*'3
CGHCIJKIFC23B?3?FGJ>?C23A>?IJBHGIFC3I>3IEF3CMFABPBA3MKIE>MELCB>O>NL3IEKI3G?=FJOBFC3'%<3#G0/#2%/1/,/('#-=%#'0&*#042='0/*&*#0+*#3//(#,/9=(*'%+'/,#&(#'0/#*'.,4#=-#b8XN!#-.(1'&=(#=.'*&,/#'0/#1=('/L'#=-#'0/#(/%@=.*#*4*'/9A#2%&=%#'=#&'*#&92"&1+'&=(#&(#!;F##</%/)."+'&=(#=-#b8XN!#*.3*'%+'/*#0+@/#3//(#&,/('&-&/,#+*#1=('%&3.'&()#-+1'=%*#&(#='0/%#(=(7(/.%="=)&1+"#,&*/+*/*A#*.10#+*#1+(1/%UU#>;//#M&).%/#EF[?F##6+(4#=-#'0/*/#b8XN!#*.3*'%+'/*#'0+'#0+@/#3//(#&,/('&-&/,#+%/#(='#%/"/@+('#&(#(/%@=.*#*4*'/9#3&="=)4#=%#(='#'0=.)0'#'=#&('/%+1'#$&'0#b8XN!#=.'*&,/#'0/#2+'0="=)&1+"#1=('/L'#=-#d^m#&(-/1'&=(F#d=$/@/%A#'0/*/#*'.,&/*#*/%@/#+*#+#2%==-7=-72%&(1&2"/#'0+'#,/%/)."+'&=(#=-#b8XN!#*.3*'%+'/*#0+@/#3//(#*0=$(#'=#1=('%&3.'/#'=#%=3.*'A#3&="=)&1+"#20/(='42/*F##
!
!
 26 
*/5+,2@:2+4!+50-.+86!B0IB,-8,5B!.@!N>'J$!V(#=%,/%#'=#&,/('&-4#(/.%=(+"#*.3*'%+'/*#=-#b8XN!A#*'.,&/*#0+@/#/92"=4/,#'0/#.*/#=-#9&1/F#G0/#b8XN!#)/(/#&*#"=1+'/,#=(#'0/#9=.*/#=%'0="=)=.*#10%=9=*=9/#[5#+(,#'0/#&92%&('&()#=-#'0&*#"=1.*#+22/+%*#'=#3/#/@=".'&=(+%&"4#1=(*/%@/,F#V(#+,,&'&=(A#'0/#0.9+(#b8XN!#2%='/&(#*/S./(1/#/L0&3&'*#WWP#*&9&"+%&'4#$&'0#'0+'#=-#'0/#9=.*/A#'0.*#+""=$&()#-=%#9=.*/#9=,/"*#=-#!;F#G0/#9=*'#1=99=(#!;#9=.*/#9=,/"#1=('+&(*#+#,/"/'&=(#&(#+#BN#i3#%/)&=(#&(#XL=(IA#%/*."'&()#&(#+#-%+9/*0&-'#9.'+'&=(#'0+'#"/+,*#'=#(=(*/(*/#9/,&+'/,#,/1+4#=-#b8XN!#'%+(*1%&2'#+(,#'='+"#"=**#=-#2%='/&(#&(#'0/#3%+&(CNF#G0/*/#9&1/#0+@/#3//(#/L'%/9/"4#.*/-."#-=%#&,/('&-4&()#9="/1."+%#'+%)/'*#=-#b8XN!A#+(,#-=%#'/*'&()#9="/1."+%#042='0/*/*#%/)+%,&()#'0/#1=('%&3.'&=(#=-#'0/*/#*.3*'%+'/*#'=#'0/#2+'0="=)4#=-#!;CQACUF#G=#&,/('&-4#*.3*'%+'/*#=-#b8XN!#&(#(/.%=(*A#+#*'/2$&*/#*/%&/*#=-#9="/1."+%#+22%=+10/*#+%/#)/(/%+""4#/92"=4/,F#5+(,&,+'/#9="/1."/*#1+(#3/#&,/('&-&/,#'0%=.)0#3&=&(-=%9+'&1*#=%#2%='/=9&1#3+*/,#+22%=+10/*A#&(1".,&()#9+**7*2/1'%=9/'%4#+(,#4/+*'7'$=#043%&,#*1%//(*NWACC7CWF#!"'/%(+'&@/"4#&(#*=9/#1+*/*A#'0/#(/.%=(+"#2+'0=204*&="=)4#=3*/%@/,#&(#!;#(/.%=(*#1+(#&(-=%9#+3=.'#+#2='/('&+"#*.3*'%+'/[O7[IF#!#2='/('&+"#1+(,&,+'/#&*#1=(*&,/%/,#+#*.3*'%+'/#=-#b8XN!#&-#&'#&*#=3*/%@/,#'=#0+@/#b8XN!7,/2/(,/('#.3&S.&'&(+'&=(#+(,#,/)%+,+'&=(#&(#B?3@BIJ>3+(,#1/""#1."'.%/#+**+4*F#!#1+(,&,+'/#*.3*'%+'/#'0+'#,&*2"+4*#b8XN!7,/2/(,/('#.3&S.'&(+'&=(#+(,#,/)%+,+'&=(#B?3@BIJ>3&*#'0/(#S.+('&-&/,3B?3@B@>3&(#'0/#3%+&(#=-#!;#9&1/F#;.3*'%+'/*#'0+'#+%/#,&%/1'#'+%)/'*#=-#b8XN!#&(#(/.%=(*#+%/#2%/,&1'/,#'=#0+@/#&(1%/+*/,#"/@/"*#=-#/L2%/**&=(#&(#!;#(/.%=(*#1=92+%/,#'=#_GF#G0&*#/L2/%&9/('+"#2&2/"&(/#0+*#"/,#'=#'0/#&,/('&-&1+'&=(#=-#*/@/%+"#(/.%=(+"#'+%)/'*#=-#b8XN!A#&(1".,&()#^8`:X5GICDA#g!GENWA#;!;5VaC[A#X^dX]VaUCCA#!R5C[A#+"20+7*4(.1"/&([OA#;iI[E#+(,#2%='/+*=9/7+**=1&+'/,#2%='/&(*#R^aEOA#b5d7`U#+(,#5gDIOWCWF###
 27 
############
!
!
!
A240-5!)3R!>2.6.42186!=-.15BB5B!.@!N>'J$!B0IB,-8,5B!</%/)."+'&=(#=-#b8XN!#>XC!^?#*.3*'%+'/*#1=('%&3.'/#'=#+#,&@/%*/#*/'#=-#3&="=)&1+"#2+'0="=)&/*#%/"+'/,#'=#1+(1/%#>&9+)/#'+H/(#-%=9#o0=.#]#/'#+"FAIOEU?F#
!
!
!
!
!
 28 
G0/#9+Y=%&'4#=-#'0/*/#*.3*'%+'/*#0+@/#+*1%&3/,#3&="=)&1+"#-.(1'&=(*F#G0/#R0=7gXM#^8`#$+*#&,/('&-&/,#&(#+#*1%//(#.*&()#:J>C>MEBOK3QFOK?NKCI>J#+(,#&*#H(=$(#'=#%/)."+'/#14'=H&(/*&*#+(,#9&)%+'&=(#=-#1/""*#,.%&()#/93%4=(&1#,/@/"=29/('CDF##!"20+7*4(.1"/&(#&*#9=*'#1=99=("4#*'.,&/,#-=%#&'*#+))%/)+'&=(#&(#+94"=&,#2"+S./*#=-#!"T0/&9/%e*#,&*/+*/Z#'0/#-.(1'&=(#&*#"+%)/"4#.(H(=$(#3.'#'0=.)0'#'=#3/#&(@="@/,#&(#(/.%='%+(*9&''/%#%/"/+*/#&(#'0/#(/%@=.*#*4*'/9F##G0/#g!8!#'%+(*2=%'/%#>g!GE?#&*#&92=%'+('#-=%#9/,&+'&()#'0/#.2'+H/#=-#/L'%+1/""."+%#g!8!#&('=#'0/#&('%+1/""."+%#1=92+%'9/('*A#+(,#;iI#&*#+#1+"1&.97+1'&@+'/,#10+((/"#'0+'#&*#/**/('&+"#-=%#%/)."+'&()#'0/#/L1&'+3&"&'4#=-#+#1/""#'0%=.)0#1=(,.1'+(1/#=-#2='+**&.9#&=(*NWA[EA[NF##G0/#-.(1'&=(#-=%#;!5;Va#&*#(='#H(=$(A#0=$/@/%A#9.'+'&=(*#&(#'0&*#)/(/#%/*."'#&(#'0/#(/.%="=)&1+"#,&*=%,/%#50+%"/@=&L7;+)./(+4A#10+%+1'/%&T/,#34#1/%/3/""+%#+'+L&+#+(,#2/%&20/%+"#(/.%=2+'04[NF##!#'+%)/'#'0+'#0+*#%/1/&@/,#+#)%/+'#,/+"#=-#+''/('&=(#=-#"+'/#&*#'0/#&99/,&+'/#/+%"4#)/(/A#!R5#>!1'&@&'4#R/)."+'/,#54'=*H/"/'=(7!**=1&+'/,#^%='/&(?[QA[UF#G%+(*1%&2'*#/(1=,&()#
'JA#+%/#"=1+"&T/,#'=#,/(,%&'/*#+(,#'JA#9Ra!#&*#'%+(*"+'/,#%+2&,"4#&(#%/*2=(*/#'=#+(#&(1%/+*/#&(#*4(+2'&1#+1'&@&'4F##!'#'0/#*4(+2*/A#!R5#2"+4*#+#1%&'&1+"#%="/#&(#%/)."+'&()#'0/#"/@/"*#=-#/L1&'+'=%4#)".'+9+'/#%/1/2'=%*#&(#'0/#2=*'*4(+2'&1#9/93%+(/A#+--/1'&()#2"+*'&1&'4#9/10+(&*9*#*.10#+*#`
 29 
10+()/*#&(#+1'&@&'4A#&(#+,,&'&=(#'=#)"=3+"#,+92/(&()#=-#/L1&'+3&"&'4#$&'0&(#(/.%=(+"#(/'$=%H*F##X^dX]Va#>XU?#&*#+#R0=!7gXM#>g.+(&(/#a.1"/='&,/#XL10+()/#M+1'=%?#'0+'#%/)."+'/*#'0/#'&9&()#=-#*4(+2*/#-=%9+'&=(#+(,#9+'.%+'&=(#&(#'0/#0&22=1+92.*#=-#9&1/CCF#<.%&()#'0/#2/%&=,#=-#/+%"4#*4(+2*/#-=%9+'&=(A#XU#+1'&@+'/*#+#*9+""#gG^+*/A#R0=!A#$0&10#&(0&3&'*#14'=*H/"/'=(#+%%+()/9/('*#$&'0&(#'0/#2=*'*4(+2'&1#,/(*&'4#+(,#*2&(/F#G0/#9+'.%+'&=(#=-#+#*4(+2*/#%/S.&%/*#+1'&@/#%/+%%+()/9/('*#+'#'0/#2=*'*4(+2'&1#*2&(/A#'0.*#'0/#2%/*/(1/#=-#XU#&(0&3&'*#'0&*#3&="=)&1+"#2%=1/**F#;&9&"+%#'=#!R5A#'0/#"/@/"*#=-#XU#/L2%/**&=(#+%/#&(1%/+*/,#&(#'0/#0&22=1+92.*#=-#'0/#!;#9=.*/F#V(1%/+*/,#"/@/"*#=-#XU#+%/#2%/,&1'/,#'=#%/*."'#&(#-/$/%#+(,#"/**#9+'.%/#*4(+2*/*#&(#'0/#0&22=1+92.*#=-#'0/#!;#9=.*/[[F###
R?3IEBC3=BCCFJIKIB>?3R3IFCI3IEF3ELM>IEFCBC3IEKI3=FJFNGOKIB>?3>P34+/*'3CGHCIJKIFC3'$,3
K?=3/1&/"R(S3A>?IJBHGIF3I>3IEF3HFEK@B>JKO3KH?>JQKOBIBFC3>HCFJ@F=3B?3'%<3R3EK@F3IFCIF=3IEBC3
ELM>IEFCBC3HL3NF?FIBAKOOL3JF=GAB?N3IEF3OF@FOC3>P3IEFCF3CGHCIJKIFC3B?=B@B=GKOOL23B?3IEF3
HKATNJ>G?=3>P3IEF3'%3Q>GCF3Q>=FO<3RP3JF=GAIB>?3>P3'$,3>J3/1&/"R(S3BC3KHOF3I>3Q>=BPL3K?L3>P3
IEF3HFEK@B>JKO3KH?>JQKOBIBFC3IEBC3U>GO=3MJ>@B=F3CGMM>JIB?N3F@B=F?AF3IEKI3IEFCF3CMFABPBA3
CGHCIJKIFC3MOKL3K3=BJFAI3J>OF3B?3IEF3CLQMI>QC3>P3'%3V9BNGJF36<;W<33###
 30 
#############
A240-5!)3S#T./56!@.-!,<5!N>'J$!B0IB,-8,5!<:=.,<5B2B3#</%/)."+'&=(#=-#!R5#+(,#X^dX]VaU#&(#!;#9&1/#&*#2%/,&1'/,#'=#%/*."'#&(#+#*2/1&-&1#,4*-.(1'&=(#&(#/L1&'+'=%4#*4(+2*/#,/@/"=29/('#+(,#-.(1'&=(F#V(#'0/#_G#1=(,&'&=(A#'0/#2=*'*4(+2'&1#2%='/&(*A#X^dX]VaU#+(,#!R5A#%/)."+'/#'0/#(.93/%#=-#*4(+2*/*#+(,#/L1&'+'=%4#)".'+9+'/#%/1/2'=%*#&(#'0/#2=*'*4(+2'&1#9/93%+(/F##V(#!;A#,/%/)."+'&=(#=-#!R5#+(,#X^dX]VaU#%/*."'*#&(#%/,.1/,#*4(+2*/#(.93/%#+(,#&(1%/+*/,#/(,=14'=*&*#=-#!6^!#%/1/2'=%*#-%=9#'0/#2=*'*4(+2'&1#9/93%+(/A#'0/%/34#,+92/(&()#/L1&'+3&"&'4#=-#'0/#(/.%=(F#>V9+)/#'+H/(#-%=9#^/'/%#;10/&--&"/#+(,#!*&9#!F#8/)A#IOEO?!!!#
 31 
)3L!U272,8,2.+B!.@!8!T.0B5!T./56!.@!$+45678+!9:+/-.75!#G=#'/*'#'0/#b`G^A#&*#+#0&)0"4#%/2%=,.1&3"/#204*&="=)&1+"#,/-&1&'#=3*/%@/,#&(#!;#(/.%=(*#=-#'0/#0&22=1+92.*CNF#V(#'0&*#/L2/%&9/('+"#2+%+,&)9A#_G#(/.%=(*#0+@/#+#*.*'+&(/,#,/2="+%&T+'&=(#-=""=$&()#0&)0#-%/S./(14#*'&9."+'&=(A#+(,#'0&*#*.*'+&(/,#%/*2=(*/#&*#+3*/('#&(#!;#(/.%=(*F##`G^#&*#'0=.)0'#'=#3/#+#1/""."+%#1=%%/"+'/#=-#"/+%(&()#+(,#9/9=%4#+(,#'0.*A#3/0+@&=%+"#*'.,&/*#0+@/#"+%)/"4#-=1.*/,#=(#9/+*.%&()#'0/#"/+%(&()#+(,#9/9=%4#-.(1'&=(*#=-#!;#9&1/F#d=$/@/%A#.("&H/#'0/#`G^#,/-&1&'*A#'0/#"/+%(&()#+(,#9/9=%4#20/(='42/*#&(#!;#9&1/#+%/#0&)0"4#@+%&+3"/#+1%=**#&(,/2/(,/('#*'.,&/*#CN7
CUA[DADIADN#>M&).%/#EFW?F#G0/#(=(7%/2%=,.1&3&"&'4#=-#"/+%(&()#+(,#9/9=%4#20/(='42/*#1+(#3/#=3*/%@/,#&(#'0/#5=(,&'&=(/,#M/+%#!**+4A#6=%%&*#_+'/%#6+T/A#+(,#a=@/"#j3Y/1'#2+%+,&)9F##
 32 
# # ############
A240-5!)3V#W8-28I262,:!2+!,<5!I5<8?2.-86!=<5+.,:=5!.@!$9!7215!!!>!?!! !#%/2%/*/('+'&@/!/L+92"/#=-#(=(7%/2%=,.1&3"/#"/+%(&()#+(,#9/9=%4#20/(='42/*F#M&(,&()*#-%=9#'0/#1=(,&'&=(/,#-/+%#+**+4#+%/#,&*2"+4/,F##G0/#,&--/%/(1/#&(#20/(='42/*#3/'$//(#!;#9&1/#&(#'0/*/#*'.,&/*#1+((='#3/#/L2"+&(/,#34#+)/A#)/(,/%A#=%#)/(/'&1#3+1H)%=.(,#>Gj^Z#&9+)/#'+H/(#-%=9#d.+()#d#/'#+"FA#IOENA#8jGGj6n#V9+)/#'+H/(#-%=9#h&+()#d#/'#+"FA#EWWW?F##>8?!! G0/#042=+1'&@&'4#20/(='42/#&(#!;#9&1/#,/2/(,*#=(#)/(/'&1#*'%+&(#+(,#+)/F#G0/#EIW;@X#*'%+&(#,=/*#(='#2%=,.1/#+#20/(='42/#$0/(#9/+*.%/,#+'#+(#/S.&@+"/('#'&9/#2=&('#'=#'0/#5U[8C#1=.('/%2+%'#>V9+)/#'+H/(#-%=9#d.+()#/'#+"FA#IOEN?F#!
A B 
 33 
n#
g#>M&).%/#EFEO?F##8/0+@&=%+"#,/-&1&'*#'0+'#@+%4#+11=%,&()#'=#)/(,/%A#+)/#+(,#*'%+&(#$/%/#1=(1".,/,#'=#3/#1"&(&1+""4#(=(7.*/-."#20/(='42/*F##_&'0#'0/*/#).&,/"&(/*A#V#0+@/#,/*1%&3/,#&(#'0&*#'0/*&*#'0/#1=(*&*'/('#-/+'.%/*#=-#Y.@/(&"/#
 34 
9&1/#$&'0#!()/"9+(#;4(,%=9/#'0+'#1+(#3/#.*/,#'=#/L+9&(/#'0/#9/10+(&*9*#=-#1/""."+%A#(/.%+"#1&%1.&'A#+(,#3/0+@&=%+"#,4*-.(1'&=(#'0+'#"/+,#'=#!;F#####
!
!
!
A240-5!)3)X!91<578,21!.@!I5<8?2.-86!I8,,5-:!G0/#'&9/1=.%*/#-=%#3/0+@&=%+"#'/*'&()#=-#!;#+(,#_G#9&1/#&*#,/2&1'/,F#G0/#Y.@/(&"/#,/@/"=29/('+"#2/%&=,#&*#,/-&(/,#34#2=*'(+'+"#,+4#O#'0%=.)0#2=*'(+'+"#,+4#QIA#'0/#+,."'#,/@/"=29/('+"#2/%&=,#&*#f#2=*'(+'+"#,+4#QI#>+)/#=-#*/L.+"#9+'.%&'4#&(#9&1/?F#G0/#,=''/,#"&(/#*&)(&-&/*#'0/#/+%"&/*'#2.3"&*0/,#3/0+@&=%+"#,/-&1&'#&(#'0/#!;#9=.*/F
0          5         10         15         20         25           30         35            40            45           - ! !120        !
Motor Behavior!
Communication!
Seizures+ EEG!
Adulthood!Juvenile Period!
Postnatal Day!
= Earliest published behavioral deficit in the AS mouse!
 35 
(5@5-5+15B!
!
1. Baio J: Prevalence of Autism Spectrum DisordeAmong Children Aged 8 Years — 
Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 
2010. MMWR 63:1-22, 2014 
 
2. Parellada M, Penzol MJ, Pina L, et al: The neurobiology of autism spectrum disorders. 
Eur Psychiatry 29:11-9, 2014 
 
3. Kasari C, Brady N, Lord C, et al: Assessing the minimally verbal school-aged child with 
autism spectrum disorder. Autism Res 6:479-93, 2013 
 
4. Tager-Flusberg H, Kasari C: Minimally verbal school-aged children with autism 
spectrum disorder: the neglected end of the spectrum. Autism Res 6:468-78, 2013 
 
5. Dawson G, Osterling J, Meltzoff AN, et al: Case Study of the Development of an Infant 
with Autism from Birth to Two Years of Age. Journal of Applied Developmental 
Psychology 21:299-313, 2000 
 
6. Lee BH, Smith T, Paciorkowski AR: Autism spectrum disorder and epilepsy: Disorders 
with a shared biology. Epilepsy Behav 47:191-201, 2015 
 
7. Kindregan D, Gallagher L, Gormley J: Gait deviations in children with autism spectrum 
disorders: a review. Autism Res Treat 2015:741480, 2015 
 
8. Maski KP, Jeste SS, Spence SJ: Common neurological co-morbidities in autism spectrum 
disorders. Curr Opin Pediatr 23:609-15, 2011 
 
9. Robinson EB, Neale BM, Hyman SE: Genetic research in autism spectrum disorders. 
Curr Opin Pediatr, 2015 
 
10. Neale BM, Kou Y, Liu L, et al: Patterns and rates of exonic de novo mutations in autism 
spectrum disorders. Nature 485:242-5, 2012 
 
11. Iossifov I, O'Roak BJ, Sanders SJ, et al: The contribution of de novo coding mutations to 
autism spectrum disorder. Nature 515:216-21, 2014 
 
12. Iossifov I, Ronemus M, Levy D, et al: De novo gene disruptions in children on the 
autistic spectrum. Neuron 74:285-99, 2012 
 
13. De Rubeis S, Buxbaum JD: Genetics and genomics of autism spectrum disorder: 
embracing complexity. Hum Mol Genet 24:R24-31, 2015 
 
14. Behnia F, Parets SE, Kechichian T, et al: Fetal DNA methylation of autism spectrum 
disorders candidate genes: association with spontaneous preterm birth. Am J Obstet 
Gynecol 212:533 e1-9, 2015 
 36 
15. Ecker C, Bookheimer SY, Murphy DGM: Neuroimaging in autism spectrum disorder: 
brain structure and function across the lifespan. The Lancet Neurology, 2015 
 
16. Peters SU, Kaufmann WE, Bacino CA, et al: Alterations in white matter pathways in 
Angelman syndrome. Dev Med Child Neurol 53:361-7, 2011 
 
17. Ziats MN, Edmonson C, Rennert OM: The autistic brain in the context of normal 
neurodevelopment. Front Neuroanat 9:115, 2015 
 
18. Liu X, Takumi T: Genomic and genetic aspects of autism spectrum disorder. Biochem 
Biophys Res Commun 452:244-53, 2014 
 
19. Oddi D, Crusio WE, D'Amato FR, et al: Monogenic mouse models of social dysfunction: 
implications for autism. Behav Brain Res 251:75-84, 2013 
 
20. Dindot SV, Antalffy BA, Bhattacharjee MB, et al: The Angelman syndrome ubiquitin 
ligase localizes to the synapse and nucleus, and maternal deficiency results in abnormal 
dendritic spine morphology. Hum Mol Genet 17:111-8, 2008 
 
21. Gogolla N, Takesian AE, Feng G, et al: Sensory integration in mouse insular cortex 
reflects GABA circuit maturation. Neuron 83:894-905, 2014 
 
22. Cianfaglione R, Clarke A, Kerr M, et al: A national survey of Rett syndrome: age, 
clinical characteristics, current abilities, and health. Am J Med Genet A 167:1493-500, 
2015 
 
23. Tatsuya Kishino MLJW: UBE3A/E6-AP mutations cause Angelman Syndrome. Nature 
Genetics, 1997 
 
 24. Jeavons BDBaPM: The 'Happy Puppet' Syndrome. Arch. Dis. Childh 42:298, 1967 
 
25. Glessner JT, Wang K, Cai G, et al: Autism genome-wide copy number variation reveals 
ubiquitin and neuronal genes. Nature 459:569-73, 2009 
 
26. Angelman H: 'Puppet' children. A report on 3 cases. Develop. Med. Child Neurol. 7, 1965 
 
27. Tan WH, Bacino CA, Skinner SA, et al: Angelman syndrome: Mutations influence 
features in early childhood. Am J Med Genet A 155A:81-90, 2011 
 
28. j Cayton-Smith LL: Angelman Syndrome: a review of the clinical and genetic aspects. 
Journal of Medical Genetics 40:87-95, 2003 
 
29. Williams CA: The behavioral phenotype of the Angelman syndrome. Am J Med Genet C 
Semin Med Genet 154C:432-7, 2010 
 
 37 
30. Williams CA, Driscoll DJ, Dagli AI: Clinical and genetic aspects of Angelman syndrome. 
Genet Med 12:385-95, 2010 
 
31. Larson AM, Shinnick JE, Shaaya EA, et al: Angelman syndrome in adulthood. Am J Med 
Genet A 167A:331-44, 2015 
 
32. Thibert RL, Larson AM, Hsieh DT, et al: Neurologic manifestations of Angelman 
syndrome. Pediatr Neurol 48:271-9, 2013 
 
33. Hall BD: Adjunct diagnostic test for Angelman syndrome: the tuning fork response. Am J 
Med Genet 109:238-40, 2002 
 
34. Vendrame M, Loddenkemper T, Zarowski M, et al: Analysis of EEG patterns and 
genotypes in patients with Angelman syndrome. Epilepsy Behav 23:261-5, 2012 
 
35. Pelc K, Boyd SG, Cheron G, et al: Epilepsy in Angelman syndrome. Seizure 17:211-7, 
2008 
 
36. Dagli A, Buiting K, Williams CA: Molecular and Clinical Aspects of Angelman 
Syndrome. Molecular Syndromology, 2011 
 
 37. agli AI MJ, Williams CA.: Angelman Syndrome, GeneReviews® 1998 
 
38. Radstaake M, Didden R, Oliver C, et al: Functional analysis and functional 
communication training in individuals with Angelman syndrome. Dev Neurorehabil 
15:91-104, 2012 
 
39. Kiyoshi Egawa KK, Koichi Inoue, Masakazu Takayama, Chitoshi Takayama, Shinji 
Saitoh, Tatsuya Kishino,Masatoshi Kitagawa, Atsuo Fukuda: Decreased Tonic Inhibition 
in Cerebellar Granule Cells Causes Motor Dysfunction in a Mouse Model of Angelman 
Syndrome. Sci Transl Med 4:1-10 
 
40. Wilson BJ, Sundaram SK, Huq AH, et al: Abnormal language pathway in children with 
Angelman syndrome. Pediatr Neurol 44:350-6, 2011 
 
41. Mertz LG, Thaulov P, Trillingsgaard A, et al: Neurodevelopmental outcome in Angelman 
syndrome: genotype-phenotype correlations. Res Dev Disabil 35:1742-7, 2014 
 
42. Bekim Sadikovic PF, Victor Wei Zhang, Patricia A. Ward, Irene Miloslavskaya, William 
Rhead, Richard Rosenbaum, RObert Gin, Benjamin Roa and Ping Fang: Mutation Update 
for UBE3A variants in Angelman Syndrome. Human genome variation society 35:1407-
1417, 2014 
 
43. Coppola A, Ruosi P, Santulli L, et al: Neurological features and long-term follow-up in 
15q11.2-13.1 duplication. Eur J Med Genet 56:614-8, 2013 
 38 
45. Noor A, Dupuis L, Mittal K, et al: 15q11.2 Duplication Encompassing Only the UBE3A 
Gene Is Associated with Developmental Delay and Neuropsychiatric Phenotypes. Hum 
Mutat 36:689-93, 2015 
 
46. Mabb AM, Judson MC, Zylka MJ, et al: Angelman syndrome: insights into genomic 
imprinting and neurodevelopmental phenotypes. Trends Neurosci 34:293-303, 2011 
 
47. Robert D. Nicholls JHMK, Merlin G. Butlet, Susan Karam & Marc Lalande: Genetic 
imprinting suggested by maternal heterodisomy in non-deletion Prader-Willi syndrome. 
Nature 342:281-284, 1989 
 
48. Meng L, Person RE, Huang W, et al: Truncation of Ube3a-ATS unsilences paternal 
Ube3a and ameliorates behavioral defects in the Angelman syndrome mouse model. 
PLoS Genet 9:e1004039, 2013 
 
49. Huang HS, Allen JA, Mabb AM, et al: Topoisomerase inhibitors unsilence the dormant 
allele of Ube3a in neurons. Nature 481:185-9, 2012 
 
50. Yamasaki K: Neurons but not glial cells show reciprocal imprinting of sense and 
antisense transcripts of Ube3a. Human Molecular Genetics 12:837-847, 2003 
 
51. Grier MD, Carson RP, Lagrange AH: Toward a Broader View of Ube3a in a Mouse 
Model of Angelman Syndrome: Expression in Brain, Spinal Cord, Sciatic Nerve and 
Glial Cells. PLoS One 10:e0124649, 2015 
 
52. Malkki H: Neurodevelopmental disorders. Unmuting Ube3a in mice alleviates Angelman 
syndrome. Nat Rev Neurol 11:66, 2015 
 
53. Meng L, Ward AJ, Chun S, et al: Towards a therapy for Angelman syndrome by targeting 
a long non-coding RNA. Nature 518:409-12, 2015 
 
54. Jon M. Huibregtse MSaPMH: A cellular protein mediates association of p53 with the E6 
oncoprotein of human papillomavirus types 16 or 18. The EMBO Journal 10:4129-4135, 
1991 
 
55. Xiaofang Zhou NJ, Shishan Deng, Cai Huang: The Function of Ubiquitin Protein Ligase 
E3A and its Roles in Human Diseases. Journal of Biochemistry and Molecular Biology 
1:14-18, 2015 
 
56. Chowdhury M, Enenkel C: Intracellular Dynamics of the Ubiquitin-Proteasome-System. 
F1000Res 4:367, 2015 
 
57. Kravtsova-Ivantsiv Y, Sommer T, Ciechanover A: The lysine48-based polyubiquitin 
chain proteasomal signal: not a single child anymore. Angew Chem Int Ed Engl 52:192-
8, 2013 
 39 
58. Winn PJ, Religa TL, Battey JN, et al: Determinants of functionality in the ubiquitin 
conjugating enzyme family. Structure 12:1563-74, 2004 
 
59. Huang L: Structure of an E6AP-UbcH7 Complex: Insights into Ubiquitination by the E2-
E3 Enzyme Cascade. Science 286:1321-1326, 1999 
 
60. El Hokayem J, Nawaz Z: E6AP in the brain: one protein, dual function, multiple diseases. 
Mol Neurobiol 49:827-39, 2014 
 
61. WYNN H. KAO SLB, ANDREA L. TALIS, JON M. HUIBREGTSE, AND PETER M. 
HOWLEY Human Papillomavirus Type 16 E6 Induces Self-Ubiquitination of the E6AP 
Ubiquitin-Protein Ligase. JOURNAL OF VIROLOGY 74:408–6417, 2000 
 
62. Cooper EM, Hudson AW, Amos J, et al: Biochemical analysis of Angelman syndrome-
associated mutations in the E3 ubiquitin ligase E6-associated protein. J Biol Chem 
279:41208-17, 2004 
 
63. Yong-hui Jiang DA, Urs Albrecht, Coleen M. Atkins, Jeffrey L. Noebels, Gregor Eichele, 
J. David Sweatt and Arthur L. Beaudet: Mutation of the Angelman Ubiquitin Ligase in 
Mice Causes Increased Cytoplasmic p53 and Deficits of Contextual Learning and Long-
Term Potentiation. Neuron 21:799-811, 1998 
 
64. Huang HS, Burns AJ, Nonneman RJ, et al: Behavioral deficits in an Angelman syndrome 
model: effects of genetic background and age. Behav Brain Res 243:79-90, 2013 
 
65. Jana NR: Understanding the pathogenesis of Angelman syndrome through animal 
models. Neural Plast 2012:710943, 2012 
 
66. Margolis SS, Salogiannis J, Lipton DM, et al: EphB-mediated degradation of the RhoA 
GEF Ephexin5 relieves a developmental brake on excitatory synapse formation. Cell 
143:442-55, 2010 
 
67. Greer PL, Hanayama R, Bloodgood BL, et al: The Angelman Syndrome protein Ube3A 
regulates synapse development by ubiquitinating arc. Cell 140:704-16, 2010 
 
68. Reiter LT, Seagroves TN, Bowers M, et al: Expression of the Rho-GEF Pbl/ECT2 is 
regulated by the UBE3A E3 ubiquitin ligase. Hum Mol Genet 15:2825-35, 2006 
 
69. Lee SY, Ramirez J, Franco M, et al: Ube3a, the E3 ubiquitin ligase causing Angelman 
syndrome and linked to autism, regulates protein homeostasis through the proteasomal 
shuttle Rpn10. Cell Mol Life Sci 71:2747-58, 2014 
 
70. Mulherkar SA, Sharma J, Jana NR: The ubiquitin ligase E6-AP promotes degradation of 
alpha-synuclein. J Neurochem 110:1955-64, 2009 
 
 40 
71. Sun J, Zhu G, Liu Y, et al: UBE3A Regulates Synaptic Plasticity and Learning and 
Memory by Controlling SK2 Channel Endocytosis. Cell Rep 12:449-61, 2015 
 
73. Blumkin L, Bradshaw T, Michelson M, et al: Molecular and functional studies of retinal 
degeneration as a clinical presentation of SACS-related disorder. Eur J Paediatr Neurol 
19:472-6, 2015 
 
74. Shepherd JD, Bear MF: New views of Arc, a master regulator of synaptic plasticity. Nat 
Neurosci 14:279-84, 2011 
 
75. Bramham CR, Worley PF, Moore MJ, et al: The immediate early gene arc/arg3.1: 
regulation, mechanisms, and function. J Neurosci 28:11760-7, 2008 
 
76. Plath N, Ohana O, Dammermann B, et al: Arc/Arg3.1 is essential for the consolidation of 
synaptic plasticity and memories. Neuron 52:437-44, 2006 
 
 77. BEG PSAA: Angelman syndrome connections. nature 468:907-908, 2010 
 
78. Miura K, Kishino T, Li E, et al: Neurobehavioral and electroencephalographic 
abnormalities in Ube3a maternal-deficient mice. Neurobiol Dis 9:149-59, 2002 
 
79. Mardirossian S, Rampon C, Salvert D, et al: Impaired hippocampal plasticity and altered 
neurogenesis in adult Ube3a maternal deficient mouse model for Angelman syndrome. 
Exp Neurol 220:341-8, 2009 
 
80. Yashiro K, Riday TT, Condon KH, et al: Ube3a is required for experience-dependent 
maturation of the neocortex. Nat Neurosci 12:777-83, 2009 
 
81. Riday TT, Dankoski EC, Krouse MC, et al: Pathway-specific dopaminergic deficits in a 
mouse model of Angelman syndrome. J Clin Invest 122:4544-54, 2012 
 
82. van Woerden GM, Harris KD, Hojjati MR, et al: Rescue of neurological deficits in a 
mouse model for Angelman syndrome by reduction of alphaCaMKII inhibitory 
phosphorylation. Nat Neurosci 10:280-2, 2007 
 
83. Godavarthi SK, Sharma A, Jana NR: Reversal of reduced parvalbumin neurons in 
hippocampus and amygdala of Angelman syndrome model mice by chronic treatment of 
fluoxetine. J Neurochem 130:444-54, 2014 
!
 41 
!
!
!
!
!
!
!
!
"#$%&'(!)!
*+,-./+01,2+!345,6,57!,8!3!9.6+8,1+!$8:+1;38!*78</=;+!;=.>+!;=<+1!,>!355+8.35+<!?7!
/+<.4,8:!!"#!+@A/+>>,=8!
!
 42 
$.5B=/!"=85/,?.5,=8>!"#$#%&#!'()!$#*#+#!),-./(,)!0,-,'012!!"#$#%&#!'()!3#4#!5,06708,)!0,-,'012!4#"#9#!'()!:#;#!17(<0.=><,)!(,?!0,'/,(<-@'('AB<.1!<77A-!"#$#%&#!'()!4#"#9#!'('ABC,)!)'<'!!"#$#%&#D!3#4#D!'()!$#*#+#!?07<,!<2,!5'5,0#!
!
!
!
! !
 43 
:<!<2,!<.8,!76!<2,!->=8.--.7(!76!<2.-!).--,0<'<.7(D!8>12!76!<2,!?70E!50,-,(<,)!.-!<2.-!12'5<,0!2'-!=,,(!1785.A,)!'-!'!8'(>-10.5<!,(<.<A,)F!
!
*+,-./+01,2+!345,6,57!,8!3!9.6+8,1+!$8:+1;38!*78</=;+!;=.>+!;=<+1!,>!355+8.35+<!?7!
/+<.4,8:!$("!+@A/+>>,=8!!
!
!
$.5B=/>!38<!3.5B=/!3<</+>>+>!"'A,./2!$'(),A%&0,28'D!372(!4'A7/.'((.-'D!4'8,,0!"#!92'8(,=D!:A,G'(),0!;7<,(=,0/=D!$.12',A!+0,,(=,0/'H!!
'I,>07=.7A7/BD!J'0K'0)!$,).1'A!41277AD!&7-<7(!$:!LMHHNO!J'0K'0)!$,).1'A!41277AD!&7-<7(!$:!LMHHNO!=9,5'0<8,(<!76!I,>07A7/BD!&7-<7(!"2.A)0,(P-!J7-5.<'AD!J'0K'0)!$,).1'A!41277AD!&7-<7(D!$'--'12>-,<<-!LMHHN!!
C"=//+>A=8<,8:!3.5B=0!$.12',A!*#!+0,,(=,0/!Q8,/R28-#2'0K'0)#,)>S!! !
 44 

!!!
 45 
`![#!!:4!8.1,!2'K,!=,,(!>-,6>A!670!),6.(.(/!<2,!1,AA>A'0!'()!87A,1>A'0!6>(1<.7(!76!W&*Z:!.(!(,>07(-#!!Y2,!!"#$%&/,(,!,(17),-!'(!*Z!>=.]>.<.(!A./'-,!<2'<!1'<'ABC,-!<2,!')).<.7(!76!>=.]>.<.(!<7!-5,1.6.1!507<,.(-!<2,0,=B!87).6B.(/!<2,.0!6>(1<.7(!'()@70!<'0/,<.(/!<2,!507<,.(!670!),/0')'<.7(!=B!<2,!507<,'-78,!a#!!;,1,(<!-<>).,-!2'K,!.),(<.6.,)!-,K,0'A!(,>07('A!507<,.(-!<2'<!'0,!8.-%0,/>A'<,)!.(!:4!(,>07(-D!.(1A>).(/!":$bTTD!*\J*cTIND!:;"D!+:YHD!dH%I:b:D!I:XH#[!'()!:Ibe;TI%+!f%HM#!!478,!76!<2,-,!507<,.(-!'0,!<27>/2<!<7!=,!).0,1<!->=-<0'<,-!76!W&*Z:!?27-,!,G50,--.7(!.-!.(10,'-,)!.(!<2,!'=-,(1,!76!W&*Z:!)>,!<7!<2,!6'.A>0,!76!<2,-,!->=-<0'<,-!<7!=,!<'0/,<,)!670!),/0')'<.7(#!!J7?,K,0D!.<!.-!57--.=A,!<2'<!-78,!
 46 
76!<2,-,!507<,.(-!'0,!(7<!).0,1<!<'0/,<-!76!<2,!W&*Z:!A./'-,!=><!0'<2,0D!<2,.0!8.-%0,/>A'<.7(!17>A)!=,!'(!.().0,1<!17(-,]>,(1,!76!<2,!).-0>5<.7(!76!W&*Z:!6>(1<.7(#!T<!0,8'.(-!<7!=,!),<,08.(,)!27?!507<,.(-!<2'<!'0,!8.-%0,/>A'<,)!>57(!A7--!76!W&*Z:!17(<0.=><,!<7!<2,!,<.7A7/B!76!:4#!!Y2,!:4!87>-,!87),A!2'-!=,,(!>-,)!,G<,(-.K,AB!670!<,-<.(/!57<,(<.'A!)0>/-!'()!/,(,!<2,0'5.,-!670!<0,'<.(/!:4!HZDH^#!g
!"#$%!<2,0,!.-!'!).-0>5<.7(!76!,G1.<'<70B@.(2.=.<70B!='A'(1,!.(!<2,!=0'.(![DHLDHMDHZDHa%Hh#!T(!')).<.7(D!:4!8.1,!).-5A'B!),6,1<-!.(!A,'0(.(/!'()!8,870BD!87<70!1770).('<.7(D!A71787<70!'1<.K.<B!H^DHaDMLDMH!'()!'(!.(10,'-,)!(>8=,0!76!-,.C>0,-!?2,(!,G57-,)!<7!'(!'>).7/,(.1!12'AA,(/,![DHH#!!J7?,K,0D!<2,0,!2'K,!=,,(!17(6A.1<.(/!0,570<-!0,/'0).(/!<2,!07=>-<(,--!76!<2,!:4!52,(7<B5,-!7=-,0K,)!MM#!g(,!57--.=A,!,G5A'('<.7(!670!<2,!).-5'0'<,!6.().(/-!.-!<2'<!<2,-,!-<>).,-!2'K,!=,,(!17()>1<,)!>-.(/!')>A<!8.1,!'<!'!<.8,!?2,(!<2,!'=,00'(<!:4!=,2'K.70-!8'B!2'K,!=,/>(!<7!->=-.),#!!T(),,)D!-,.C>0,-!'0,!5078.(,(<!.(!:4!.(!,'0AB!12.A)277)!QiZ!B,'0-!76!'/,S!=><!=,/.(!<7!K'0B!17(-.),0'=AB!.(!60,]>,(1B!'()!-,K,0.<B!'-!12.A)0,(!?.<2!:4!'/,!MDMZDM^#!T(!')).<.7(D!-78,!170,!6,'<>0,-!76!2>8'(!:4!<2'<!'0,!-,,(!.(!,'0AB!12.A)277)!->12!'-!'=(708'A!1788>(.1'<.7(D!2'K,!(7<!B,<!=,,(!12'0'1<,0.C,)!.(!<2,!:4!87>-,#!j.('AABD!.<!
 47 
j.('AABD!?,!6.()!<2'<!0,)>1.(/!<2,!A,K,A!76!<2,!'1<.K.<B%0,/>A'<,)!1B<7-E,A,<'A!507<,.(!:;"!.(!:4!8.1,!-,A,1<.K,AB!'<<,(>'<,-!<2,!-,.C>0,%A.E,!'()!**+!),6.1.<-!.(!<2,-,!'(.8'A-#!!V,!17(1A>),!<2'<!B7>(/!:4!8.1,!0,1'5.<>A'<,!2'AA8'0E!6,'<>0,-!76!:4!.(!12.A)0,(D!'()!<2'<!<2,!,'0AB!7(-,<!=,2'K.70-!?,!2'K,!12'0'1<,0.C,)!.(!<2,-,!8.1,!8'B!507K.),!(,?!'5507'12,-!670!,K'A>'<.(/!<2,!,66.1'1B!76!<2,0'5.,-!670!<0,'<.(/!:4!.(!2>8'(-#!
!
!
!
!
!
!
!
 48 
)DG!H35+/,31>!38<!H+5B=<>!
&
$8,;31>I!!!$.1,!2'0=70.(/!'!(>AA!8><'<.7(!.(!!'($)!?,0,!7=<'.(,)!6078!3'1E-7(!k'=70'<70.,-!'()!8'.(<'.(,)!7(!"Na&k@[3!_&[`!70!HMh4M@4K\'-"0A!_HMh`!='1E/07>()#!j70!'AA!=,2'K.70'A!,G5,0.8,(<-D!&[!W=,Z'8l@5%!6,8'A,-!?,0,!>-,)!670!8'<.(/D!?.<2!<2,!,G1,5<.7(!76!,G5,0.8,(<-!5,06708,)!7(!'!5>0,!HMh!='1E/07>()#!Y7!/,(,0'<,!8.1,!<2'<!2'K,!8'<,0('A!),6.1.,(1B!76!!'($)!_0,6,00,)!<7!.(!<2.-!5'5,0!'-!:4!8.1,`D!W=,Z'8l@5%!6,8'A,-!?,0,!107--,)!?.<2!,.<2,0!'!&[!70!HMh!?.A)<B5,!8'A,#!jH!507/,(B!_JB=0.)`!0,50,-,(<!'!NLFNL!17(<0.=><.7(!76!&[!'()!HMh#!j70&/,(,<.1!.(<,0'1<.7(!,G5,0.8,(<-D!8'A,!8.1,!2,<,07CB/7>-!670!%*+!_0,6,00,)!<7!'-!:;"l@%`!70!#,-(./01&_0,6,00,)!<7!'-!*Nl@%`!?,0,!107--,)!<7!W=,Z'8l@5%!6,8'A,-#!:;"l@%!8.1,!?,0,!507K.),)!'-!'!/.6<!6078!<2,!A'=!76!90#!\'>A!V70A,B!'()!8'.(<'.(,)!7(!'!&[!='1E/07>()!670!'<!A,'-<!HL!/,(,0'<.7(-#!!*Nl@%!8.1,!?,0,!/,(,0'<,)!.(%27>-,!'()!8'.(<'.(,)!7(!'!HMh!='1E/07>()!670!'<!A,'-<!HL!/,(,0'<.7(-#!:(.8'A-!?,0,!E,5<!7(!'!HM%2!A./2<@)'0E!1B1A,!'()!/.K,(!677)!'()!?'<,0!')!A.=#!:AA!,G5,0.8,(<-!?,0,!5,06708,)!'()!'('ABC,)!=A.()!<7!/,(7<B5,#!+,(7<B5.(/!?'-!17()>1<,)!=B!\";!6078!<'.A!<.-->,!-'85A,-!'<!A,'-<!<?.1,!670!K'A.)'<.7(#!:AA!5071,)>0,-!?,0,!17()>1<,)!.(!-<0.1<!1785A.'(1,!?.<2!<2,!T(-<.<><.7('A!:(.8'A!"'0,!'()!W-,!"788.<<,,!'<!J'0K'0)!$,).1'A!41277A#&!
H35+/8310,>=135,=8!,8<.4+<!J15/3>=8,4!K=431,-35,=8!$>>37!L%MN!G!O!CPQI!!\0,/('(1.,-!?,0,!0,170),)!=B!K.->'A!.(-5,1<.7(!'()!<2,!)'B!76!=.0<2!?'-!17(-.),0,)!57-<('<'A!)'B!L!Q\I9!LS#!j70!<2,!)>0'<.7(!76!<2,!,G5,0.8,(<!Q*Hf!%!\I9!HhS!<2,!8'<.(/!5'.0!0,8'.(,)!<7/,<2,0!.(!<2,!1'/,!'()!<2,!=,)).(/!?'-!12'(/,)!8.(.8'AAB!Q\I9!fD!\I9!H[S!<7!
 49 
E,,5!7)70-!>(5,0<>0=,)#!W4X!<,-<.(/!711>00,)!,K,0B!7<2,0!)'B!6078!\I9!Z%Hh!)>0.(/!<2,!27>0-!h:$!m!H\$#!\>5-!?,0,!87K,)!6078!<2,!278,!1'/,!.(<7!<2,!0,170).(/!,(K.07(8,(<!=B!27A).(/!<2,.0!<'.AD!'()!<2,!50,-,(1,!70!'=-,(1,!76!2.()A.8=!1A'-5!'1<.K.<B!?'-!(7<,)#!\>5-!?,0,!E,5<!.(!'!?'08.(/!1'/,!>(<.A!'AA!A.<<,08'<,-!2')!=,,(!<,-<,)#!!! T().K.)>'A!5>5-!?,0,!5A'1,)!.(<7!'!5A'-<.1!=>1E,<!17(<'.(,)!?.<2.(!'!-7>()!'<<,(>'<,)!12'8=,0!Q$,)%:--71.'<,-D!T(1#S!670!67>0!8.(><,-#!W4X-!?,0,!-'85A,)!'<!MNL!EJC!>-.(/!'!=07')='()!8.107527(,!Q:K.-76<S!->-5,(),)!HL!.(12,-!'=7K,!<2,!5>5#!j7AA7?.(/!<,-<.(/!7(!\I9!ZD!5>5-!?,0,!/.K,(!>(.]>,!.),(<.6.,0-!7(!<2,.0!5'?-!>-.(/!<'<<77!.(E!Qb,<12>8!T(1#S#!!!
J15/3>=8,4!K=431,-35,=8!$8317>,>2&
&j70! '17>-<.1'A! '('AB-.-D! -7>()! 6.A,-! ?,0,! '('ABC,)! >-.(/! :K.-76<! 4:4k'=! \07!QK,0-.7(!^#NLS#!Y2,! <7<'A! 67>0!8.(><,! 0,170).(/! <.8,! 670! ,'12! <0.'A!?'-!>-,)! 670! '('AB-.-#!j'-<! j7>0.,0! Y0'(-6708'<.7(! ?'-! 17()>1<,)! >-.(/! J'88.(/! ?.()7?D! NHM! jjY! k,(/<2D!HLLn! j0'8,! '()! NLn! gK,0A'5! 507K.).(/! ^ff! JC! 60,]>,(1B! 0,-7A><.7(! '()! H#LM^! 8-!<,8570'A!0,-7A><.7(#!W4X!),<,1<.7(!?'-!5,06708,)!>-.(/!'!6.G,)!'85A.<>),!<20,-27A)!76!%[L!)&!'()!8.(.8>8!1'AA!)>0'<.7(!76!H!8-#!j70!-<0>1<>0'A!'('AB-.-D!?,!8,'->0,)!<2,!60,]>,(1B!QJCS!'<!<2,!57.(<!76!8'G.8>8!'85A.<>),!'()!<2,!8,'(!'85A.<>),!76!,'12!K71'A.C'<.7(#!j70!<2,!<,8570'A!'('AB-.-D!?,!'('ABC,)!.(<,01'AA!.(<,0K'A!Q<2,!<.8,!.(%=,<?,,(!-,]>,(<.'A!1'AA-!<2'<! 711>0! A,--! <2'(!HLL!8-! 6078!7(,! '(7<2,0S! '()! .(<,0=>0-<! .(<,0K'A! Q<.8,! .(%=,<?,,(!=>0-<-! 76! 1'AA-! <2'<! 711>0!870,! <2'(!HLH!8-! '()! A,--! <2'(!NLL8-! 6078!7(,! '(7<2,0S! 670!,'12! 0,170).(/! Q-,,! j./>0,! M#HS#! &'1E/07>()@87K,8,(<! (7.-,! ?'-! ,A.8.('<,)! >-.(/! '(!,(<075B!'A/70.<28!?.<2!'!8'G!,(<075B!<20,-27A)!76!L#^#!W4X!)'<'!?'-!K.->'AAB!.(-5,1<,)!670!
 50 
6'A-,!57-.<.K,-!'()!'('AB-.-!-,<<.(/-!?,0,!K'A.)'<,)!?.<2!<0.'A-!76!')>A<!8.1,!87K.(/!60,,AB!'=7><! <2,! <,-<.(/! 12'8=,0#! o,07! K71'A.C'<.7(-! .),(<.6.,)! .(! 7>0! '><78'<,)! '('AB-.-!?,0,!0,87K,)!6078!<2,!)'<'-,<!70!87).6.,)#!!
&
!
!
!
R,:./+! )DC! *4/++8>B=5! =F! J15/3>=8,4! K=431,-35,=8! $8317>,>! <+A,45,8:! S85+/4311! 38<!
S85+/?./>5! S85+/631D!$'<,0('AAB! .-7A'<,)!W4X-! '0,! K.->'A.C,)! '()! '('ABC,)! >-.(/! :K.-76<!47>()! :('AB-.-! 476<?'0,#! *G'85A,-! 76! <2,! .(<,01'AA! .(<,0K'A! '0,! ),5.1<,)! '-! p:q! '()!,G'85A,-!76!<2,!.(<,0=>0-<!.(<,0K'A!'0,!),5.1<,)!'-!p&#q!Y.8,!?.()7?!.-!'5507G.8'<,AB!7(,!-,17()#!! !
BB
A A
A
m
pl
itu
de
 
(dB
)
Fr
eq
u
en
cy
 
(kH
z)
Inter-call Interval Inter-burst Interval Vocalization Count
A
 51 
TA+8!R,+1<!$>>37!L%MN!)CQI!!!:1<.K.<B!?'-!8,'->0,)!Q?,'(.(/!'/,S!.(!'!MLq!GMLq!GMLq!5A,G./A'--!=7G!.(!MLL!A>G!A./2<.(/#!$7K,8,(<!?'-!0,170),)!>-.(/!'(!7K,02,')!""X!1'8,0'!670!HL!8.(><,-#!Y7<'A!).-<'(1,!<0'K,A,)!?'-!'('ABC,)!766A.(,!>-.(/!<0'1E.(/!'('AB-.-!-76<?'0,!QI7A)>-D!*<27K.-.7(!cYS#!!
&
iH!-,17()!1A'-5.(/SD!H#L!Q=,<?,,(!H!'()!N!-,17()-SD!H#N!Q=,<?,,(!N!'()!HL!-,17()-!1A'-5.(/S!'()!M#L!Qr!HL!-,17()-!1A'-5.(/S#!!
&
$.<,=:+8,4!*5,;.1.>!$>>37!L%MN!GUQI&&
&:(.8'A-!?,0,!2'=.<>'<,)!<7!<,-<.(/!,(K.07(8,(<!Q5A,G./A'--!1BA.(),0!HLq!).'8,<,0D!HMq!2,./2<S!670!N!8.(><,-#!:>).7/,(.1!-<.8>A>-!?'-!5,06708,)!=B!-10'5.(/!<2,!8,<'A!='0-!76!'!1'/,!<75!'5507G.8'<,AB!HNq!'=7K,!<,-<!->=U,1<#!Y2,!-<.8>A>-!A'-<,)!^N!-,17()-!70!>(<.A!<7(.1%1A7(.1!-,.C>0,!?'-!7=-,0K,)!K.->'AAB#!j7AA7?.(/!1,--'<.7(!76!<2,!-<.8>A>-!<2,!A'<,(1B!<7!0,17K,0!?'-!0,170),)#!;,17K,0B!?'-!1'AA,)!?2,(!'(B!76!<2,!67>0!5'?-!?,0,!A.6<,)!6078!<2,!/07>()D!.(1A>).(/!?'AE.(/D!/0778.(/!70!-<0,<12!'<<,().(/!=,2'K.70-#!
 52 
&
''VW'HV!*./:+/,+>I!
&$7>-,!*$+@**+!Z%"2'((,A!2,')87>(<-!'()!'11,--70.,-!670!->=)>0'A!170<.1'A!**+!0,170).(/-!?,0,!5>012'-,)!6078!\.(('1A,D!T(1#!Q$7),A!I7#!fMLHD!fMLMD!fML[S#!g(!\I9!MfD!'(.8'A-! ?,0,! '(,-<2,-.C,)! ?.<2! 17(<.(>7>-! 6A7?! 76! Hnn!jA7>G,<.(,!'<!<2,!,()!76!->0/,0B!'()!87(.<70,)!)'.AB!?2.A,!0,1,.K.(/!<?7!)7-,-!76!jA7>G,<.(,!,K,0B!M^!27>0-!670!Z!)'B-!67AA7?.(/!->0/,0B#!**+!'()!*$+!'1<.K.<B!?'-!8,'->0,)!7(!)'B!N!67AA7?.(/!->0/,0B#!&!
'1+45/=+84+AB31=:/3AB,4!(+4=/<,8:>!L%MN!GXQI&&&$.1,!?,0,!'1><,AB!'(,-<2,<.C,)!.(!T-76A7>0'(,!<7!8.(.8.C,!'(G.,<B!)>0.(/!<2,!5071,--!76!17((,1<.(/!<2,!2,')87>(<!<7!<2,!50,'85A.6.,0#!**+@*$+!0,170).(/!-<'0<,)!?2,(!0,17K,0B!76!87K,8,(<!?'-!7=-,0K,)!'()!)'<'!?'-!17AA,1<,)!17(<.(>7>-AB!670!<20,,!27>0-!Q-'85A.(/!0'<,!^LL!JCS#!9'<'!>-,)!670!'('AB-.-!-<'0<,)!7(,!27>0!'6<,0!0,170).(/!-<'0<!<.8,#!4,,!4T!8,<27)-!670!),<'.A-!0,/'0).(/!->0/,0B!5071,)>0,!'()!-5.E.(/!'('AB-.-#&!
 53 
''V!*A,2,8:!$8317>,>2&&
&;'?! **+! 6.A,-! ?,0,! 17(K,0<,)! <7! <2,! /,(,0.1! #,)6! 6708'<! Q*9j! =07?-,0! KH#MMD!Y,>(.-!K'(!&,,A,(D!I,<2,0A'()S!'()!<2,(!.8570<,)!.(<7!$'<A'=!Q$'<2?70E-!T(1#D!MLHH'S!670!'('AB-.-#! j'-<! j7>0.,0! <0'(-6708'<.7(! 76! #,)6! 6.A,-!?,0,! 5071,--,)! '()! K.->'A.C,)! >-.(/! '!1>-<78! 507/0'8! .(! $'<A'=! ),K,A75,)! =B! 90#! +'0B! e,AA,(D! J$4#! **+! -./('A-! ?,0,!<0'(-6708,)!<7!60,]>,(1B!)78'.(!'()!57?,0!.(!60,]>,(1B!='()-!76!M%^JCD!^%fJCD!f%HMJCD!HM%MLJCD!'()!ML%fLJC#!j70!<2,!57?,0!-5,1<0>8D!<2,!'87>(<!76!**+!.(!'!='()!.-!]>'(<.6.,)!.(!>(.<-!76!8.107K7A<-!-]>'0,)#!W-.(/!-5,1<07/0'8!'('AB-.-!?,!67>()!<2'<!<2,!-5.E,-!.(!**+!57--,--,)!2'087(.1-! <207>/27><! <2,!^%fLJC! 0'(/,D!?2.12! 0,A.'=AB! 1'>-,)! '(! .(10,'-,! .(!57?,0! .(! <2,! ML%fLJC! 0'(/,#! 4.(1,! <2,! 8'U70.<B! 76! 57?,0! )>0.(/! (708'A! =0'.(! '1<.K.<B!711>0-!.(!<2,!A7?,0!60,]>,(1B!='()-!QiMLJCSD!<2,-,!-8'AA!p=>85-q!.(!57?,0!.(!<2,!2./2,0!60,]>,(1B!='()-!QML%fLJCS!1'>-,)!=B!-5.E.(/!'1<.K.<BD!?,0,!,'-B!<7!).66,0,(<.'<,#!:!-5.E.(/!,K,(<!?'-! 0,170),)!?2,(!'! 12'(/,! .(!57?,0!r!HL)&!711>00,)! .(! <2,!ML%fLJC! 60,]>,(1B!='()#!V,!127-,!<7!>-,!'!57?,0!<20,-27A)!Q)&S!.(-<,')!76!'85A.<>),!QsXS!<20,-27A)!)>,!<7!K'0.'(1,! .(! K7A<'/,! ='-,A.(,-#! 45.E.(/! ,K,(<-! ?,0,! 0,170),)! 8'(>'AAB! ?2.A,! K.->'AAB!-1'((.(/! **+! 6.A,-! 766A.(,! .(! HL%-,17()! ?.()7?! .(<,0K'A-#! g>0! **+! -5.E,! '('AB-.-! ?'-!K'A.)'<,)! '/'.(-<! '(! '><78'<,)! -,.C>0,! ),<,1<.7(! 'A/70.<28! QHS#! g>0! 0,->A<-! ?,0,! K,0B!17(-.-<,(<!?.<2! <2.-! .(),5,(),(<!87),! 76! '('AB-.-! '()! ,G2.=.<,)! '! 2./2! 1700,A'<.7(! Q0! t!L#haS!=,<?,,(!=7<2!'5507'12,-!Qj./>0,!M#MS#&!
!
!
!
 54 
!
!
!
!
!
!
!
!
!
!
!
!
!
!
R,:./+!)D)!K31,<35,=8!=F!>A,2,8:!38317>,>!F=/!''V!/+4=/<,8:>!Y2,!<7<'A!(>8=,0!76!-5.E.(/!,K,(<-!?,0,!]>'(<.6.,)!8'(>'AAB!.(%27>-,#!Y7!K'A.)'<,!7>0!'('AB-.-D!'!->=-,<!76!**+!6.A,-!QVY!(tZD!:4!(tZS!?,0,!'('ABC,)!?.<2!'(!'><78'<,)!-5.E,!),<,1<.7(!507/0'8#!\,'0-7(P-!1700,A'<.7(!?'-!>-,)!670!-<'<.-<.1'A!'('AB-.-M[#!!
!
!
!
!
!
 55 
%/=5+,8!'@5/345,=8W!Y+>5+/8!E1=5I!
&j0,-2AB!).--,1<,)!87>-,!2.5571'85.!70!1>A<>0,)!1,AA-!Q5A'<,)!*H[#N!'()!-<.8>A'<,)!9TXaS!?,0,!17AA,1<,)!'()!)7>(1,!2787/,(.C,)!.(!;T\:!=>66,0!QNL!8$!Y0.-!5J!f#LD!HNL!8$!I'"AD!Hn!Y0.<7(!c%HLLD!L#Nn!47).>8!9,7GB127A'<,D!L#Hn!494D!N!8$!*9Y:D!HL!8$!I'jD!1785A,<,!507<,'-,!.(2.=.<70!171E<'.A!<'=A,<!Q;712,SD!H!8$!-7).>8!70<27K'(')'<,D!H!8$!=%/AB1,07527-52'<,S#!j70!?,-<,0(!=A7<-D!-'85A,-!?,0,!=7.A,)!670!N!8.(!.(!494!-'85A,!=>66,0D!0,-7AK,)!=B!494!\:+*D!<0'(-6,00,)!<7!(.<071,AA>A7-,D!'()!.88>(7=A7<<,)#!:(<.=7).,-!?,0,!).A><,)!HFHLLL!.(!Zn!&4:!?.<2!47).>8!:C.),!'()!(,K,0!>-,)!870,!<2'(!Z!<.8,-!670!.88>(7=A7<<.(/#!:(<.=7).,-!'0,!'-!67AA7?-F!d:;"!Q/.6<!6078!90#!\'>A!V70A,BSO!d*[:\!Q4./8'SD!dI\:4^!Q.(%27>-,SD!d&M%:"YTI!Q4./8'SD!d+:\9J!Q:=1'8S#!j70!]>'(<.6.1'<.7(D!,'12!-'85A,!?'-!0'(!.(!<0.5A.1'<,!'()!(708'A.C,)!<7!'!A7').(/!17(<07A#&
!
!
!
!
!
!
!
!
!
!
!
!
 56 
)DZ!(+>.15>!
!
T6+/6,+[!=F!?+B36,=/31!38317>,>!j70!<2,!-<>).,-!),-10.=,)!=,A7?D!?,!1A'--.6.,)!8.1,!A,--!<2'(!57-<('<'A!)'B!^M!Qi\I9!^MS!'-!U>K,(.A,D!'()!8.1,!7A),0!<2'(!57-<('<'A!)'B!^M!Qr\I9!^MS!'-!')>A<-#!!V,!'--,--,)!:4!52,(7<B5,-!>-.(/!<?7!).66,0,(<!87>-,!-<0'.(-D!5>0,!&[!_&[`!'()!jH!JB=0.)-!76!&[FHMh!_JB=0.)`D!>(A,--!7<2,0?.-,!(7<,)#!T(!'AA!1'-,-!<2,!,G5,0.8,(<-!?,0,!1'00.,)!7><!>-.(/!=7<2!8'A,!'()!6,8'A,!8.1,!'<!'(!'5507G.8'<,AB!HFH!0'<.7#!Y2,!<.8,!?.()7?!670!=,2'K.70'A!12'0'1<,0.C'<.7(!,G<,()-!6078!\I9!Z!<7!\I9!ZN#&&
&
$*!;,4+!<,>A137!38!315+/+<!<+6+1=A;+8531!5,;+!4=./>+!=F!.15/3>=8,4!6=431,-35,=8>!WA<0'-7(.1!K71'A.C'<.7(-!QW4X-S!507)>1,)!=B!87>-,!5>5-!?2,(!<2,B!'0,!.-7A'<,)!6078!<2,.0!87<2,0!2'K,!=,,(!->//,-<,)!<7!=,!'!8,'(-!=B!?2.12!<2,!5>5-!-,,E!5'0,(<'A!1'0,#!!I7<'=ABD!<2.-!6708!76!1788>(.1'<.7(!.-!).-0>5<,)!.(!K'0.7>-!87>-,!87),A-!76!'><.-8!
Ma%Mh#!!Y7!),<,08.(,!.6!<2,0,!.-!'!),6,1<!.(!W4X!507)>1<.7(!.(!:4!8.1,!?,!0,170),)!'()!]>'(<.6.,)!W4X-!,8.<<,)!=B!?.A)<B5,!_VY`!'()!:4!A.<<,08'<,-!?2.A,!.-7A'<,)!6078!<2,.0!278,1'/,!670!67>0!8.(><,-#!V,!67>()!<2'<!<207>/27><!,'0AB!57-<('<'A!),K,A758,(<D!<2,!60,]>,(1B!'()!'85A.<>),!76!W4X-!'0,!-.8.A'0!=,<?,,(!VY!'()!:4!8.1,!Qj./>0,!M#Z!%&'()&"S#!T(!')).<.7(D!<2,!.(<,01'AA!'()!.(<,0=>0-<!.(<,0K'A!=,<?,,(!W4X-!?'-!>(5,0<>0=,)!.(!:4!8.1,!Qj./>0,!M#Z!+&'()&3S#!!Y2,-,!)'<'!->//,-<!<2,!07=>-<!-<0>1<>0'A!'()!<,8570'A!6,'<>0,-!76!W4X!507)>1<.7(!'0,!A'0/,AB!.(<'1<!.(!:4!8.1,#!!
 57 
!
R,:./+!)DG!*5/.45./31!38<!5+;A=/31!F+35./+>!=F!.15/3>=8,4!6=431,-35,=8>!,8!$*!;,4+!3/+!
,8<,>5,8:.,>B3?1+!F/=;!Y&!1,55+/;35+>D!!Q:S!:K,0'/,!60,]>,(1B!76!K71'A.C'<.7(-!QVY!(tfD!:4!(thS!!Q&S!:K,0'/,!'85A.<>),!76!K71'A.C'<.7(-!QVY!(tfD!:4!(thS!Q"S!:K,0'/,!.(<,01'AA!.(<,0K'A!QVY!(tfD!:4!(thS!!Q9S!:K,0'/,!T(<,0=>0-<!.(<,0K'A!QVY!(tfD!:4!(thS#!!!4<'<.-<.1-! 670! Q:%9SF! Y?7%?'BD! (7(%0,5,'<.(/! 8,'->0,-! :IgX:O! &7(6,007(.! 8>A<.5A,!1785'0.-7(-!1700,1<.7(#!!
! " # $ %% %! %" %#&
'&&&&(&&&&
)&&&&*&&&&
%&&&&& +,-./-012
3456076789:72
+,-./-
0129;<=
>
! " # $ %% %! %" %#?*&
?)&
?(&
?'&
& @AB8C6/D-
3456076789:72
DE
! " # $ %%&F&&
&F&%&F&'
&F&!&F&(
&F&" G06-,17889G06-,H78
3456076789:72
ICA-9;5
>
JI@K
! " # $ %%&F&
&F%
&F'
&F! G06-,L/,569G06-,H78
3456076789:72
ICA-9;5
>
! "
#$
 58 
T(!17(<0'-<D!?,!67>()!'!-./(.6.1'(<!).66,0,(1,!.(!<2,!<7<'A!(>8=,0!76!W4X-!,8.<<,)!=B!:4!8.1,!Qj./>0,!M#^!%4+S#!!:-!.(!50,K.7>-!-<>).,-!ZLD!?,!67>()!<2'<!VY!8.1,!).-5A'B!'!2./2AB!-<,0,7<B5,)!<.8,%17>0-,!76!W4X!507)>1<.7(D!?.<2!'!5,'E!.(!<2,!<7<'A!(>8=,0!76!1'AA-!507)>1,)!7(!\I9!a!'()!'!)0'-<.1!0,)>1<.7(!=B!\I9!HN#!V,!67>()!<2'<!:4!8.1,!507)>1,!'!A'0/,0!(>8=,0!76!W4X-!0,A'<.K,!<7!VY!8.1,!=,<?,,(!\I9!HZ%\I9!Ha#!!4.8.A'0!6.().(/-!?,0,!7=<'.(,)!?2,(!<2,!:4!8><'<.7(!?'-!107--,)!<7!<20,,!).66,0,(<!='1E/07>()!-<0'.(-!76!8.1,#!! Y7!),<,08.(,!?2,<2,0!).-0>5<.7(!76!<2,!8'<,0('AAB!.(2,0.<,)D!(,>07('AAB!,G50,--,)!
j./>0,!M#^!3S#!!X'0.'=A,-!.(2,0,(<!.(!7>0!,G5,0.8,(<'A!),-./(!17>A)!'117>(<!670!<2,!.(10,'-,!.(!W4X!507)>1<.7(!.(!:4!8.1,#!g(,!57--.=.A.<B!.-!<2'<!<2,!.(10,'-,!.(!W4X!507)>1<.7(!.-!)>,!<7!.85075,0!70!.(->66.1.,(<!1'0,!76!:4!87>-,!5>5-!=B!<2,.0!87<2,0!ZH#!Y7!'))0,--!<2.-!57--.=.A.<B!?,!?,./2,)!:4!'()!VY!5>5-!.88,).'<,AB!'6<,0!W4X!<,-<.(/!7(!,'12!)'B#!V,!67>()!<2'<!:4!'()!VY!A.<<,08'<,-!-27?!(7!).66,0,(1,-!.(!?,./2<!/'.(!<207>/27><!,'0AB!),K,A758,(<!Qj./>0,!M#N!%4+S!->//,-<.(/!<2'<!<2,!5>5-!2'K,!'11,--!<7!8'<,0('A!1'0,D!.00,-5,1<.K,!76!/,(7<B5,#!\0,K.7>-!-<>).,-!2'K,!-27?(!<2'<!57-<('<'A!2'()A.(/!76!87>-,!5>5-!1'(!87).6B!,87<.7('A!1.01>.<-D!0,)>1.(/!'(G.,<B%A.E,!=,2'K.70-!'()!-<0,--!0,-57(-,-!.(!')>A<277)!ZMDZZ#!!!
 59 
!
!
!
!
!
!
!
!
!
!
!
!
!
"#$%&'!()*!!+,--!,.!/0'!12/'&32445!#30'&#/'6!!"#$%!$'3'!4'26-!/,!273,&124!%4/&2-,3#8!

!"#$%&'()*+,'*%")-%#)'(&+./0
1 2 3 4 55 51 52 53 546
766
866
066
966
:'&#(%#%"+;%<
=+'>+!?
,& @ @@@@
A?BC
!"#$%&'()*+,'*%")-%#)'(&+.+D<E$)F
1 2 3 4 55 51 52 536
766
866
066
966
:'&#(%#%"+;%<
=+'>+!?
,&
BC:AC
1 2 3 4 55 51 52 53 546
766
866
066
966
:'&#(%#%"+;%<
=+'>+!?
,&
!"#$%&'()*+,'*%")-%#)'(&+.+574A?BC
@
1 2 3 4 55 51 52 53 546
766
866
066
966
:'&#(%#%"+;%<
=+'>+!?
,&
!"#$%&'()*+,'*%")-%#)'(&+.+D<E$)F
@@@ @
BCA?
! "
# $
 60 
L&U$8$-H!U#$)!/01!6-&4*@%3&)!U'2!+&)3%&-$4!&)!RVO!AJ!U3%#!;0!')4!?"!+3@$!%#'%!#'4!$]6$-3$)@$4!)&!6-3&-!3)8$2%37'%&-!#')4(3)7H!U$!.&*)4!%#'%!;0!+3@$!2%3((!6-&4*@$4!237)3.3@')%(5!+&-$!/012!%#')!%#$3-!?"!(3%%$-+'%$2!;^37*-$!B9G!/0')401>9!"#32!2*77$2%2!%#'%!-$6$%3%38$!#')4(3)7!32!)&%!(3N$(5!')!$]6(')'%3&)!.&-!%#$!&,2$-8$4!6#$)&%56$9!!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
"#$%&'!()A!!<=>!@0'3,/5@'!#3!B=!1#8'!#-!3,/!6%'!/,!6#..'&'38'-!#3!@,-/32/24!C'#$0/!,&!
&'@'/#/#9'!02364#3$9!!
!
3 5 7 9 11 13 15 17 19 30
0
5
10
15
20
Weight- 129
Postnatal Day
W
eig
ht 
(g)
WT
AS
3 5 7 9 11 13 15 17 19 21 30
0
5
10
15
20
Postnatal Day
W
eig
ht 
(g)
Weight- B6
WT
AS
3 5 7 9 11 13 15 17 19 21 30
0
5
10
15
20
Weight- Hybrid 
Postnatal Day
W
eig
ht 
(g)
WT
AS
WT AS
0
50
100
150
200
# o
f U
SV
s
Ultrasonic Vocalizations- B6
WT
AS
**
WT AS
0
100
200
300
400
Ultrasonic Vocalizations - Hybrid
# o
f U
SV
's *
A B
ED
C
 61 
!
!
!
!
!
"#$%&'!()A!;D,3/E6?!:;<=>!?$37#%!&.!?"!')4!;0!(3%%$-+'%$2!4*-3)7!$'-(5!6&2%)'%'(!4$8$(&6+$)%!'-$!@&+6'-$4!&)!'!ABC!,'@N7-&*)4!:?"!)EAAF!;0!)E_>H!IJ!,'@N7-&*)4!:?"!)EACH!;0!)EAG>H!')4!#5,-34!,'@N7-&*)4!:?"!)EAAH!;0!)EA[>H!!"#$"%&'(")*9!!!:O<\>!/012!+$'2*-$4!.-&+!)'`8$!?"!')4!;0!+3@$!'%!RVO!AJ!'2!4&)$!6-$83&*2(5!:2$$!^37*-$!B9B!;<O>9!;0!+3@$!$]#3,3%$4!237)3.3@')%(5!+&-$!/012!%#')!?"!(3%%$-+'%$2!&)!'!IJ!,'@N7-&*)4!!:?"!)EATF!;0!)EAG>!')4!#5,-34!,'@N7-&*)4!:?"!)E_F!;0!)EG>9!!
!0%'%32%3@2!.&-!:;<=>D!"U&<U'5H!)&)<-$6$'%3)7!+$'2*-$2!;VW1;F!I&).$--&)3!+*(%36($!@&+6'-32&)2!@&--$@%3&)9!!!0%'%32%3@2!.&-!:O<\>D!/)6'3-$4!%U&<%'3($4!%<%$2%9!XY)43@'%$2!$Z9[GH!XX$Z9[A9!\--&-!,'-2!-$6-$2$)%!0\P9!
!
!
!
!
!
 62 
F2&45!@,-/32/24!1,/,&!6'.#8#/-!#3!B=!1#8'!"&!'22$22!+&%&-!@&&-43)'%3&)!4*-3)7!$'-(5!6&2%)'%'(!4$8$(&6+$)%!U$!%$2%$4!(&@&+&%&-!'@%383%5!&.!;0!')4!?"!+3@$!'%!RVO!BA!*23)7!%#$!&6$)!.3$(4!'22'5)!Y)!%#32!'22'5H!+3@$!'-$!'((&U$4!%&!.-$$(5!$]6(&-$!')!'-$)'!.&-!A[!+3)*%$2!U#3($!+&8$+$)%!&.!%#$!+3@$!32!-$@&-4$4!')4!%#$)!')'(5ab*$)@5!&.!%#32!,$#'83&-!32!4-'+'%3@'((5!3)@-$'2$4!U3%#3)!%#$!6&6*('%3&)!&.!;0!+3@$!'%!'!23+3('-!%3+$!%&!%#$!&)2$%!&.!/01!',)&-+'(3%3$2!!:^37*-$!B9_!3!')4!249!!!!
!
!
!
!
!
!
 63 
!
!
!
!
!
!
!
!
!
"#$%&'!()G!H,%3$!B=!1#8'!029'!273,&124!1,/,&!28/#9#/5!8,1@2&'6!/,!IJ!4#//'&12/'-!
a$4!3)43834*'((5!U3%#!')!*)6'3-$4H!%U&<%'3($4!%<%$2%!6-3&-!%&!6(&%%3)7!&)!'!23)7($!7-'6#9!XY)43@'%$2!$Z9[G9!\--&-!,'-2!-$6-$2$)%!0\P9!
!
!" #$%&'()
*)))+))))
+*))),))))
,*)))
-./.0'12!3145&67/(
8'903/1
.2:1;<
=>./2?'.@(2A10'B'0$CDAE F FFF
!" #$%&'()G)
)G*
+G)
+G*
-./.0'12!3145&67/(
E.B.&'0
$2E16&.
#'/(@';%2H@39>CDAE F F
! "
 64 
!
!
!
!
!
"#$%&'! ()KL! B=! 1#8'! 029'! #38&'2-'6! .&'M%'385! ,.! 0#364#17! 842-@#3$! #3! '2&45!
6'9'4,@1'3/! C0'3! 8,1@2&'6! /,! IJ! 4#//'&12/'-)! L3)4(3+,! @('26! '@%383%5! @&+6'-$4!,$%U$$)!?"!')4!;0!+3@$!.-&+!RVO!T!%#-&*7#!RVO!BA9!!:;>!IJ!7$)$%3@!,'@N7-&*)4!:?"!)E!G<AJF!;0!)E!_<C>9!!:I>!L5,-34!7$)$%3@!,'@N7-&*)4!:?"!)ECF!;0!)E_<A[>9!!
!
!! !
!
!
!" !# !$ !% &!'
&'('
)'*'
!'' +,-./,0123/456728)
9:5;-4;4/2<4=
>2:?26:
6@/4;,:
- ABCD
!# !$ !% &!'
&'('
)'*'
!'' +,-./,012E/45672+=1F,.
9:5;-4;4/2<4=
>2:?26:
6@/4;,:
-
! "
 65 
N%9'3#4'!B=!1#8'!029'!23!'30238'6!-'#:%&'O4#P'!&'-@,3-'!/,!2%6#,$'3#8!-/#1%4%-!236!
273,&124!8,&/#824!FFQ-!0$3a*-$2!3)!;0!&@@*-!'2!$'-(5!'2!23]!+&)%#2!&.!'7$H!')4!&.%$)!6-$@$4$!@(3)3@'(!43'7)&232!&.!;0!3)!#*+')29!"#$!2*2@$6%3,3(3%5!%&!2$3a*-$2!#'2!,$$)!2%*43$4!3)!'4*(%!;0!+3@$!:cRVO!MB>!*23)7!')!'*43&7$)3@!2%3+*(*2!'22'5!JHAA9!R-$83&*2!2%*43$2!3)43@'%$!%#'%!'4*(%!+3@$!&)!'!6*-$!IJ!,'@N7-&*)4!'-$!+&-$!-$232%')%!%&!2$3a*-$!3)4*@%3&)!%#')!&%#$-!2%-'3)2H!2*@#!'2!ABCH!#&U$8$-!d*8$)3($!+3@$!#'8$!)&%!,$$)!3)8$2%37'%$4!TM9!Y)!&*-!63(&%!$]6$-3+$)%2!*23)7!%#$!'*43&7$)3@!2%3+*(*2!'22'5!'%!RVO!BGH!U$!.&*)4!%#'%!J[e!&.!?"!+3@$!&)!'!ABC!,'@N7-&*)4!$]#3,3%$4!4$,3(3%'%3)7!%&)3@<@(&)3@!2$3a*-$2!%#'%!($4!%&!4$'%#9!"#$!#37#!.-$b*$)@5!&.!.'%'(!2$3a*-$2!&,2$-8$4!3)!%#$!ABC!?"!6&6*('%3&)!+'5!(3+3%!&*-!',3(3%5!%&!4$%$@%!43..$-$)@$2!3)!2$3a*-$!'@%383%5!,$%U$$)!?"!')4!;0!+3@$9!"#*2H!U$!.&@*2$4!&)!+3@$!3)!%#$!IJ!,'@N7-&*)4H!U#3@#!'-$!N)&U)!%&!#'8$!($22!2$8$-$!2$3a*-$29!R3(&%!$]6$-3+$)%2!*23)7!IJ!+3@$!-$8$'($4!%#'%!)&)$!&.!&*-!?"!+3@$!$]#3,3%$4!2$3a*-$<3)4*@$4!4$'%#!')4!%#$!+3@$!@$'2$4!+&83)7!')4!4326('5$4!.-$$a3)7!,$#'83&-!U#$)!%#$!'*43&7$)3@!2%3+*(*2!U'2!%$-+3)'%$4!:-$.$--$4!%&!3)!%#32!6'6$-!'2!'!f2$3a*-$<(3N$g!-$26&)2$>9!"#*2H!U$!U$-$!',($!%&!b*')%3.5!%#$!2$3a*-$<(3N$!-$26&)2$!&.!%#$2$!+3@$!,5!+$'2*-3)7!%#$!('%$)@5!U3%#!U#3@#!%#$2$!+3@$!-$7'3)!+&%&-!'@%383%5!U#$)!%#$!'*43&7$)3@!2%3+*(*2!32!432@&)%3)*$49!!"#32!')'(5232!-$8$'($4!%#'%!5&*)7!;0!+3@$!%'N$!'!237)3.3@')%(5!(&)7$-!%3+$!%&!-$@&8$-!.&((&U3)7!%#$!@$22'%3&)!&.!%#$!'*43&7$)3@!2%3+*(*2!:^37*-$!B9K!30')4!2>9!!Y)!#*+')2!U3%#!;0H!2$3a*-$!6-&7-$223&)!32!b*3%$!8'-3',($!U3%#!'7$9!!?#3($!2$3a*-$2!'-$!.3-2%!&,2$-8$4!3)!$'-(5!@#3(4#&&4H!%#$5!'-$!%563@'((5!($22!6-$8'($)%!3)!&(4$-!@#3(4-$)!,*%!@')!-$'66$'-!3)!'4*(%2!BT9!"#$-$.&-$H!U$!'2N$4!3.!%#$!-$26&)2$!&.!?"!')4!;0!+3@$!%&!')!'*43&7$)3@!2%3+*(*2!@#')7$2!'2!%#$!+3@$!+'%*-$9!/23)7!%#$!'*43&7$)3@!2%3+*(*2!6-&%&@&(H!
 66 
U$!.&*)4!%#'%!3)!@&)%-'2%!%&!&*-!&,2$-8'%3&)2!U3%#!5&*)7!+3@$H!4*-3)7!'4*(%#&&4!:RVO!MB<C[>!%#$-$!32!)&!237)3.3@')%!43..$-$)@$!,$%U$$)!?"!')4!;0!+3@$!3)!%#$3-!('%$)@5!%&!-$@&8$-!.-&+!')!'*43&7$)3@!2%3+*(*2!:^379!B9K!5>9!!"#$!'8$-'7$!?"!('%$)@5!%&!-$@&8$-!.-&+!%#$!'*43&7$)3@!2%3+*(*2!4&$2!)&%!@#')7$!'2!?"!+3@$!+'%*-$H!2*77$2%3)7!%#'%!'2!;0!+3@$!+'%*-$H!%#$3-!',3(3%5!%&!-$@&8$-!.-&+!')!'*43&7$)3@!2%3+*(*2!3+6-&8$29!"&!3)8$2%37'%$!.*-%#$-!%#$!)$*-&(&73@'(!,'232!&.!%#$!$)#')@$4!2$3a*-$!2*2@$6%3,3(3%5!3)!;0!+3@$H!U$!*2$4!2*,4*-'(!$($@%-&$)@$6#'(&7-'6#3@!-$@&-43)72!:\\h2>!%&!+$'2*-$!,'2'(!@&-%3@'(!'@%383%59!!\($@%-&4$2!U$-$!3+6(')%$4!3)!+3@$!3)!%#$!6&2%$-3&-!@&-%$]!&)!RVO!BG!')4!-$@&-43)72!U$-$!6$-.&-+$4!,$%U$$)!'7$2!RVO!T[!%&!RVO!TG9!I'2'(!,-'3)!'@%383%5!3)!;0!+3@$!U'2!3)432%3)7*32#',($!.-&+!%#$3-!?"!(3%%$-+'%$2H!#&U$8$-H!;0!+3@$!6&22$22$4!3).-$b*$)%!#37#!'+6(3%*4$!f263N3)7g!$8$)%29!"#$2$!#37#!'+6(3%*4$!:cB[[i1>!263N$2!&@@*--3)7!U3%#3)!%#$!M<K!La!-')7$!#'8$!,$$)!&,2$-8$4!3)!%#$!#366&@'+6*2!')4!@&-%$]!&.!'4*(%!;0!+3@$!')4!b*'(3%'%38$(5!4$2@-3,$4!B[9!?$!b*')%3.3$4!263N3)7!'@%383%5!:2$$!P$%#&42>!')4!.&*)4!;0!+3@$!#'8$!237)3.3@')%(5!+&-$!263N3)7!$8$)%2!@&+6'-$4!%&!?"!(3%%$-+'%$2!:^37*-$!B9AA>9!"#*2H!',)&-+'(!\\h!'@%383%5!@')!,$!&,2$-8$4!3)!;0!+3@$!'2!$'-(5!'2!RVO!T[9!!!!!!!!
!
!
!
 67 
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
"#$%&'!()RL!!B=!1#8'!029'!23!'30238'6!42/'385!/,!&'8,9'&!.&,1!23!2%6#,$'3#8!
-/#1%4%-)!!:;<I>!"&%'(!%3+$!%&!-$@&8$-!+&%&-!'@%383%5!.&((&U3)7!')!'*43&7$)3@!2%3+*(*2!,$%U$$)!;0!+3@$!')4!?"!(3%%$-+'%$2!&)!'!IJ!,'@N7-&*)4!:)D!?"E_F!;0EG>!')4!L5,-34!,'@N7-&*)4!:)D!?"E_F!;0EK>9!!!:=>!;*43&7$)3@!2%3+*(*2!6#$)&%56$!3)!;0!+3@$!,$@&+$2!($22!-&,*2%!3)!'4*(%#&&49!?"!')4!;0!+3@$!U$-$! 2*,d$@%! %&! %#$! '*43&7$)3@! 2%3+*(*2! '22'5! %#-&*7#&*%! %#$! '4*(%!6$-3&4!RVO!MB<!C[9!j'%$)@5!%&!-$@&8$-!U'2!3)432%3)7*32#',($!,$%U$$)!?"!')4!;0!+3@$!(3%%$-+'%$2!:?"!)E!KF!;0!)EA[>9!!!0%'%32%3@2D!/)6'3-$4H!%U&<%'3($4!%<%$2%9!XY)43@'%$2!$Z9[GH!XX$Z9[A9!\--&-!,'-2!-$6-$2$)%!0\P9!!!!!
!" #$%
&%
'%
(%
)% #*+,-./0,12$3,4*5*62728(
9:3/01;
23-2</1-
=/<2>6/
1-0+6? @
!" #$%
A%
B%%
BA%
&%% #*+,-./0,12$3,4*5*6272C;D<,+
9:3/01;
23-2</1-
=/<2>6/
1-0+6? @@
!" #$%
&%'%
(%)%
B%% #*+,-./0,12$3,4*5*6272C;D<,+
9:3/01;
23-2</1-
=/<2>6/
1-0+6?
! "!"#$ !"#$
!"#$
#
 68 
+,C'&#3$!/0'!4'9'4!,.!&'()&'-8%'-!273,&124!7&2#3!28/#9#/5!#3!B=!1#8'!L'83)7!34$)%3.3$4!2%-'3)<3)4$6$)4$)%!')4!-&,*2%!,$#'83&-'(!4$.3@3%2H!U$!)$]%!'2N$4!3.!3%!U'2!6&223,($!%&!-$8$-2$!%#$2$!6#$)&%56$2!,5!4$@-$'23)7!%#$!$]6-$223&)!&.!)$*-&)'(!6-&%$3)2!U#&2$!$]6-$223&)!#'2!,$$)!2*77$2%$4!%&!,$!*6<-$7*('%$4!3)!%#$!;0!+&*2$9!"&U'-42!%#32!$)4!U$!.&@*2$4!&*-!'%%$)%3&)!&)!;k=!')4!\RL\lYVG!Q\GS!%U&!6-&%$3)2!%#'%!-$7*('%$!25)'62$!)*+,$-!')4m&-!.*)@%3&)!KHCHTGHTJ9!"&!-$4*@$!%#$!($8$(!&.!;k=!$]6-$223&)!3)!;0!+3@$H!U$!+'%$4!/,$T'+nm6<!.$+'($2!U3%#!+'($2!%#'%!'-$!#$%$-&a57&*2!.&-!'!N)&@N&*%!'(($($!.&-!365!Q;k=nm<S9!!"#32!@-&22!6-&4*@$2!.&*-!7$)&%56$2D!/,$T'+<m6n!+3@$!Q;0!+3@$SH!/,$T'+<m6n!+3@$!%#'%!'(2&!#'8$!%#$!;k=nm<!'(($($!!Q;0<;k=nm<!+3@$S!'2!U$((!'2!?"!+3@$!')4!;k=nm<!+3@$!.&-!(3%%$-+'%$!@&+6'-32&)9!"&!@&).3-+!%#'%!%#$!$]6-$223&)!&.!365!32!-$4*@$4!*23)7!%#32!7$)$%3@!'66-&'@#H!U$!b*')%3.3$4!3650+kV;!($8$(2!*23)7!bR=k!')'(5232!&)!'((!.&*-!7$)&%56$29!;2!365032!')!'@%383%5<-$7*('%$4!7$)$!T_H!U$!3)4*@$4!3%2!$]6-$223&)!,5!$]6&23)7!+3@$!%&!')!$)-3@#$4!$)83-&)+$)%!.&-!&)$!#&*-!6-3&-!%&!#'-8$2%3)7!#366&@'+6'(!+kV;9!?$!.&*)4!%#'%!;k=nm<!+3@$H!,&%#!3)!%#$!?"!')4!;0!,'@N7-&*)4H!4326('5!')!'66-&]3+'%$(5!G[e!-$4*@%3&)!3)!%#$!($8$(!&.!365!+kV;!$]6-$223&)!:^37*-$!B9C>9!I5!@&)%-'2%H!%#$!$]6-$223&)!&.!&%#$-!'@%383%5<-$7*('%$4!7$)$2!:39$9H!78#902:;<!')4!=$.#>>!U'2!)&%!-$4*@$4!3)!;k=nm<!+3@$H!2*77$2%3)7!%#'%!%#$!4$@-$'2$!3)!365!+kV;!$]6-$223&)!32!'!43-$@%!@&)2$b*$)@$!&.!%#$!+*%'%3&)!&.!365H!')4!32!)&%!4*$!%&!'!7(&,'(!@#')7$!3)!'@%383%5<-$7*('%$4!7$)$!)$%U&-N2!:^37*-$!B9C>9!!!!!!!
!
 69 
!
!
!
!
!
!
!
!
!
!
!
"#$%&'!()SL!T'/'&,:5$,-#/5!,.!BUD!244'4'!4'26-!/,!AVW!&'6%8/#,3!#3!BUD!1UXB!4'9'4-)!^&((&U3)7!$]6&2*-$!%&!')!$)-3@#$4!$)83-&)+$)%H!;k=nm<!')4!;0<;k=nm<!+3@$!#'8$!-$4*@$4!
365!+kV;!$]6-$223&)!@&+6'-$4!%&!?"!(3%%$-+'%$29!!365!#$%$-&a57&23%5!4&$2!)&%!'..$@%!3)4*@%3&)!($8$(2!&.!&%#$-!N)&U)!3++$43'%$<$'-(5!7$)$2!78#902:;<!')4!=$.#>?0k$('%38$!/)3%2!-$.($@%2!=%!8'(*$2!)&-+'(3a$4!%&!"*,*(3)9!:)D!?"EBF!;0EMF!;k=nm<EKF!;0<;k=nm<EM>9!0%'%32%3@2D!"U&<U'5!;VW1;F!I&).$--&)3!@&--$@%3&)!.&-!+*(%36($!@&+6'-32&)29!XXY)43@'%$2!
$Z9[AH!XXX$Z9[[A9!\--&-!,'-2!-$6-$2$)%!0\P9!!! !
!
!
!"!!"#
$"!$"#
%"!%"#
&'()*
+,-.+/
/012*
3'+45607
+*8206/
9
).:
;; ;;;
)<=)'>?@=
AB)<)'>?@=
!
#
$!
$# C1/
!"!
!"#
$"!
$"#
%"! (-5/D
!
%
D
E
F GH2I
 70 
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
"#$%&'!()YV!+,C'&#3$!4'9'4-!,.!&'(Z!7%/!3,/!*+,#-./0Z!&'-8%'-!2%6#,$'3#8!-/#1%4%-!
@0'3,/5@'!#3!B=!1#8'Z!7%/!3,/!<=>!,&!1,/,&!6'.#8#/-)!!!:;<L>!I$#'83&-'(!')'(5232!&.!6-&7$)5!7$)$-'%$4!.-&+!+,"-.0]0365!:+'./>!')4!+,"-.!]!1@!:U#$0/>!7$)$%3@!3)%$-'@%3&)9!!
!
! " # $ %% %! %" %# %$&
%&&
'&&
!&&
(&&
)*+,-.,./01.2
30*4056
7+
89:6:;<0=>?:6?:;<0=>?
89 :6 :;<@>? :6?:;<@>?&
"&&&%&&&&
%"&&&'&&&&
'"&&&
1A+,.-B
C0DBEF
G GGG
89 :6 :;<@>? :6?:;<@>?&
%
'
!
6CHCIA,
206B*IC G
GGG
! " # $ %% %! %" %# %$&
'&&
(&&
J&&
K&&
)*+,-.,./01.2
30*4056
7+
89:6L"0=>?:6?L"0=>?
89 :6 L"0=>? 0:6?L"0=>?&
"&&&%&&&&
%"&&&'&&&&
'"&&&
1A+,.-B
C0DBEF
GGG
89 :6 L"0=>? 0:6?L"0=>?&M&
&M"
%M&
%M"
'M&
6CHCIA,
206B*IC
GGG
! "
# $
% &
!" #$ #%&'() #$)#%&'()*
+*
,**
,+*
-**
"./012
3140536
0417805
89 :8;;
!" #$ <+1=() 1#$)<+1=()*
,**
-**
>**
"./012
3140536
0417805
89 ;;
! "
 71 
!
!
!
!
"#$%&'!()YV!;D,3/E6?!:;<I>!"&%'(!)*+,$-!&.!/012!$+3%%$4!4*-3)7!+'%$-)'(!32&('%3&)!%#-&*7#&*%!6&2%)'%'(!4$8$(&6+$)%!:+,"-.0]0365D!?"EAJF!;0EAKF!;k=nm<EATF!;0<;k=nm<EA[!m+,"-.!]!1@D!?"EA_F!;0EAJF!\Gnm<EACF!;0<\Gnm<EA_>9!!:=<O>!!"&%'(!432%')@$!%-'8$($4!3)!&6$)!.3$(4!'-$)'!'%!RVOBA9!:+,"-.0]0365D!?"EATF!;0EJH!;k=nm<EGF!;0<;k=nm<EG!m+,"-.!]!1@D!?"E_F!;0ETF!\Gnm<EMF!;0<\Gnm<EG>!:\<^>!L3)4(3+,!@('26!2$8$-3%5!+$'2*-$4!'%!RVO!T[0:+,"-.0]0365D!?"EABF!;0EABF!;k=nm<EA[F!;0<;k=nm<E_!m+,"-.!]!1@D!?"ECF!;0E_F!\Gnm<E_F!;0<\Gnm<E_>!!!!:h<L>0j'%$)@5!%&!-$@&8$-!+&%&-!'@%383%5!.&((&U3)7!'*43&7$)3@!2%3+*(*2!'%!RVO!T[0:+,"-.0]0
365D!?"EABF!;0EATF!;k=nm<EA[F!;0<;k=nm<E_!m+,"-.!]!1@D!?"ECF!;0E_F!\Gnm<E_F!;0<\Gnm<E_>!0%'%32%3@2!.&-!:;<L>D!"U&<U'5!;VW1;F!I&).$--&)3!@&--$@%3&)!.&-!+*(%36($!@&+6'-32&)29!XY)43@'%$2!6Z9[GH!XX6Z9[A!XXX6Z9[[A9!!\--&-!,'-2!-$6-$2$)%!0\P9!!!!!!!!
 72 
?$!)$]%!'2N$4!3.!-$4*@3)7!%#$!($8$(!&.!;k=!&-!\G!$]6-$223&)!-$8$-2$2!%#$!4$.$@%2!3)!/01!6-&4*@%3&)H!+&%&-!.*)@%3&)H!')4!2$3a*-$<-$('%$4!'@%383%5!%#'%!U$!4$%$@%!3)!;0!+3@$9!!?$!.&*)4!%#'%!-$4*@3)7!%#$!($8$(!&.!;k=!&-!\G!$]6-$223&)!#'2!)&!$..$@%!&)!%#$!)*+,$-!&.!/012!3)!%#$!;0!+3@$!:^37*-$!B9A[!;!')4!I>H!4&$2!)&%!+&43.5!%#$!#56&'@%383%5!&,2$-8$4!3)!%#$!&6$)!.3$(4!'22'5!:^37*-$!B9A[!=!')4!O>H!')4!4&$2!)&%!-$8$-2$!%#$!6-&)&*)@$4!#3)4(3+,!@('26!&,2$-8$4!3)!;0!+3@$!:^37*-$!B9A[!\!')4!^>9!!!!h38$)!%#'%!;k=!-$7*('%$2!2*-.'@$!;PR;!-$@$6%&-!$]6-$223&)!'%!$]@3%'%&-5!25)'62$2H!')4!@&)2$b*$)%(5!3).(*$)@$2!)$*-&)'(!$]@3%',3(3%5H!')4!\G!#'2!,$$)!2#&U)!%&!-$2%-3@%!%#$!)*+,$-!&.!$]@3%'%&-5!25)'62$2H!U$!@&)234$-$4!%#$!6&223,3(3%5!%#'%!')!3)@-$'2$!3)!%#$!($8$(!&.!;k=!')4m&-!\G!+37#%!*)4$-(3$!%#$!2$3a*-$<-$('%$4!6#$)&%56$2!3)!;0!+3@$9!!"&!3)8$2%37'%$!2$3a*-$!'@%383%5!*)4$-!@&)43%3&)2!U#$-$!;k=!&-!\G!($8$(2!'-$!-$4*@$4H!U$!$]6&2$4!+3@$!%&!')!'*43&7$)3@!2%3+*(*2!'2!4$2@-3,$4!',&8$!')4!'22$22$4!%#$!%3+$!3%!%&&N!.&-!%#$!+3@$!%&!-$7'3)!+&,3(3%5!'.%$-!%#$!2%3+*(*2!U'2!%$-+3)'%$49!?$!.&*)4!%#'%!-$4*@3)7!%#$!($8$(!&.!;k=!$]6-$223&)!3)!;0!+3@$!@&+6($%$(5!-$8$-2$2!%#$3-!$)#')@$4!-$26&)2$!%&!%#$!'*43&7$)3@!2%3+*(*29!I5!@&)%-'2%!-$4*@3)7!%#$!($8$(!&.!\G!$]6-$223&)!#'4!)&!$..$@%!&)!%#$!-$26&)2$!&.!;0!+3@$!%&!%#$!'*43&7$)3@!2%3+*(*2!:^37*-$!B9A[!h!')4!L>9!!"&!'22$22!43-$@%(5!%#$!$..$@%!&.!-$4*@3)7!;k=!$]6-$223&)!&)!%#$!2$3a*-$<(3N$!'@%383%5!&,2$-8$4!3)!;0!+3@$!\\h!-$@&-43)72!U$-$!6$-.&-+$49!"#32!')'(5232!-$8$'($4!%#'%!-$4*@3)7!;k=!+kV;!$]6-$223&)!@&+6($%$(5!-$8$-2$2!%#$!3)@-$'2$4!263N3)7!.-$b*$)@5!&,2$-8$4!3)!;0!+3@$!:^37*-$!B9AA>9!!!!!
 73 
!!!
!
!
!
!
!
!
!
!
!
!
!
!
!
"#$%&'! ()YY! B=! 1#8'! 029'! -#$3#.#823/45! 1,&'! 42&$'! 21@4#/%6'! -@#P#3$! '9'3/-!
8,1@2&'6!/,!IJ!1#8'!236!/0#-!@0'3,/5@'!823!7'!&'9'&-'6!75!4,C'&#3$!4'9'4-!,.!&'(1!!:;>!k$6-$2$)%'%38$!\\h!.-&+!?"!')4!;0!+3@$!'%!RVO!T[9!L37#!'+6(3%*4$!:o!B[[i1>H!M<K!La!263N3)7!$8$)%2!'-$!4$63@%$4!3)!%#$!;0!\\h!%-'@$9!V&%$D!03+*(%')$&*2!\Ph!-$@&-43)7!2#&U2!3++&,3(3%5!&.!;0!+&*2$!4*-3)7!263N3)7!'@%383%59!!!!
!" #$ #%&'() #$)#%&'()*
+*
,*
-*
.*
$/01023
4565278
99:4#2;<=808
>> 28
!"499:4
#$499:
!"49?:4
#$49?:
@485AB2C@**DE
0 50 100 150
0
50
100
150
Spike Analysis Validation
IN-HOUSE
Go
od
ric
h e
t a
l, 2
01
3 R= .97
indicates Spike Count
!
" #
 74 
!
!
!
!
!
!
"#$%&'!()YY!;D,3/[6?!:I>!p*')%3.3@'%3&)!&.!263N3)7!'@%383%5!.-&+!6-&7$)5!&.!/I\T;!]!;k=!7$)$%3@!3)%$-'@%3&)!:)D!?"ECF!;0ECF!;k=nm<EATF!;0<;k=nm<E_>9!0%'%32%3@2D!"U&<U'5!;VW1;F!I&).$--&)3!@&--$@%3&)!.&-!+*(%36($!@&+6'-32&)29!XXY)43@'%$2!6Z9[A9!\--&-!,'-2!-$6-$2$)%!0\P9!!:=>!1'(34'%3&)!&.!263N3)7!')'(5232!.&-!\\h!-$@&-43)729!"&%'(!)*+,$-!&.!263N3)7!$8$)%2!U'2!+$'2*-$4!+')*'((5! :0$$! 0*66($+$)%'(!P$%#&42>! 3)<#&*2$9! "&! 8'(34'%$! &.! &*-! ')'(5232H! '!2*,2$%! &.! \\h! .3($2! :?"!)ETH! ;0! )EM>!U$-$! ')'(5a$4!U3%#! ')! '*%&+'%$4! 263N$! 4$%$@%3&)!6-&7-'+!:A>9!R$'-2&)q2!@&--$('%3&)!U'2!*2$4!.&-!2%'%32%3@'(!')'(52329!k!E![9C_!!
!
!
!
!
!
!
!
!
 75 
U'.'&'38'-!A9! ;)7$(+')!LD! rR*66$%r!@#3(4-$)9!;!-$6&-%!&)!T!@'2$29!O$8$(&69!P$49!=#3(4!V$*-&(9!_H!ACJG!!B9! "')! ?LH! I'@3)&! =;H! 0N3))$-! 0;H! $%! '(D! ;)7$(+')! 25)4-&+$D! P*%'%3&)2! 3).(*$)@$!.$'%*-$2!3)!$'-(5!@#3(4#&&49!;+!s!P$4!h$)$%!;!AGG;DKA<C[H!B[AA!!T9! "'%2*5'!t32#3)&!Pjs?D!/I\T;m\J<;R!+*%'%3&)2!@'*2$!;)7$(+')!05)4-&+$9!V'%*-$!h$)$%3@2H!ACC_!!M9! k&,$-%! O9! V3@#&((2! sLPtH!P$-(3)! h9! I*%($%H! 0*2')! t'-'+!u!P'-@! j'(')4$D! h$)$%3@!3+6-3)%3)7! 2*77$2%$4! ,5! +'%$-)'(! #$%$-&432&+5! 3)! )&)<4$($%3&)! R-'4$-<?3((3!25)4-&+$9!V'%*-$!TMBDBKA<BKMH!ACKC!!G9! d!='5%&)<0+3%#!jjD!;)7$(+')!05)4-&+$D!'!-$83$U!&.!%#$!@(3)3@'(!')4!7$)$%3@!'26$@%29!s&*-)'(!&.!P$43@'(!h$)$%3@2!M[DK_<CGH!B[[T!!J9! v&)7<#*3!s3')7!O;H!/-2!;(,-$@#%H!=&($$)!P9!;%N3)2H!s$..-$5!j9!V&$,$(2H!h-$7&-!\3@#$($H!s9!O'834!0U$'%%!')4!;-%#*-!j9!I$'*4$%D!P*%'%3&)!&.!%#$!;)7$(+')!/,3b*3%3)!j37'2$!3)!P3@$! ='*2$2! Y)@-$'2$4! =5%&6('2+3@! 6GT! ')4! O$.3@3%2! &.! =&)%$]%*'(! j$'-)3)7! ')4!j&)7<"$-+!R&%$)%3'%3&)9!V$*-&)!BAD_CC<KAAH!ACCK!!_9! s&)!P9!L*3,-$7%2$!P0'RPLD!;!@$((*('-!6-&%$3)!+$43'%$2!'22&@3'%3&)!&.!6GT!U3%#!%#$!\J! &)@&6-&%$3)! &.! #*+')! 6'63((&+'83-*2! %56$2! AJ! &-! AK9! "#$! \PIW! s&*-)'(!A[DMABC<MATGH!ACCA!!K9! h-$$-!RjH!L')'5'+'!kH!I(&&47&&4!IjH!$%!'(D!"#$!;)7$(+')!05)4-&+$!6-&%$3)!/,$T;!-$7*('%$2!25)'62$!4$8$(&6+$)%!,5!*,3b*3%3)'%3)7!'-@9!=$((!AM[D_[M<AJH!B[A[!!C9! P'-7&(32!00H!0'(&73'))32!sH!j36%&)!OPH!$%!'(D!\6#I<+$43'%$4!4$7-'4'%3&)!&.!%#$!k#&;!h\^!\6#$]3)G!-$(3$8$2!'!4$8$(&6+$)%'(!,-'N$!&)!$]@3%'%&-5!25)'62$!.&-+'%3&)9!=$((!AMTDMMB<GGH!B[A[!!A[9! t'6#a')!LH!I*..3)7%&)!0;H!s*)7!sYH!$%!'(D!;(%$-'%3&)2!3)!3)%-3)23@!+$+,-')$!6-&6$-%3$2!')4! %#$!']&)! 3)3%3'(! 2$7+$)%! 3)!'!+&*2$!+&4$(!&.!;)7$(+')!25)4-&+$9! s!V$*-&2@3!TADA_JT_<MKH!B[AA!!AA9! 8')!?&$-4$)!hPH!L'--32!tOH!L&dd'%3!PkH!$%! '(D!k$2@*$!&.!)$*-&(&73@'(!4$.3@3%2! 3)!'!+&*2$! +&4$(! .&-! ;)7$(+')! 25)4-&+$! ,5! -$4*@%3&)! &.! '(6#'='PtYY! 3)#3,3%&-5!6#&26#&-5('%3&)9!V'%!V$*-&2@3!A[DBK[<BH!B[[_!!AB9! \7'U'!tH!t3%'7'U'!tH!Y)&*$!tH!$%!'(D!O$@-$'2$4!%&)3@!3)#3,3%3&)!3)!@$-$,$(('-!7-')*($!@$((2!@'*2$2!+&%&-!452.*)@%3&)!3)!'!+&*2$!+&4$(!&.!;)7$(+')!25)4-&+$9!0@3!"-')2(!P$4!MDAJT-'AG_H!B[AB!
 76 
AT9! I'*4-5!PH! t-'+'-! \H! l*! lH! $%! '(D! ;+6'N3)$2! 6-&+&%$! 263)$! '@%3)! 6&(5+$-3a'%3&)H!(&)7<%$-+! 6&%$)%3'%3&)H! ')4! ($'-)3)7! 3)! '! +&*2$! +&4$(! &.! ;)7$(+')! 25)4-&+$9!V$*-&,3&(!O32!M_DBA[<GH!B[AB!!AM9! O'3(5! sjH! V'2#! tH! s3)U'(! /H! $%! '(D! ;4$)&<'22&@3'%$4! 83-*2<+$43'%$4! -$2@*$! &.! %#$!@&7)3%38$! 4$.$@%2! 3)! '!+&*2$!+&4$(! .&-! ;)7$(+')! 25)4-&+$9! Rj&0!W)$! JD$B_BBAH!B[AA!AG9! P$)7! jH! R$-2&)!k\H!L*')7!?H! $%! '(D! "-*)@'%3&)! &.! /,$T'<;"0! *)23($)@$2! 6'%$-)'(!/,$T'!')4!'+$(3&-'%$2!,$#'83&-'(!4$.$@%2!3)!%#$!;)7$(+')!25)4-&+$!+&*2$!+&4$(9!Rj&0!h$)$%!CD$A[[M[TCH!B[AT!!AJ9! L*')7!L0H!;(($)!s;H!P',,!;PH!$%!'(D!"&6&32&+$-'2$!3)#3,3%&-2!*)23($)@$!%#$!4&-+')%!'(($($!&.!/,$T'!3)!)$*-&)29!V'%*-$!MKADAKG<CH!B[AB!!A_9! O3)4&%!01H!;)%'(..5!I;H!I#'%%'@#'-d$$!PIH!$%!'(D!"#$!;)7$(+')!25)4-&+$!*,3b*3%3)!(37'2$! (&@'(3a$2! %&! %#$! 25)'62$! ')4! )*@($*2H! ')4! +'%$-)'(! 4$.3@3$)@5! -$2*(%2! 3)!',)&-+'(!4$)4-3%3@!263)$!+&-6#&(&759!L*+!P&(!h$)$%!A_DAAA<KH!B[[K!!AK9! v'2#3-&!tH!k34'5!""H!=&)4&)!tLH!$%!'(D!/,$T'!32!-$b*3-$4!.&-!$]6$-3$)@$<4$6$)4$)%!+'%*-'%3&)!&.!%#$!)$&@&-%$]9!V'%!V$*-&2@3!ABD___<KTH!B[[C!!AC9! k34'5!""H!O')N&2N3!\=H!t-&*2$!P=H!$%!'(D!R'%#U'5<26$@3.3@!4&6'+3)$-73@!4$.3@3%2!3)!'!+&*2$!+&4$(!&.!;)7$(+')!25)4-&+$9!s!=(3)!Y)8$2%!ABBDMGMM<GMH!B[AB!!B[9! P3*-'! tH! t32#3)&! "H! j3! \H! $%! '(D! V$*-&,$#'83&-'(! ')4! $($@%-&$)@$6#'(&7-'6#3@!',)&-+'(3%3$2!3)!/,$T'!+'%$-)'(<4$.3@3$)%!+3@$9!V$*-&,3&(!O32!CDAMC<GCH!B[[B!!BA9! L$@N!OLH!w#'&!vH!k&5!0H!$%!'(D!;)'(5232!&.!@$-$,$(('-!.*)@%3&)!3)!/,$T'<4$.3@3$)%!+3@$!-$8$'(2!)&8$(!7$)&%56$<26$@3.3@!,$#'83&-29!L*+!P&(!h$)$%!A_DBAKA<CH!B[[K!!BB9! L*')7! L0H! I*-)2! ;sH! V&))$+')! ksH! $%! '(D! I$#'83&-'(! 4$.3@3%2! 3)! ')! ;)7$(+')!25)4-&+$!+&4$(D!$..$@%2!&.!7$)$%3@!,'@N7-&*)4!')4!'7$9!I$#'8!I-'3)!k$2!BMTD_C<C[H!B[AT!!BT9! R$(@!tH!I&54!0hH!=#$-&)!hH!$%!'(D!\63($625!3)!;)7$(+')!25)4-&+$9!0$3a*-$!A_DBAA<_H!B[[K!!BM9! "#3,$-%! kjH! j'-2&)! ;PH! L23$#! O"H! $%! '(D! V$*-&(&73@! +')3.$2%'%3&)2! &.! ;)7$(+')!25)4-&+$9!R$43'%-!V$*-&(!MKDB_A<CH!B[AT!!BG9! O'+3$)!=&('2'!s?H!R'%-3@$!^&-%@H!O$)32$!0'(8$-%@H!V3@&($!0'-4''D!0($$6!432%*-,')@$2!3)! /,$T'!+'%$-)'(<4$.3@3$)%!+3@$!+&4$(3)7! ;)7$(+')! 25)4-&+$9! V$*-&,3&(&75! &.!O32$'2$!B[DM_A<M_KH!B[[G!!BJ9! h&&4-3@#!h0H!t','N&8!;vH!L'+$$4!PpH!$%!'(D!=$.%-3']&)$!%-$'%+$)%!'.%$-!%-'*+'%3@!,-'3)! 3)d*-5! -$2%&-$2! $]6-$223&)! &.! %#$! 7(*%'+'%$! %-')26&-%$-H! hj"<AH! -$4*@$2!
 77 
-$73&)'(! 7(3&232H! ')4! -$4*@$2! 6&2%<%-'*+'%3@! 2$3a*-$2! 3)! %#$! -'%9! s! V$*-&%-'*+'!T[DAMTM<MAH!B[AT!B_9! \26&23%&! hH! v&2#34'! 0H! W#)32#3! kH! $%! '(D! Y).')%! @'(+3)7! -$26&)2$2! 4*-3)7!+'%$-)'(!@'--53)7!3)!#*+')2!')4!+3@$9!=*--!I3&(!BTD_TC<MGH!B[AT!!BK9! k&4-37*3a! kPH! =&(83)! s0H!?$%2$(!?=D!V$*-&6#$)&%563)7! 7$)$%3@'((5!+&43.3$4!+3@$!.&-!2&@3'(!,$#'83&-9!P$%#&42!P&(!I3&(!_JKDTMT<JTH!B[AA!!BC9! 0@'%%&)3! PjH! =-'U($5! sH! k3@@$-3! jD! /(%-'2&)3@! 8&@'(3a'%3&)2D! '! %&&(! .&-! ,$#'83&*-'(!6#$)&%563)7!&.!+&*2$!+&4$(2!&.!)$*-&4$8$(&6+$)%'(!432&-4$-29!V$*-&2@3!I3&,$#'8!k$8!TTDG[K<AGH!B[[C!!T[9! P'-%3)! \! L'#)! jtH! j&*32! ?$3)-,H! ;)4-$U! L$)-5H! V&-+')! 0@#')a! ')4! \8$(5)! P9!L'#)9D!h$)$%3@!')4!O$8$(&6+$)%'(!Y).(*$)@$2!&)!Y).')%!P&*2$!/(%-'2&)3@!='((3)79!YY9!O$8$(&6+$)%'(! R'%%$-)2! 3)! %#$! ='((2! &.! P3@$! B<AB! O'52! &.! ;7$9! I$#'83&-! h$)$%3@2!BKDTAG<TBGH!ACCK!!TA9! j'8&&5! P\L'PsD! ;! k$83$U! &.! %#$! P$%#&42! &.! 0%*43$2! &)! Y).')%! /(%-'2&*)4!R-&4*@%3&)! ')4!P'%$-)'(! k$%-3$8$(! 3)! 0+'((! k&4$)%29! I$#'83&-! h$)$%3@2! TGDTA<GAH!B[[G!!TB9! P3@#'$(! I9! L$))$225! sjH! \4)'! j9! j&$H! 0$5+&*-! j$83)$D! P'%$-)'(! I$#'83&-H! R*6!1&@'(3a'%3&)2H! ')4! R*6! "$+6$-'%*-$! =#')7$2! ^&((&U3)7! L')4(3)7! 3)! P3@$! &.! B!Y),-$4!0%-'3)29!O$8$(&6+$)%'(!R25@#&,3&(&75!ATDG_T<GKMH!ACK[!!TT9! =-',,$!s=D!h$)$%3@2!&.!P&*2$!I$#'83&-D!Y)%$-'@%3&)2!U3%#!j',&-'%&-5!\)83-&)+$)%9!0@3$)@$!BKMDAJ_[<AJ_BH!ACCC!!! TM9! s-9!sj^'^L0D!;*43&7$)3@!0$3a*-$2!3)!\($8$)!P&*2$!0%-'3)29!"#$!s&*-)'(!&.!L$-$43%5!!! TG9! ='&! =H! k3&*(%<R$4&%%3!P0H!P37')3! RH! $%! '(D! Y+6'3-+$)%! &.! "-NI<R0O<CG! 237)'(3)7! 3)!;)7$(+')!25)4-&+$9!Rj&0!I3&(!AAD$A[[AM_KH!B[AT!!TJ9! 03+&)$! tx#)($! IPH! t&)2%')%3)! P'%$)%a&7(*! ')4! P'-%3)! 0@#$..)$-D! k&($! &.! %#$!*,3b*3%3)!(37'2$!\J;Rm/I\T;!3)!@&)%-&((3)7!($8$(2!&.!%#$!25)'6%3@!6-&%$3)!;-@9!RV;0!AA[DKKKK<KKCTH!B[AT!!T_9! 0#$6#$-4! sOH!I$'-!P^D!V$U!83$U2!&.!;-@H!'!+'2%$-!-$7*('%&-!&.!25)'6%3@!6('2%3@3%59!V'%!V$*-&2@3!AMDB_C<KMH!B[AA!
 78 
!
!
!
!
!
!
!
"#$%&'(!)!
*+,-.,,+/0!
!
!
!
!
!
!
!
!
!
!
!
 79 
)12!3.44567!/8!8+09+0:,!

 80 
/"'0$1'0,&1#&$'0$.'&0/$()2'.#0/#1$13&'2+$#)&-*$:"'-1",,1@$03++#0/'2+$/")/$)2)-*E'2+$9#")?',&0$'2$J3?#2'-#$8;$(':#$A,3-1$9#$)1?)2/)+#,30GKHGL<$$=$/#0/$/"'0$"*%,/"#0'0$9*$#?)-3)/'2+$M'-1/*%#$NM!O$)21$8;$(':#$'2$:-'2':)--*$&#-#?)2/$9#")?',&)-$%)&)1'+(0$13&'2+$J3?#2'-#$1#?#-,%(#2/$PQRL$1)*0$,-1S<$$$

 81 
.,&$)11&#00'2+$.321)(#2/)-$B3#0/',20$&#-)/#1$/,$/"#$9',-,+*$,.$8;$)21$.,&$/#0/'2+$:)21'1)/#$(,-#:3-)&$)21\,&$+#2#/':$/"#&)%#3/':$)%%&,):"#0<$$$

Motor impairment and seizure phenotype becomes less robust with time!
0          5         10         15         20         25           30         35            40            45           - ! !120        !
Communication!
Brain Activity!
Deficits:  Abnormal EEG,!
Enhanced seizure-like response!
!
Adulthood!Juvenile Period!
Deficits:  Prolonged USV production,  excessive audible squeaking!
!
Deficits: Hypoactivity, Hindlimb clasp!
More severe! Less severe!
!"#$%&'()*"+,-,!)./0)12,&0%3#,
Abnormal EEG,!
Enhanced seizure-like response+,
 *     = Indicates phenotype variability between published studies!
Postnatal Day!
= Previously described behavioral deficit !
= AS phenotype present!
Motor Behavior!
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EphB-mediated degradation of the RhoA GEF Ephexin5 relieves
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Abstract
The mechanisms that promote excitatory synapse formation and maturation have been extensively
studied. However, the molecular events that limit excitatory synapse development so that synapses
form at the right time and place and in the correct numbers are less well understood. We have
identified a RhoA guanine nucleotide exchange factor, Ephexin5, which negatively regulates
excitatory synapse development until EphrinB binding to the EphB receptor tyrosine kinase
triggers Ephexin5 phosphorylation, ubiquitination, and degradation. The degradation of Ephexin5
promotes EphB-dependent excitatory synapse development and is mediated by Ube3A, a ubiquitin
ligase that is mutated in the human cognitive disorder Angelman syndrome and duplicated in some
forms of Autism Spectrum Disorders (ASDs). These findings suggest that aberrant EphB/
Ephexin5 signaling during the development of synapses may contribute to the abnormal cognitive
function that occurs in Angelman syndrome and, possibly, ASDs.
Introduction
A crucial early step in the formation of excitatory synapses is the physical interaction
between the developing presynaptic specialization and the postsynaptic dendrite (Jontes et
al., 2000; Ziv and Smith, 1996). This step in excitatory synapse development is thought to
be mediated by cell surface membrane proteins expressed by the developing axon and
dendrite and appears to be independent of the release of the excitatory neurotransmitter
glutamate (reviewed in Dalva et al., 2007). Several recent studies have revealed an
important role for Ephrin cell surface-associated ligands and Eph receptor tyrosine kinases
in this early cell-cell contact phase that is critical for excitatory synapse formation (Dalva et
al., 2000; Ethell et al., 2001; Henkemeyer et al., 2003; Kayser et al., 2006; Kayser et al.,
2008; Lai and Ip, 2009; Murai et al., 2003). Ephs can be divided into two classes, EphA and
EphB, based on their ability to bind the ligands EphrinA and EphrinB, respectively
(reviewed in Flanagan and Vanderhaeghen, 1998). EphBs are expressed postsynaptically on
the surface of developing dendrites, while their cognate ligands, the EphrinBs, are expressed
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on both the developing axon and dendrite (Grunwald et al., 2004; Grunwald et al., 2001;
Lim et al., 2008). When an EphrinB encounters an EphB on the developing dendrite, EphB
becomes autophosphorylated, thus increasing its catalytic kinase activity (reviewed in
Flanagan and Vanderhaeghen, 1998). This leads to a cascade of signaling events including
the activation of guanine nucleotide exchange factors (GEFs) Tiam, Kalirin, and Intersectin,
culminating in actin cytoskeleton remodeling that is critical for excitatory synapse
development (reviewed in Klein, 2009). Consistent with a role for EphBs in excitatory
synapse development, EphB1/EphB2/EphB3 triple knockout mice have fewer mature
excitatory synapses in vivo in the cortex, and hippocampus (Henkemeyer et al., 2003;
Kayser et al., 2006). In addition, the disruption of EphB function postsynaptically in
dissociated hippocampal neurons leads to defects in spine morphogenesis and a decrease in
excitatory synapse number (Ethell et al., 2001; Kayser et al., 2006). Conversely, activation
of EphBs in hippocampal neurons leads to an increase in the number of dendritic spines and
functional excitatory synapses (Henkemeyer et al., 2003; Penzes et al., 2003). These
findings indicate that EphBs are positive regulators of excitatory synapse development.
While there has been considerable progress in characterizing the mechanisms by which
EphBs promote excitatory synapse development, it is not known if there are EphB-
associated factors that restrict the timing and extent of excitatory synapse development. We
hypothesized that neurons might have evolved mechanisms which act as checkpoints to
restrict EphB-mediated synapse formation, and that the release from such synapse formation
checkpoints might be required if synapses are to form at the correct time and place and in
appropriate numbers.
We considered the possibility that likely candidates to mediate the EphB-dependent
restriction of excitatory synapse formation might be regulators of RhoA, a small G protein
that functions to antagonize the effects of Rac (Tashiro et al., 2000). In previous studies we
identified a RhoA GEF, Ephexin1 (E1), which interacts with EphA4 (Fu et al., 2007; Sahin
et al., 2005; Shamah et al., 2001). E1 is phosphorylated by EphA4 and is required for the
EphrinA-dependent retraction of axonal growth cones and dendritic spines (Fu et al., 2007;
Sahin et al., 2005). While E1 does not appear to interact with EphB, E1 is a member of a
family of five closely related GEFs. Of these GEFs, Ephexin5 (E5) (in addition to E1) is
highly expressed in the nervous system. Therefore, we hypothesized that E5 might function
to restrict the EphB-dependent development of excitatory synapses by activating RhoA.
In this study we report that EphB interacts with E5, that E5 suppresses excitatory synapse
development by activating RhoA, and that this suppression is relieved by EphrinB activation
of EphB during synapse development. Upon binding EphrinB, EphB catalyzes the tyrosine
phosphorylation of E5 which triggers E5 degradation. We identify Ube3A as the ubiquitin
ligase that mediates E5 degradation, thus allowing synapse formation to proceed. As UBE3A
is mutated in Angelman syndrome and duplicated in some forms of Autism Spectrum
Disorders (ASDs), these findings suggest a possible mechanism by which the mutation of
Ube3A might lead to cognitive dysfunction (Jiang et al., 1998; Kishino et al., 1997).
Specifically, we provide evidence that in the absence of Ube3A, the level of E5 is elevated
and propose that this may lead to the enhanced suppression of EphB-mediated excitatory
synapse formation, thereby contributing to Angelman syndrome and, possibly, ASDs.
Results
Ephexin5 interacts with EphB2
To identify mechanisms that restrict the ability of EphBs to promote an increase in
excitatory synapse number, we searched for RhoA guanine nucleotide exchange factors
(GEFs) that specifically activate RhoA signaling, are expressed in the same population of
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neurons that express EphB, are expressed at the same time during development as EphB,
and interact with EphB. Structure-function studies of GEFs identified amino acid residues in
the activation domain of Rho family GEFs that specifically identify the GEFs as activators
of RhoA rather than Rac or Cdc42. Applying this criterion, fourteen GEFs were identified
that specifically activate RhoA (Rossman et al., 2005). Of these GEFs we found by in situ
hybridization that E5 has a similar expression pattern to EphB in the hippocampus (Fig 1A).
These findings raised the possibility that E5 might mediate the effect of EphB on developing
synapses.
We asked if E5 interacts physically with EphB. We transfected HEK293T (293) cells with
plasmids encoding Myc-tagged E5, E1, or a vector control together with Flag-tagged EphB2
or EphA4 and asked if these proteins co-immunoprecipitate. Extracts were prepared from
the transfected 293 cells and EphA4 or EphB2 immunoprecipitated with Flag antibodies.
The immunoprecipitates were subjected to SDS polyacrylamide gel electrophoresis (SDS-
PAGE) and blotted with anti-Myc antibody (α-Myc). We found that E5 co-
immunoprecipitates with EphB2 but not with EphA4 (Fig 1B). The relatively weak E5
interaction with EphA4 is consistent with published experiments (Ogita et al., 2003). By
contrast, E1 is co-immunoprecipitated by EphA4 but not EphB2 (Shamah et al., 2001).
These findings suggest that E5 interacts preferentially with EphB2.
To extend this analysis we investigated whether EphB2 interacts with E5 in neurons.
Neurons from embryonic day 16 (E16) mouse brains were lysed in RIPA buffer and the
lysates incubated with affinity purified anti-C-terminal E5 (α-C-E5) or control (IgG)
antibodies. The immunoprecipitates were then resolved by SDS-PAGE and immunoblotted
with affinity purified anti-N-terminal E5 (α-N-E5) or EphB2 (α-EphB2) antibodies (Fig 1C).
This analysis revealed that endogenous, neuronal EphB2 is immunoprecipitated by α-C-E5
but not IgG. Moreover, using lysates from brains of wild type or E5 knockout mice (E5−/−,
see Fig S1), we find that α-C-E5 immunoprecipitates EphB2 only from brain lysates when
E5 is present (Fig 1D). Taken together, these findings suggest that EphB interacts with
Ephexin5 in neurons.
As an independent means of assessing if EphB and E5 interact with one another, we used
immunofluorescence microscopy to determine if these two proteins co-localize in neurons.
Cultured mouse hippocampal neurons were transfected with a plasmid expressing green
fluorescent protein (GFP). The GFP-expressing neurons were imaged and quantified for the
co-localization of EphB2 and E5 puncta by staining with α-C-E5 and α-EphB2. This
analysis revealed that EphB2 and E5 co-localize along dendrites (Fig 1E). We find that 40%
of EphB staining overlaps with α-C-E5 staining early during the development of excitatory
synapses. After eight days in vitro (DIV) the overlap of EphB with E5 within neuronal
dendrites decreases to below the level that would be detected by random chance. This
change suggests that EphB interacts with E5 early during development, possibly to inhibit
EphB synapse formation.
Ephexin5 is a guanine nucleotide exchange factor that activates RhoA
To determine if E5 activates RhoA, we transfected 293 cells with a control plasmid or a
plasmid that drives the expression of Myc-tagged mouse E5. We prepared extracts from the
transfected cells and incubated the extracts with a GST-fusion protein that includes the
Rhotekin-Binding Domain (GST-RBD), a protein domain that selectively interacts with
active (GTP-bound) but not inactive (GDP-bound) RhoA. Following SDS-PAGE of the
proteins in the extract that bind to GST-RBD, RhoA binding to GST-RBD was measured by
immunoblotting with α-RhoA antibodies. We found that cells expressing E5 exhibited
higher levels of activated RhoA compared to cells transfected with a control plasmid,
indicating that E5 activates RhoA (Fig 2A).
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When a similar series of experiments were performed using a GST-fusion Pak-Binding
Domain (GST-PBD) which specifically interacts with active forms of two other Rho
GTPases, Rac1 and Cdc42, we found that E5 does not induce the binding of GST-PBD to
Rac1 or Cdc42. In contrast, E1-expressing cells displayed enhanced binding of Rac1 and
Cdc42 to GST-PBD. We conclude that E5 activates RhoA but not Rac1 or Cdc42 (Fig S2A).
To determine whether E5 activation of RhoA requires the GEF activity of E5, we generated
a mutant form of E5 in which its GEF activity is impaired. To identify the residues required
for Ephexin5 guanine nucleotide exchange activity we compared its Dbl-homology (DH)
domain to the DH domain of other RhoA-specific GEFs (Snyder et al., 2002). We identified
within the α5 helix of E5’s DH domain three amino acids that are conserved in other GEFs
that, like E5, activate RhoA but not Rac1 and Cdc42 (Fig S2B). To generate a form of E5
predicted to be inactive as a GEF, we mutated these three conserved amino acids (L562,
Q566, and R567) to alanine (E5-LQR). Using the GST-RBD pull down assay we found that
although E5-WT and E5-LQR are expressed at similar levels, the E5-LQR mutant is
significantly impaired relative to WT in its ability to activate RhoA (Fig 2B). As a control,
we mutated other conserved residues within the α5 DH region to alanine (Q547, S548,
R555, and L556). When we tested this mutant we observed no defect in RhoA activation,
suggesting that the E5-LQR mutation specifically disrupts the GEF activity of E5 and that
the inability of the LQR mutant to activate RhoA is not a general consequence of disrupting
the α5 region of Ephexin5 (Fig S2C). Taken together, these findings indicate that E5
requires an intact conserved GEF domain to promote RhoA activity in 293 cells, suggesting
that E5 functions as a RhoA GEF.
We next asked if E5 expression affects RhoA activity in the brain. We lysed P3 whole brains
from wild type or E5−/− mice and performed a GST-RBD pull down assay. This analysis
revealed a significant decrease in RhoA activation in brain extracts from E5−/− mice
compared to wild type mice, suggesting that E5 is required to maintain wild type levels of
RhoA activity in the brain (Fig 2C).
Ephexin5 negatively regulates excitatory synapse number
Our findings indicate that E5 interacts with EphB, a key regulator of excitatory synapse
development. Thus, we asked whether E5 plays a role in the development of excitatory
synapses. We generated two short hairpin RNA constructs that each knocks down E5 protein
levels when expressed in 293 cells or cultured hippocampal neurons (Fig S3A–S3B). These
shRNAs were introduced into cultured hippocampal neurons together with a plasmid that
drives expression of green fluorescent protein (GFP) to allow detection of the transfected
cells. We found by staining with α-N-E5 antibodies that the E5 shRNAs (E5-shRNA), but
not scrambled hairpin control shRNAs (ctrl-shRNA), efficiently knocked down E5
expression in the transfected neurons (Fig S3C).
By staining with antibodies that recognize pre- and post- synaptic proteins or by visualizing
dendritic spines in GFP transfected neurons we observed a significant increase in the
number of excitatory synapses and dendritic spines that are present on the E5-shRNA-
expressing neurons compared to neurons expressing ctrl-shRNAs (Fig 3A and 3B). By
contrast, we failed to detect a significant change in dendritic spine length or width under
these conditions (Fig S3D). These findings suggest that E5 functions to restrict spine/
excitatory synapse number but has no significant effect on spine morphology. Consistent
with these conclusions, we found that overexpression of E5 in hippocampal neurons leads to
a decrease in the number of excitatory synapses that are present on the E5-overexpressing
neurons (Fig 3C). This ability of E5 to negatively regulate excitatory synapse number
requires its RhoA GEF activity, as overexpression of E5-LQR had no effect on synapse
number (Fig 3D).
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To assess the effect of reducing E5 levels on the functional properties of excitatory
synapses, we recorded miniature excitatory postsynaptic currents (mEPSCs) from cultured
hippocampal neurons transfected with E5-shRNA or ctrl-shRNA. We observed an increase
in the frequency and amplitude of mEPSCs on neurons expressing E5-shRNA compared to
ctrl-shRNA (Fig 3E). This suggests that E5 acts postsynaptically to restrict excitatory
synapse function. The increase in mEPSC frequency could be due to an increase in
presynaptic vesicle release onto the transfected neuron or an increase in the number of
excitatory synapses that are present on the transfected neuron. We favor the latter possibility
since our transfection protocol selectively reduces E5 levels postsynaptically and also
because the increase in synapse number is most consistent with the increase in co-staining of
pre- and post-synaptic markers that we observe when the level of E5 is reduced. The
possibility that E5 functions postsynaptically is further supported by immunofluorescence
staining experiments demonstrating that E5 is enriched in dendrites relative to axons (Fig
S1F).
As an independent means of assessing the importance of E5 in the control of excitatory
synapse number, we cultured hippocampal neurons from E5−/− mice or their wild type
littermates for 10 days in vitro and then, following transfection of a GFP-expressing plasmid
into these neurons, quantified the number of excitatory synapses present on the transfected
neuron at DIV14. We observed a three-fold increase in the number of synapses that are
present on E5−/− neurons compared to E5+/− neurons (Fig 4A). Taken together with the E5-
shRNA knockdown and E5 overexpression analyses, these findings suggest that E5 acts
postsynaptically to reduce excitatory synapse number.
We next asked if E5 regulates synapse number in the context of an intact developing
neuronal circuit using conditional E5 (E5fl/fl) animals (see Fig S1). Upon introduction of Cre
recombinase into E5fl/fl cells, exons 4–8 of the E5 gene are excised resulting in a cell that no
longer produces E5 protein (data not shown). Organotypic slices were prepared from the
hippocampus of the E5fl/fl mice or their wild type littermates. Using the biolistic transfection
method, a plasmid expressing Cre recombinase was introduced into a low percentage of
neurons in the slices. We found that introduction of a Cre-expressing plasmid into E5fl/fl
neurons in the hippocampal slice led to a significant increase in the density of dendritic
spines present on the Cre-expressing neurons (Fig 4B). By contrast, expression of Cre in
neurons of a wild type hippocampal slice has no effect on dendritic spine density. The length
and width of dendritic spines analyzed in these experiments showed no significant
difference between wild type and E5−/− neurons (Fig S4). Thus, elimination of E5
expression in neurons in the context of an intact neuronal circuit leads to an increase in the
number of dendritic spines.
To assess the role of E5 in hippocampal circuit development in vivo, we performed acute
slice physiology experiments in the CA1 region of the hippocampus from wild type or E5−/−
mice. We find that relative to wild type neurons, in E5−/− CA1 pyramidal neurons there are
more frequent excitatory events that have larger amplitude (Fig 4C). A possible explanation
for these findings is that when E5 function is disrupted during in vivo development more
excitatory synapses form resulting in more excitatory post-synaptic events. To test this
possibility, we used array tomography to quantify the number of excitatory synapses that
form in the CA1 stratum radiatum of wild type and E5−/− mice. We observed a ~2-fold
increase in the number of excitatory synapses within the CA1 region of the E5−/−
hippocampus compared to wild type mice (Fig 4D). Specifically, the number of juxtaposed
synapsin and PSD-95 puncta was quantified and considered a measurement of the number of
excitatory synapses that form within the CA1 region of the hippocampus in vivo. This
analysis revealed a significant increase in the number of PSD-95 puncta but no change in the
number of synapsin puncta density (Fig 4D). This suggests that the increase in excitatory
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synapse number in the stratum radiatum of E5−/− mice is likely due to the absence of E5
post-synaptically and that when E5 is present within dendrites it functions to negatively
regulate synapse number in vivo. On the basis of these results, we conclude that a key
function of E5 is to restrict excitatory synapse number during the development of neuronal
circuits.
Ephexin5 restricts EphB2 control of excitatory synapse formation
We next considered the possibility that the ability of E5 to restrict excitatory synapse
number might be controlled by EphB2 signaling. To test this idea, we asked whether
reducing EphB2 signaling eliminates the increase in excitatory synapse number detected
when E5 levels are knocked down by expression of E5-shRNA. To block EphB2 activation,
we introduced into neurons a kinase dead version of EphB2 (EphB2-KD) which has been
previously shown to block EphB2 signaling (Dalva et al., 2000). As described above,
expression of E5-shRNA in neurons leads to a significant increase in the number of
synapses that are present on the E5-shRNA-expressing neuron. However, this increase was
reversed if the E5-shRNA was co-transfected with a plasmid that drives expression of
EphB2-KD, but was not affected by co-transfection of a control plasmid (Fig 4E). These
findings suggest that the increase in excitatory synapse number that occurs when E5 levels
are reduced requires EphB signaling. Consistent with this conclusion, we find that if we
overexpress wild type EphB2 in neurons more synapses are present on the EphB-expressing
neuron. However, this effect is reduced if E5 is overexpressed in neurons together with
EphB (Fig 4F). It is possible that the ability of overexpressed E5 to suppress the synapse-
promoting effect of EphB2 reflects independent actions of these two signaling molecules.
However, given that EphB2 and E5 interact with one another in neurons, the most likely
interpretation of these results is that E5 functions directly to restrict the synapse-promoting
effects of EphB2. If this were the case, we would predict that for EphB2 to positively
regulate excitatory synapse development it would be necessary to inactivate and/or degrade
E5.
EphB mediates phosphorylation of Ephexin5 at tyrosine-361
We considered the possibility that since EphB2 is a tyrosine kinase it might inhibit the GEF
activity or expression of the E5 protein by catalyzing the tyrosine phosphorylation of E5. In
support of this possibility, stimulation of dissociated mouse hippocampal neurons with EB1
for 15 minutes led to an increase in the level of E5 tyrosine phosphorylation as detected by
probing immunoprecipitated E5 with the pan-anti-phosphotyrosine antibody, 4G10 (Fig 5A).
We have previously shown that EphrinA1 stimulation of cultured neurons leads to the
tyrosine phosphorylation of E1 at tyrosine 87 (Sahin et al., 2005). On the basis of this
finding we hypothesized that exposure of neurons to EphrinB1 (EB1) might promote the
phosphorylation of the analogous tyrosine residue (Y361) on E5 (Fig 5B) and that
phosphorylation at this site might lead to E5 inactivation. To address this possibility, we
overexpressed EphB2 in 293 cells together with wild type E5 or a mutant form of E5 in
which Y361 is converted to a phenylalanine (E5-Y361F). Lysates were prepared from the
transfected cells and after SDS-PAGE were immunoblotted with 4G10 (Fig 5C). We found
that in the presence of EphB2, E5-WT, but not E5-Y361F, becomes tyrosine
phosphorylated. These findings suggest that EphB2 catalyzes the tyrosine phosphorylation
of E5 primarily at Y361.
To show definitively that E5 Y361 is tyrosine phosphorylated, we generated E5 phospho-
Y361 antibodies (α-pY361). To demonstrate that these antibodies specifically recognizes the
Y361-phosphorylated form of E5, we immunoblotted cell lysates prepared from 293 cells
that express EphB2 and either E5-WT or E5-Y361F with α-pY361. This analysis
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demonstrated that the α-pY361 bind to wild type E5 but not E5-Y361F (Fig 5C).
Furthermore, using α-pY361 we found that when wild type EphB2, but not a kinase dead or
cytoplasmic truncated version of EphB2, is expressed in 293 cells together with E5, E5
becomes phosphorylated at Y361 (Fig S5A). In contrast, when EphA4 or EphA2 were
expressed in 293 cells we detected little to no phosphorylation of E5 at Y361 (Fig S5B).
These findings suggest that EphB2, but not EphAs, promote E5 Y361 phosphorylation
(pY361).
We also found by immunoblotting with the α-pY361 that E5 is phosphorylated at Y361 in
the hippocampus of wild type but not E5−/− mice (Fig S5C), and that EB1 stimulation of
cultured hippocampal neurons leads to E5 Y361 phosphorylation (Fig 5D). By
immunofluorescence microscopy we detect punctate α-pY361 staining along the dendrites of
EB1-treated wild type neurons, but less staining in untreated neurons (Fig 5E). This result
suggests that E5 becomes newly phosphorylated at Y361 upon exposure of hippocampal
neurons to EB1.
EphB2-mediated degradation of Ephexin5 is kinase and proteasome dependent
We asked if EB1 stimulation of E5 Y361 phosphorylation leads to a change in E5 activity or
expression. To investigate this possibility we asked if EphB suppresses E5-dependent RhoA
activation in a phosphorylation-dependent manner. We transfected 293 cells with E5 in the
presence or absence of EphB2 and measured RhoA activity using the RBD pull down assay
(Fig 5F). We found that E5-dependent RhoA activation was reduced in 293 cells expressing
EphB2 and E5 compared to cells expressing E5 alone. These findings are consistent with the
possibility that EphB2-mediated tyrosine phosphorylation of E5 either leads to a suppression
of E5’s ability to activate RhoA, or alternatively might trigger a decrease in E5 protein
expression resulting in a decrease in RhoA activation. We found this latter possibility to be
the case (Fig 5F, E5 loading control). Furthermore, when we compared lysates from the
brains of wild type or EphB2−/− mice, we observed that E5 phosphorylation at Y361 is
decreased while the levels of E5 expression are increased in the lysates from EphB2−/− mice
(Fig 5G). These data suggest that EphB2 functions to phosphorylate and degrade E5.
Consistent with the idea that E5 expression is destabilized in the presence of EphB, we
observed that in the dendrites of cultured hippocampal neurons overexpressing EphB2,
endogenous E5 expression levels are reduced compared to control transfected neurons or
neurons transfected with a kinase dead version of EphB2 (Fig S6A and B). When neurons
were exposed to EB1 compared to EA1 for 60 minutes, we found by immunoblotting of
neuronal extracts, or immunofluorescence staining with α-N-E5, that exposure to EB1 leads
to a decrease in E5 expression (Fig 6A). The lack of complete loss of E5 expression by
western blot may be due to the fact that EB1 stimulation leads to dendritic and not somatic
loss of E5 expression. Moreover, immunofluorescence staining revealed a loss of E5 puncta
specifically within the dendrites of EB1-stimulated neurons, consistent with the possibility
that EB1/EphB-mediated degradation of E5 relieves an inhibitory constraint that suppresses
excitatory synapse formation on dendrites. In support of this idea, we find by
immunoblotting of extracts from mouse hippocampi that endogenous E5 protein levels are
highest at postnatal day 3 prior to the time of maximal synapse formation and then decrease
as synapse formation peaks in the postnatal period (Fig S6C). Northern blotting revealed
that this decrease in E5 protein is not due to a change in the level of E5 mRNA expression
(Fig S6C). Given that E5 protein levels decrease dramatically during the time period P7-P21
when synapse formation is maximal, these findings suggest that E5 may need to be degraded
prior to synapse formation.
We asked whether EphB-mediated degradation of E5 could be reconstituted in heterologous
cells. When EphB and Myc-tagged E5 were co-expressed in 293 cells we observed a
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significant decrease in E5 protein expression in the presence of EphB2. The presence of
EphB2 had no effect on the level of expression of a related GEF, E1 (Fig 6B). We asked
whether EphB-mediated degradation of E5 depends upon Y361 phosphorylation. We found
that in 293 cells overexpressing Myc-tagged E5, the co-expression of EphB2, but not
EphB2-KD, resulted in a significant decrease in E5 levels (Fig 6C). This suggests that EphB
tyrosine kinase activity is required for E5 degradation. The EphB-mediated reduction in E5
levels is dependent on Y361 phosphorylation, as EphB2 expression had no effect on the
level of E5 Y361F expression (Fig 6D). This suggests that the phosphorylation of E5 at
Y361 triggers E5 degradation.
We considered the possibility that the Y361 phosphorylation-dependent decrease in E5
protein levels might be due to EphB-dependent stimulation of E5 proteasomal degradation.
Consistent with this possibility we found that addition of the proteasome inhibitor
lactacystin to 293 cells leads to a reversal of the EphB-dependent decrease in E5 protein
levels, as measured by an increase in total ubiquitinated E5 (Fig S6D). In addition, in
neuronal cultures the EB1 induced decrease in E5 protein expression is blocked if the
proteasome inhibitor lactacystin is added prior to EB1 addition (Fig 6E). Notably, in the
presence of lactacystin, E5 is ubiquitinated, further supporting the idea that E5 is degraded
by the proteasome.
To test whether E5 is ubiquitinated in the brain, we incubated wild type or E5−/− brain
lysates with α-C-E5 and after immunoprecipitation and SDS-PAGE, probed with α-ubiquitin
antibodies. This analysis detected the presence of ubiquitinated species in α-C-E5
immunoprecipitates prepared from wild type but not E5−/− brain lysates (Fig 6F). These
findings indicate that E5 is ubiquitinated in the brain.
EphB2-mediated degradation of Ephexin5 requires Ube3A
During proteasome-dependent degradation of proteins, specificity is conferred by E3 ligases
or E2 conjugating enzymes that recognize the substrate to be degraded. The E3 ligase binds
to the substrate and catalyzes the addition of polyubiquitin side chains to the substrate
thereby promoting degradation via the proteasome (Hershko and Ciechanover, 1998). We
considered several E3 ligases that have recently been implicated in synapse development as
candidates that catalyze E5 degradation. One of these E3 ligases, Cbl-b, has previously been
implicated in the degradation of EphAs and EphBs (Fasen et al., 2008; Sharfe et al., 2003).
A second E3 ligase, Ube3A, has been shown to regulate synapse number. To determine if
Ube3A and/or Cbl-b catalyze E5 degradation we first asked if either of these E3 ligases
interacts with and degrades E5 in 293 cells. When these E3 ligases were epitope-tagged and
expressed in 293 cells together with E5 we found that E5 co-immunoprecipitates with
Ube3A but not with Cbl-b (Fig 7A). The co-immunoprecipitation of Ube3A with E5 was
specific in that Ube3A was not co-immunoprecipitated with two other neuronal proteins, E1
or the transcription factor MEF2. In a previous study we have shown that Ube3A binds to
substrates via a Ube3A binding domain (hereafter referred to as UBD (Greer et al., 2010).
Using protein sequence alignment programs, ClustalW and ModBase, we identified a UBD
in E5, providing further support for the idea that E5 might be a substrate of Ube3A (Fig
S7A). Consistent with this hypothesis, we found that the level of E5 expression is reduced in
293 cells co-transfected with Ube3A compared to cells co-transfected with Cbl-b (Fig S7B).
We asked if EB1/EphB-mediated E5 degradation in neurons is catalyzed by Ube3A. To
inhibit Ube3A activity we introduced into neurons a dominant interfering form of Ube3A
(dnUbe3A) that contains a mutation in the ubiquitin ligase domain rendering Ube3A
inactive. We have previously shown that even though dnUbe3A is catalytically inactive it
still binds to E2 ligases and to its substrates and functions in a dominant negative manner to
block the ability of wild type Ube3A to ubiquitinate its substrates (Greer et al., 2010). We
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found that when introduced into 293 cells dnUbe3A binds to E5 (Fig 7A). We also found by
immunofluorescence microscopy that when overexpressed in neurons, dnUbe3Ablocks EB1/
EphB stimulation of E5 degradation (Fig 7B). EB1/EphB stimulation of E5 degradation was
also attenuated when Ube3A expression was knocked down by a shRNA that specifically
targets the Ube3A mRNA (Fig 7B (Greer et al., 2010)). Notably, the presence of the
dnUbe3A did not affect E5 expression in neurons in the absence of EphrinB stimulation,
suggesting that EphrinB stimulation of E5 Y361 phosphorylation may be required for
Ube3A-mediated degradation of E5 (Fig S7C).
To determine if Ube3A-dependent degradation of E5 might be relevant to the etiology of
Angelman syndrome we asked if the absence of Ube3A in a mouse model of Angelman
syndrome affects the level of E5 expression in the brain. We compared the level of E5
protein expression in the brains of wild type mice to that expressed in the brains of mice in
which the maternally inherited Ube3A was disrupted (Ube3Am−/p+). Because the paternally
inherited copy of Ube3A is silenced in the brain due to imprinting, the level of Ube3A
expression in Ube3Am−/p+ neurons is very low. We found that the level of E5 expression in
the brains of Ube3Am−/p+ mice was significantly higher than that detected in the brains of
wild type mice (Fig 7C). Moreover, the level of ubiquitinated E5 in brains of Ube3Am−/p+
mice was significantly reduced compared to the brains of litter mate controls (Fig 7D). In
addition we found that when neurons from wild type and Ube3Am−/p+ brains were cultured
and then treated with EB1 the level of E5 protein was reduced upon EB1 treatment in wild
type but not in Ube3Am−/p+ neurons (Fig 7E). Taken together, these findings suggest that in
response to EB treatment E5 is tyrosine phosphorylated by an EphB-dependent mechanism,
and that this leads to E5 degradation by a Ube3A-dependent mechanism. If E5 degradation
is disrupted due to a loss of Ube3A as occurs in Angelman syndrome the result is an
increase in E5 expression and a disruption of the proper control of excitatory synapse
number during brain development.
Discussion
Previous studies have revealed a role for EphrinB/EphB signaling in the development of
excitatory synapses (Klein, 2009). However, the regulatory constraints that temper EphB-
dependent synapse development so that excitatory synapses form at the right time and place,
and in the correct number were not known. In this study we identify a RhoA GEF, E5,
which functions to restrict EphB-dependent excitatory synapse development. E5 interacts
with EphB prior to EphrinB binding, and by activating RhoA serves to inhibit synapse
development. The binding of EphrinB to EphB as synapses form triggers the
phosphorylation and degradation of E5 by a Ube3A-dependent mechanism. The reduction in
E5 expression may allow EphB to promote excitatory synapse development by activating
Rac and other proteins at the synapse.
The findings that E5 functions to restrict excitatory synapse number suggests that, even
though EphBs promote excitatory synapse development, there are constraints on the activity
of EphB so that synapse number is effectively controlled. There are several steps in the
process of synapse development where E5 may function to restrict synapse number. One
possibility is that E5 functions early in development as a barrier to excitatory synapse
formation by activating RhoA and restricting the motility or growth of dendritic filopodia
that are the sites of contact by the presynaptic neuron. For example, by inhibiting dendritic
filopodia formation or motility, E5 may decrease the number of contacts the filopodia make
with the presynaptic neuron, thus resulting in the formation of fewer synapses. An
alternative possibility is that E5 functions to restrict synapse number later in development
perhaps to counterbalance the positive effects of EphB on Rac that promote dendritic spine
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development. An additional possibility is that E5 functions after excitatory synapse
development as a regulator of synapse elimination.
Our analyses of E5 function are most consistent with the possibility that E5 functions early
in the process of synapse development. First, we find that E5 is expressed, active, and bound
to EphB prior to synapse formation. Second, the interaction of EphrinB with EphB, a
process that is thought to be an early step in excitatory synapse development, triggers the
degradation of E5. Third, our preliminary time-lapse imaging studies suggest that E5 is
localized to newly formed filopodia prior to synapse development where it appears to
restrict filopodia motility and growth (Margolis et al. unpublished). Thus, E5 might function
as an initial barrier to synapse formation until it is degraded upon EphrinB binding to EphB.
It is possible that through its interaction with EphB, E5 marks the sites where synapses will
form, and that the degradation of E5 is a critical early step in excitatory synapse
development. While the mechanisms by which E5 is degraded are not fully understood, our
studies suggest that the phosphorylation of the N-terminus of E5 at Y361 triggers the
Ube3A-mediated proteasomal degradation of E5. One possibility is that prior to pY361 the
N- and C-terminal portions of E5 interact, thereby protecting E5 from degradation. The
phosphorylation of E5 at Y361 may relieve this inhibitory constraint allowing for E5
ubiquitination and degradation. A similar mechanism has been shown to regulate the
activation of the Rac GEF Vav, (Aghazadeh et al., 2000)). During EphrinA/EphA signaling
it has been proposed that Vav-mediated endocytosis of the EphrinA/EphA complex may
allow the conversion of the initial adhesive interaction between EphrinA and EphA-
expressing cells into a repulsive interaction that results in growth cone collapse and axon
repulsion. It is possible that E5 has a related function during EphB signaling at synapses.
Typically the EB/EphB interaction is thought to be repulsive. This has been documented in
studies of EphB’s role in the process of axon guidance (Egea and Klein, 2007; Flanagan and
Vanderhaeghen, 1998). However, during synapse development the EphrinB/EphB
interaction is thought to result in synapse formation, a process that requires an interaction
between the developing pre- and post-synaptic specialization. One possibility is that when
EphrinB and EphB mediate the interaction between the incoming axon and the developing
dendrite, the interaction is facilitated by the degradation of E5 by Ube3A. Since E5 is a
RhoA GEF, its presence might initially lead to repulsion between the incoming axon and the
dendrite. However, the EphB-dependent degradation of E5 might convert this initial
repulsive interaction into an attractive one.
The finding that Ube3A is the ubiquitin ligase that controls EphB-mediated E5 degradation
is of interest given the role of Ube3A in human cognitive disorders such as Angelman
syndrome and autism. The absence of Ube3A function in Angelman syndrome would be
predicted to result in an increase in E5 protein expression, and thus a decrease in EphB-
dependent synapse formation. Consistent with this possibility, we find in a mouse model for
Angelman syndrome that the level of E5 protein expression is elevated and that in response
to EphrinB treatment E5 is not degraded. Likewise, several studies have indicated that
synapse development and function is disrupted in these mice (Jiang et al., 1998; Yashiro et
al., 2009).
The recent finding that the Ube3A gene lies within a region of chromosome 15 that is
sometimes duplicated in autism raises the possibility that altered levels of Ephexin5 and the
resulting defects in excitatory synapse restriction might also be a mechanism relevant to the
etiology of autism (Glessner et al., 2009). If this is the case, a possible therapy for treating
autism might be to reduce the level of Ube3A activity, and thus increase the level of
Ephexin5 expression. It is important to consider that in addition to Ephexin5, Ube3A
regulates the abundance of other synaptic proteins. Nevertheless, the ultimate effect of the
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aberrant expression of Ephexin5 and other Ube3A substrates on synapse development and
function will require further study. It seems likely that such studies will provide further
understanding of the development of human cognitive function and new insights into how
this process goes awry in disorders such as Angelman syndrome and autism.
Experimental Procedures
DNA Constructs
Details of DNA constructs can be found in supplementary section.
Generation of E5−/− Mice
An E5 targeting vector was electroporated into 129 J1 ES cells, and positive clones were
identified by Southern hybridization with two separate probes (See supplementary section).
Antibodies
Details of antibodies can be found in supplementary section.
Mice, Cell culture, Transfections, and Ephrin stimulations
Ube3a knockout mice were previously described (Greer et al., 2010). EphB2 knockout mice
were previously described (Kayser et al., 2008). 293T cells were cultured in DMEM and
transfected using the calcium phosphate method. Organotypic slice cultures were prepared
from P6 mouse brains and biolistically transfected. Acute slices were prepared from P12-14
mice. Dissociated neurons were cultured in Neurobasal Medium supplemented with B27 and
transfected using the Lipofectamine method. For details on cell culture, transfections and
Ephrin stimulations see supplementary section.
Cell lysis, immunoprecipitations, GEF pulldown assays and western blots
Whole rat or mouse brains or cultured cells were collected and homogenized in RIPA buffer.
For immunoprecipitations, lysed cells were centrifuged and supernatants were incubated
with appropriate antibody for 2 hours at 4°C, followed by addition of Protein-A or Protein-G
beads (Santa Cruz Biotechnology) for 1 hour, and washed three times with ice-cold RIPA
buffer. For the α-PY361 detection experiment in 293T cells, samples were boiled in SDS
buffer to disrupt the E5/EphB2 interaction and diluted 1:5 in 1.25X RIPA buffer prior to
immunoprecipitation of E5-Myc. RBD and PBD pulldown assays were conducted according
to the manufacture’s suggestions (Upstate Cell Signaling Solutions). For details see
supplementary section.
In situ hybridization
To generate probes for in situ hybridization, mouse E5 and EphB2 cDNA were subcloned
into pBluescript II SK (+). Bluescript plasmids containing E5 or EphB2 cDNA were
linearized using the restriction enzyme BssHII. Sense and antisense probes were generated
using DIG RNA labeling mix (Roche) according to manufacturer’s instructions. Full-length
DIG-labeled probes were subjected to alkaline hydrolysis as described in supplementary
section.
Immunocytochemistry
Neurons were paraformaldehyde fixed in PBS. For measuring synapse density, fixed
neurons were incubated with α-PSD-95 and α-Synapsin antibodies followed by α-Cy3 and
α-Cy5 antibodies to visualize the primary antibodies. For protein co-localization
experiments fixed neurons were similarly treated using α-EphB2 antibodies and α-N-E5
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antibodies or α-pY361-E5. For over-expression studies fixed neurons were incubated using
α-Myc or α-Flag antibodies to visualize overexpressed E5-Myc or EphB2-Flag protein in the
context of the GFP-labeled neurons. For details see supplementary section.
Synapse Assay, Image analysis and quantification
Images were acquired on a Zeiss LSM5 Pascal confocal microscope and spine and synapse
analysis was performed as previously described (see supplementary section).
Ube3A Knockout Cultures
Dissociated hippocampal neurons from Ube3A knockout and wild-type mice were prepared
as previously described (Greer et al., 2010).
Array Tomography
Array tomography was performed as previously described (Micheva and Smith, 2007) with
modifications as described in the supplementary section.
Electrophysiology
Electrophysiology was performed using standard methods (see supplementary section).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Ephexin5 interacts with EphB2
A) E5 and EphB2 are expressed in the CA1 region and dentate gyrus (DG) of the
hippocampus at P12. Adjacent 100 nm mouse brain sections were stained for E5 or EphB2
using digoxigenin-labeled RNA probes to the anti-sense strand or sense strand as a control
(top). Lower panels show nuclear staining with DAPI.
B) Immunoprecipitation with α-Flag from 293 cell lysates previously transfected with
various combinations of overexpressing plasmids containing E1-Myc, E5-Myc, Flag-EphB2,
and/or Flag-EphA4, followed by immunoblotting with α-Myc or α-Flag. Input protein levels
shown (bottom).
C) Immunoprecipitation of mouse cortical lysates with IgG or α-C-E5, followed by
immunoblotting with α-EphB2 or α-N-E5 (left). Input protein levels shown (right).
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D) Immunoprecipitation of WT or E5−/− mouse whole brain lysates with α-C-E5 followed
by immunoblotting with α-EphB2. Input EphB2 levels shown (bottom).
E) Dissociated rat hippocampal neurons were stained using α-N-E5 (Blue) and α-EphB2
(Red). A representative image of overlapped EphB2 and E5 is shown (left). White rectangle
outlines magnified dendritic region (right) showing examples of EphB2/E5 co-localization
(arrows). In three independent experiments, quantification of overlapped EphB2/E5 puncta
was determined at DIV2, DIV4 and DIV8 and is represented as percent of EphB2
overlapped with E5 (right). Error bars ±SEM; *p <0.05, non-significant (n.s.).
See also Figure S1.
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Figure 2. Ephexin5 is a GEF that activates RhoA
A) Lysates from 293 cells transfected with empty vector (Ctrl) or E5-Myc overexpressing
vector (WT) were assayed for endogenous RhoA activity using the RBD pulldown assay and
analyzed by immunoblotting with an antibody to RhoA (top). GTPγS lane is a positive
control for inducing RhoA activity. Increased endogenous RhoA activity is demonstrated by
presence of α-RhoA signal in RBD pulldown lanes. Input protein levels and α-Actin loading
control are shown (Bottom).
B) Lysates from 293 cells transfected with empty vector (Ctrl), E5-Myc (WT) or LQR
mutant of E5-Myc (LQR) were assessed for RhoA activity as measured by RBD assay
described in (A). Input protein levels and α-Actin loading control are shown (Bottom).
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C) Presence of E5 is critical for wild type levels of endogenous RhoA signaling in vivo. P3
mouse whole brain lysates from WT or E5−/− (KO) littermates were subjected to RBD
pulldown assays as described in (A). A representative immunoblot is shown (left). From
three experiments, blinded to condition, the quantification of α-RhoA signal was normalized
to input RhoA signal (Right). Error bars ±SEM; *p<0.05.
See also Figure S2.
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Figure 3. Ephexin5 negatively regulates excitatory synapse number
A) 10 ng of E5-shRNA or Ctrl-shRNA was co-transfected with GFP into rat hippocampal
neurons at DIV14. At DIV18 dendritic spines were measured as described in methods.
Representative image illustrates dendritic spines. N indicates number of neurons assessed.
Error bars ±SEM; **p < 0.01, ANOVA.
B) 10 ng or 20 ng of two different E5-shRNA or Ctrl-shRNA constructs was co-transfected
with GFP into rat hippocampal neurons at DIV10. At DIV14 excitatory synapses were
measured as described in methods. Representative image illustrates quantified synapse
puncta (White). Error bars ±SEM; **p < 0.01, ***p<0.005, ANOVA.
C) DIV10 rat hippocampal neurons were co-transfected with GFP and increasing
concentrations of E5-Myc or control plasmid. At DIV 14 excitatory synapses (gray bars) and
exogenous E5 expression (blue bars) were measured as described in methods.
Representative image illustrates localization of E5-Myc on transfected neuron (Red). Error
bars ±SEM; **p < 0.01, ANOVA.
D) Neurons were transfected with E5-Myc (E5-WT) or E5-LQR-Myc (E5-LQR) and
quantified as in (C). Error bars ±SEM; **p < 0.01, ANOVA.
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E) Quantification of mEPSC inter-event interval and amplitude from hippocampal neurons
transfected as in (B) with 20 ng of shRNA. Cumulative distribution plots, bar graphs and
representative traces are shown. Error bars are standard deviation of the mean, ***p<0.005,
*p<0.05.
See also Figures S3, and S1.
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Figure 4. Ephexin5 restricts EphB2 control of excitatory synapse formation
A) E16 hippocampi from E5+/− or E5−/− mice were dissected and dissociated for culture. At
DIV10 dissociated neurons were transfected with GFP. At DIV14 neurons were fixed,
stained and, excitatory synapses were measured as described in methods. Error bars ±SEM;
***p < 0.005, ANOVA.
B) Organotypic slices from WT or E5fl/fl mice were biolistically transfected with Cre-
recombinase (Cre) and dendritic spines were quantified as described in methods.
Representative images are shown (left). Error bars ±SEM; ***p < 0.005, KS test.
C) Quantification of mEPSC inter-event interval and amplitude from acute hippocampal
brain slices prepared from P12-P14 WT or E5−/− mice. Error bars are standard deviation of
the mean; ***p<0.005, *p<0.05.
D) Hippocampi from three independent littermate pairs consisting of P12 WT and E5−/−
mice were prepared as described in methods for quantification of synapses, Synapsin1 and
PSD-95 using array tomography. Error bars ±SEM; *p < 0.05, Mann-Whitney U-Test.
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E) Increase in excitatory synapse number following loss of E5 requires EphB2 signaling. At
DIV10, control plasmid (−) or EphB2KD plasmid (+) were co-expressed in dissociated
mouse hippocampal neurons with GFP and either Ctrl-shRNA or E5-shRNA. At DIV14
excitatory synapses were measured as described in methods. Error bars ±SEM; **p < 0.01,
***p<0.005, ANOVA.
F) E5 can suppress an EphB2-mediated increase in excitatory synapse number. At DIV10,
control plasmid (-) or EphB2-expressing plasmid (+) were co-expressed in dissociated
mouse hippocampal neurons with GFP and either control (Ctrl) plasmid or E5-Myc plasmid.
At DIV14 excitatory synapses were measured as described in methods. Error bars ±SEM;
**p < 0.01, ***p<0.005, ANOVA.
See also Figures S4, and S1.
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Figure 5. EphB2 mediates phosphorylation of Ephexin5 at tyrosine-361
A) Dissociated mouse hippocampal neurons were stimulated with either α-Fc IgG (Ctrl) or
pre-clustered Fc-EB1 for 15 minutes. Neuronal lysates were immunoprecipitated with α-N-
E5, followed by immunoblotting for pan-phosphotyrosine (α-pTyr) or E5 with α-N-E5. EB1
stimulation was determined by immunoblotting neuronal lysates for phospho-Eph (pEph).
Input protein levels and α-Actin loading control are shown (Bottom).
B) E5-Y361 is a conserved residue with E1-Y87 (Sahin et al., 2005).
C) Immunoprecipitation with α-Myc from 293 cell lysates previously transfected with
various combinations of overexpressing plasmids containing E5-Myc, E5 (Y361F)-Myc
and/or EphB2-Flag, followed by immunoblotting with α-pTyr, α-Myc, α-pY361 or α-Flag.
Input EphB2 levels are shown (bottom).
D) Neurons were treated and lysates prepared as in part A followed by immunoblotting with
α-pY361 or α-N-E5. Representative immunoblot with input phospho-Eph (pEph) levels is
shown (top). Quantification of three independent experiments is shown as a percent increase
in pY361 over Ctrl stimulation (bottom). Error bars ±SEM; *p<0.05.
E) Dissociated rat hippocampal neurons were transfected with GFP (gray) and stimulated as
in part A, followed by fixing and staining for endogenous phosphorylated E5 using α-pY361
(Red). Representative image shown (left). White rectangle outlines magnified dendritic
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region showing examples of phospho-E5 staining (left bottom). Four independent
experiments were imaged and analyzed for pY361 (bar graph). Error bars ±SEM; *p<0.05.
F) Lysates from 293 cells transfected with empty vector (-) or increasing concentrations of
E5-Myc with or without Flag-EphB2 were assessed for endogenous RhoA activity by RBD
assay (previously described). GTPγS lane is a positive control for inducing RhoA. Input
protein levels and α-Actin loading control are shown (Bottom).
G) WT and EphB2−/− (B2−/−) brain lysates were immunoblotted with α-EphB2, α-N-E5, α-
Actin, or α-pY361 according to methods (left). Quantification of α-N-E5 or α-pY361 signal
from three independent experiments is normalized to α-Actin and represented as fold change
compared to wild type. Error bars ±SEM; *p<0.05.
See also Figure S5.
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Figure 6. EphB2-mediated degradation of Ephexin5 is kinase and proteasome dependent
A) Dissociated mouse hippocampal neurons were incubated with pre-clustered Fc, Fc-EB1
or Fc-EA1 for 60 minutes, lysed, and immunoprecipitated with α-C-E5 followed by
immunoblotting with α-N-E5. Immunoblot of input with α-pEph or α-Actin (loading
control) are shown. Western is one representative image and quantification is of three
separate experiments with samples normalized to α-Actin (left). Error bars ±SEM; *p<0.05.
Right, dissociated mouse hippocampal neurons were transfected with GFP (gray) and
stimulated with either pre-clustered Fc (Ctrl) or Fc-EB1 (EB1) for 30 minutes, followed by
fixing and staining for endogenous E5 using α-N-E5 (Red). White rectangle outlines
magnified dendritic region showing examples of E5 staining (right).
B) Lysates from 293 cells previously transfected with various combinations of
overexpressing plasmids containing E5-Myc, E1-Myc and/or Flag-EphB2 were
immunoblotted with α-Myc, αFlag, or α-Actin (loading control).
C) Lysates from 293 cells previously transfected with various combinations of
overexpressing plasmids containing Flag-EphB2, Flag-EphB2KD and/or E5-Myc were
immunoblotted with α-Myc, α-Flag, or α-Actin (loading control).
D) Lysates from 293 cells previously transfected with various combinations of
overexpressing plasmids containing E5-Myc, E5-Y361F-Myc and/or Flag-EphB2 were
immunoblotted with α-Myc, α-Flag, or α-Actin (loading control). Representative
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immunoblot is shown (top). From three independent experiments E5 levels were quantified
and normalized to E5 expression in absence of EphB2-Flag (bottom). Error bars ±SEM;
**p<0.01.
E) Dissociated mouse hippocampal neurons transfected with GFP (gray) were stimulated
similar to (B) in the absence or presence of lactacystin and immunostained with α-N-E5.
White rectangle outlines magnified dendritic region showing examples of E5 staining
(right).
F) WT and E5−/− brains were lysed and immunoprecipitated with α-C-E5 followed by
immunoblotting with α-ub or α-N-E5.
See also Figure S6.
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Figure 7. EphB2-mediated degradation of Ephexin5 requires Ube3A
A) Immunoprecipitation with α-HA from 293 cell lysates previously transfected with
various combinations of plasmids containing E1-Myc, E5-Myc, HA-DNUbe3A, HA-
MEF2A, HA-Cbl-b, and/or HA-Ube3A, followed by immunoblotting with α-HA or α-Myc.
Input protein levels and αActin loading control are shown (Bottom).
B) Hippocampal mouse neurons were co-transfected with GFP and control, HA-DNUbe3A
or Ube3A-shRNA at DIV10. At DIV14, neurons were incubated with clustered Fc (-) or Fc-
EB1 (+) for 30 minutes. Neurons were fixed and stained for E5 with α-N-E5 and quantified
according to methods. Quantification is of E5 staining intensity normalized to Fc control.
Error bars ±SEM; **p < 0.01, ANOVA.
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C) Ube3A wild type and maternal-deficient (Ube3Am−/p+) mouse brains were lysed and
immunoblotted with α-N-E5, α-EphB2, α-MEF2, α-Actin (loading control), or α-Ube3A
(top). Samples were normalized to α-Actin and quantified as described in methods (bottom).
Error bars ±SEM; *p<0.05, Mann-Whitney.
D) Brain lysates from WT and Ube3Am−/p+ were collected and treated similar to E,
immunoprecipitated with α-C-E5 and immunoblotted with α-N-E5 and α-ub. Input protein
levels are shown (right).
E) Neurons from WT and Ube3Am−/p+ mice were dissociated, cultured and transfected with
GFP at DIV10. At DIV14, neurons were incubated with pre-clustered Fc or Fc-EB1 for 30
minutes. Neurons were fixed and stained for E5 with α-N-E5 and quantified according to
methods. Error bars ±SEM; **p<0.01.
See also Figure S7.
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SUMMARY
Neuronal development is characterized by a period of exuberant synaptic growth that is well
studied. However, the mechanisms that restrict this process are less clear. Here we demonstrate
that glycosyl-phosphatidylinositol-anchored cell-surface receptors of the Nogo Receptor family
(NgR1, NgR2, and NgR3) restrict excitatory synapse formation. Loss of any one of the NgRs
results in an increase in synapse number in vitro, whereas loss of all three is necessary for
abnormally elevated synaptogenesis in vivo. We show that NgR1 inhibits the formation of new
synapses in the postsynaptic neuron by signaling through the coreceptor TROY and RhoA. The
NgR family is downregulated by neuronal activity, a response that may limit NgR function and
facilitate activity-dependent synapse development. These findings suggest that NgR1, a receptor
previously shown to restrict axon growth in the adult, also functions in the dendrite as a barrier
that limits excitatory synapse number during brain development.
INTRODUCTION
The establishment of the appropriate number of synaptic connections during development is
critical for proper brain function. Failures in this process may underlie neurological
disorders including mental retardation, autism, and schizophrenia (Bassell and Warren,
2008; Eastwood, 2004; Südhof, 2008). Recent work has identified several of the cell-cell
recognition molecules that promote synapse formation (Dalva et al., 2007), but much less is
known about the mechanisms that restrict synapse number to ensure the exquisite specificity
in organization of neural circuits that occurs throughout the brain.
Excitatory synaptic development begins as contacts are made between passing axons and
dendritic filopodia (Ziv and Smith, 1996), actin-rich protrusions along dendritic shafts.
Dendritic filopodia rapidly discriminate between potential partners and appear to stabilize
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contacts with the appropriate presynaptic axons (Lohmann and Bonhoeffer, 2008). The rapid
nature of this process suggests that signaling by cell-surface receptors is likely to be
involved in determining when and where synapses form. These cell-surface receptor/ligand
complexes include neurexins/neuroligins, EphB/EphrinBs, N-cadherins, and NGL3/LAR,
which are thought to contribute to the stabilization of nascent synaptic contacts through
recruitment of scaffolding molecules and neurotransmitter receptors (Dalva et al., 2007). It
is not known whether analogous mechanisms exist to restrict synapse formation so that
synapses form at the right time and place and in the correct number.
We hypothesized that there might be cell-surface receptors that function to restrict one or
more steps in the process of synaptic maturation, thereby balancing the process of synapse
formation so that synapses form in the correct number. These steps could include
determining when and where synaptogenesis begins by preventing the inappropriate
recruitment of synaptic components to asynaptic sites, limiting the activity-dependent
growth of synapses, or mediating the pruning of weak synaptic contacts during synapse
elimination.
We report here the discovery that one subfamily of leucine-rich repeat receptors, the Nogo
receptor family, functions to restrict the number of excitatory synapses that form during
brain development. Much is known about the function of Nogo Receptor 1 (NgR1) in the
adult central nervous system (CNS) (reviewed in Yiu and He, 2006); in contrast, far less is
known about Nogo receptor 2 (NgR2) and Nogo receptor 3 (NgR3). NgR1 binds to several
ligands, including Nogo-A, MAG, and OMgp, as well as FGF-1 and FGF-2 (Lee et al.,
2008). Several of these ligands were isolated from CNS myelin, where they are thought to
induce growth-cone collapse and axon retraction following CNS injury, a function suggested
to be mediated by NgR1 and several coreceptors, including P75, Lingo, and TROY
(reviewed in Yiu and He, 2006). NgR1 signaling in axons has been shown to activate the
small GTPase RhoA as well as Rho kinase (ROCK), important cytoskeletal regulatory
proteins thought to mediate axon outgrowth inhibition (Niederöst et al., 2002). While there
is an emerging appreciation that NgR1 plays a role in restricting dendritic growth and
plasticity in several brain regions, the mechanism of this process has not been understood
(McGee et al., 2005; Lee et al., 2008, Zagrebelsky et al., 2010, Delekate et al., 2011), nor
has the functional role of the various NgR family members during brain development been
established.
Here we show that members of the NgR family function in the dendrite to restrict synapse
number in vivo. This effect appears to be due to synapse addition, not synapse elimination,
and is mediated by RhoA, which reduces overall synapse number in part by constraining
dendritic growth, thereby limiting the number of synaptic contacts made during
development. Our expression studies show that the NgR family is downregulated by
neuronal activity, suggesting a possible mechanism by which the NgR barrier for synapse
development is relieved. These findings define a family of cell surface receptors that restrict
the number of synaptic connections that form in the mammalian brain and thus ensure the
proper development of neural circuits.
RESULTS
The NgR Family Is Dendritically Localized and Inhibits Excitatory Synapse Formation In
Vitro
NgR1 was first identified based on its ability to bind Nogo-66, an inhibitor of axon
outgrowth (Fournier et al., 2001). However, NgR1 expression is not limited to the axon.
Upon examining NgR1 expression in dissociated hippocampal neuron cultures using an
NgR1-specific antibody (Figures 1A and 1C, and Figure S1A available online), we found
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that NgR1 is expressed from 7 to 18 days in vitro (DIV), a time when the majority of
synapses are forming in these cultures (Figure 1B). We used immunocytochemistry to
investigate the subcellular distribution of NgR1 and found that it is broadly expressed on
dendrites as well as axons (Figure 1D), consistent with biochemical fractionation studies
demonstrating that NgR1 is present in both pre- and postsynaptic density fractions (Lee et
al., 2008). Experiments using antibodies to specific synaptic proteins revealed that, while
NgR1 is in close apposition to synaptic proteins such as PSD95, GluR2, SV2, and GAD67,
NgR1 seldom overlaps with these proteins (Figure 1E and quantified in Figure S1B).
Whereas PSD95 and GluR2 are expressed in dendritic spines, NgR1 is expressed primarily
in the dendritic shaft (outlined in white in Figure 1Ei–v), where it colocalizes with
filamentous actin (Figure 1Ev). These observations suggest that NgR1 is largely excluded
from excitatory synapses and instead is concentrated in nonsynaptic sites along the dendritic
shaft. Importantly, staining under nonpermeabilizing conditions demonstrates that ~40% of
NgR1 is on the cell surface of dendrites (Figures S1C–S1D). Given these findings, we
considered the possibility that NgR1 might define regions of dendrites where synaptic
development is suppressed.
To assess the function of NgR1 during synapse development, we examined the effect of
reducing the expression of NgR1 in cultured hippocampal neurons. Two distinct RNAi-
based approaches were used to knockdown NgR1 expression, either direct transfection with
short interfering RNA duplexes (siNgR1) or a plasmid encoding a short hairpin RNA to
NgR1 (shNgR1) that targets a distinct region of NgR1 mRNA. These RNAis were tested in
heterologous cells and primary neuronal cultures, where they selectively reduced NgR1
protein levels while leaving NgR2 and NgR3 expression unaffected (Figures S2A–S2C). To
investigate the effect of reducing NgR1 expression on synapse number, hippocampal
neurons were cultured, transfected at 9 days in vitro with a plasmid encoding green
fluorescent protein (GFP) together with an RNAi to NgR1 or a control RNAi, and fixed 5
days later for staining with antibodies that recognize the pre-synaptic protein synapsin1
(Syn1) and the postsynaptic protein PSD95. To quantify the number of synapses formed on
the transfected neuron, we counted the number of apposed Syn1/PSD95 puncta along
dendrites of GFP-expressing neurons (see Experimental Procedures). Using this approach
we found that knockdown of NgR1 resulted in a significant increase in excitatory synaptic
number (Figures 2A–2C; all data are listed in Table S1). Similar results were obtained using
alternative sets of synaptic markers (GluR2/Syt1 or NR2B/Syt1) (Figures 2E, 2F, and S2D).
Furthermore, we also observed an increase in the average size and intensity of synaptic
puncta after NgR1 knockdown (Figures S2E and S2F).
We verified the specificity of the NgR1 RNAi phenotype by testing the ability of an RNAi-
resistant form of NgR1 (ResNgR1) to rescue the increase in synapse density observed upon
knockdown of NgR1. ResNgR1 was validated in heterologous cells (Figure S1B) and then
cotransfected in culture neurons along with shNgR. We found that ResNgR1was sufficient
to reverse the increase in synaptic number observed with knockdown of NgR1 (Figure 2D),
suggesting that the increase in synapse number in NgR1 RNAi-treated neurons is due to the
specific knockdown of NgR1 by RNAi.
NgR1 belongs to a family that includes two highly homologous proteins, NgR2 and NgR3.
All three NgRs are expressed at high levels in the dorsal telencephalon during synaptic
development (Figure S2G). To investigate whether NgR2 and NgR3 also function as
negative regulators of synapse development, we examined the effect of reducing expression
of either NgR2 or NgR3 in cultured hippocampal neurons. Short hairpin RNAs to NgR2
(shNgR2) or NgR3 (shNgR3) were validated in heterologous cells (Figure S2H) and then
expressed in neurons, where they resulted in a significant increase in excitatory synapse
density (Figure S2I). To extend this finding, we acquired knockout mice for NgR1 (Zheng et
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al., 2005), NgR2, and NgR3 (Lexicon Genetics), validated that these animals are null for the
respective NgR genes (Figures S5A and S5B), and assessed the contribution of NgR1,
NgR2, and NgR3 to synaptic development in cultured hippocampal neurons. These
experiments revealed that loss of any single NgR family member (NgR1−/−, NgR2−/−, or
NgR3−/−) results in an increase in the number of excitatory synapses relative to littermate
controls (Figure 2G). Thus, all three NgR family members have similar functions in
restricting synaptic development in vitro, regardless of whether they are removed acutely in
individual neurons with RNAi, or constitutively removed throughout neuronal cultures using
genetic loss-of-function approaches.
Since eliminating expression of members of the NgR family results in an increase in synapse
number, we asked whether overexpression of NgR1 results in a decrease in synapse number.
Cultured hippocampal neurons were transfected with varying concentrations of a wild-type
NgR1 expression construct (WTNgR1) and synaptic puncta were quantified. When
expressed at a low concentration such as that used to rescue the NgR1 shRNA phenotype
(100 ng), WTNgR1 had no effect on synapse number; however, a 2-fold higher
concentration of WTNgR1 (200 ng) significantly reduced synapse density (Figures 2H and
2I). Similarly, overexpression of WTNgR2 (Figures 2H and 2I) or WTNgR3 (Figure S7A)
significantly reduced synapse number. Thus, results from a number of different experiments
support that members of the NgR family restrict the number of excitatory synapses that form
on hippocampal neurons in culture.
We next asked whether NgR1 inhibits the development of synapses in the context of an
intact hippocampal circuit. Hippocampal slices were cultured from wild-type P6 rats and
biolistically transfected with GFP alone or GFP along with control RNAi, shNgR1, or
WTNgR1 to assess the effect of NgR1 expression on spine formation in a neuronal circuit.
Knockdown of NgR1 through the introduction of either shNgR1 or siNgR1 into
hippocampal slices for 5 days resulted in a significant increase in the number of dendritic
spines relative to control (Figures 3A and 3B), with no effect on spine width or length
(Figures 3C and 3D). In contrast, overexpression of WTNgR1 in organotypic hippocampal
slices resulted in a substantial reduction in spine number (Figures 3A and 3B). These
observations suggest that in an intact neuronal circuit, NgR1 restricts the number of
dendritic spines, the sites where the majority of excitatory synapses form.
Our experiments thus far raise the possibility that NgRs either prevent the initiation of new
synapses or mediate synapse elimination. To distinguish between these possibilities, we
quantified spine addition and elimination over time by repeatedly imaging cultured
hippocampal slices that were biolistically transfected with GFP and a control shRNA or
shNgR1. We observed that NgR1 knockdown results in a significant increase in spine
density following repeated imaging of cultured hippocampal slices (Figures 3E and 3F). A
quantification of spines added or eliminated following NgR1 knockdown revealed a
significant increase in spine addition but no change in spine elimination (Figures 3G, S3A,
and S3B), lending support to the idea that NgR1 functions to suppress the establishment of
new synapses rather than by mediating synapse elimination.
NgR1 Functions Postsynaptically
Several NgR1 ligands and coreceptors are expressed on axons and dendrites; thus, the
potential exists for NgR1 to signal bidirectionally. To address whether NgR1 functions pre-
or postsynaptically, we quantified changes in synapse density observed upon knockdown or
overexpression of NgR1 and then deconvolved these same data sets to determine whether
there was a change in the number of pre- and/or postsynaptic specializations. This analysis
revealed that the effects of NgR1 on synapse density were due to changes in the number of
postsynaptic (PSD95 or GluR2) puncta rather than the presynaptic (Syn1 or Syt1) puncta
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(Figures 4A–4C; data not shown). Similarly, de-convolution of synapse density
measurements following RNAi targeting of NgR2 and NgR3 also revealed a specific
increase in PSD95 puncta number, size, and intensity (Figures S2G and S2H). Importantly,
simulated modeling studies confirmed that the changes in synapse density following NgR1
knockdown could not be accounted for by random overlap due to increased numbers of
postsynaptic puncta (Figures S4B and S4C).
To determine whether changing the level of NgR1 throughout neuronal cultures affects the
levels of specific synaptic proteins, we infected neurons with lentiviruses to drive the
expression of NgR1 throughout neuronal cultures and found that WTNgR1 overexpression
results in a significant reduction in PSD95 protein levels as assessed by quantitative western
blotting (Figures 4D and 4E). Moreover, the opposite effect was observed upon NgR1
knockdown, which resulted in a significant increase in both PSD95 and GluR2 levels
(Figures 4D, 4E, and S4A). In contrast, the level of Syn1 was unaffected by NgR1
overexpression or knockdown (Figures 4D, 4E, and S4A). Thus, analysis of both single cells
and neuronal cultures suggests that NgR1 inhibits the development of excitatory synapses
through its action in the postsynaptic cell, where it causes reduced expression of specific
postsynaptic proteins. These findings suggest that NgR1 has a cell-autonomous role in the
dendrite that is distinct from its previously described function in the axon.
NgR1 Functions Together with a Coreceptor, TROY, to Restrict Excitatory Synapse
Number
NgR1 functions by activating intracellular signaling cascades via transmembrane
coreceptors such as P75, TROY, and Lingo-1 (Yiu and He, 2006). To investigate whether
coreceptor signaling is required for the inhibition of synapse formation by NgR1, we tested
the effect of an NgR1 mutant that lacks a co-receptor-binding region (DNNgR1 [Wang et
al., 2002a]). Unlike the effect of WTNgR1, overexpression of DNNgR1 did not result in
decreased synapse density but rather caused a small but significant increase in synapse
density relative to control, presumably due to its ability to sequester ligands away from
endogenous NgR1 (Figures 4F and 4G). This finding suggests that NgR1 requires a
coreceptor to inhibit synapse development.
Genome-wide RNA sequencing revealed that of the known NgR1 coreceptors, only Lingo-1
and TROY are expressed at appreciable levels in 7 DIV neuronal neurons (data not shown).
Since Lingo-1 is largely expressed on axons (Lee et al., 2008), we focused on TROY as a
potential NgR1 coreceptor that might function in dendrites to inhibit synapse development.
Immunostaining with protein-specific antisera revealed that TROY is expressed along the
dendrites of cultured neurons and overlaps significantly with all NgR family members
(Figure S4E). In addition, TROY knockdown (Figures S4E, S4I, S4J, and S8B) caused a
significant increase in synapse density in cultured hippocampal neurons (Figure 4H).
Together, these findings are consistent with TROY being the coreceptor that mediates the
inhibitory effects of NgR1 on synapse development.
To determine whether TROY is required for NgR1-dependent suppression of synapse
development, WTNgR1 was overexpressed with or without TROY knockdown (shTROY)
and synapse density was quantified. TROY knockdown reversed the reduction in synapse
number observed with NgR1 overexpression (Figure 4I). An increase in synapse density was
observed, similar to that seen upon TROY knockdown alone. Similar epistasis studies with
WTNgR2 and WTNgR3 overexpression revealed that TROY is required for the suppression
of synapse development by NgR2 and NgR3 (Figure S4K). Moreover, binding experiments
using recombinant TROY protein incubated with heterologous cells expressing different
NgR family members show that TROY is capable of binding NgR1 and NgR2, but not
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NgR3 (Figure S4F), suggesting that NgR1 and NgR2 may signal through TROY directly. It
remains unclear whether the affinity of the NgR3-TROY interaction falls below the
detection limit of this assay or whether NgR3 acts through an alternative coreceptor. Taken
together, these findings identify TROY as a potential coreceptor for the NgR family that
mediates their ability to restrict excitatory synapse number.
The NgR Family Cooperates in Restricting Synaptic Development In Vivo
To address whether the NgR family contributes to synaptic development in vivo, we crossed
NgR mutant mice with the GFPM line (Feng et al., 2000), in which a small subset of
neurons are genetically labeled with the Thy1-GFP allele, thus enabling visualization of
dendritic spines from hippocampal pyramidal neurons. Knockout of any one NgR family
member alone was not sufficient to affect the density of dendritic spines in vivo (Figure 5B).
Given our previous finding that all three NgR family members play a similar role in limiting
synapse development in vitro (Figures 2G and S2I), we hypothesized that these family
members might functionally compensate for one another in vivo. To address this possibility,
we generated triple knockout mice (NgRTKO−/−). NgRTKO−/− mice were born with the
appropriate Mendelian frequencies and appear largely normal, with no obvious defects in
formation of the hippocampus. Analysis of GFP-expressing neurons at P18 revealed a
significant increase in the number of dendritic spines on CA1 pyramidal neurons in
NgRTKO−/− mice relative to their triple heterozygous littermate controls (Figures 5A and
5B). These findings are consistent with the idea that the NgR family members function
together in vivo to limit the number of excitatory synapses.
To extend this analysis using an independent approach, we performed transmission electron
microscopy to visualize the ultrastructural features of excitatory synapses. In micrographs
from NgRTKO−/− mice, we observed asymmetric synapses of typical morphology,
suggesting that the overall structure and vesicle content of excitatory synapses are normal in
the absence of NgRs. However, quantification of the number of excitatory synapses in the
apical dendritic regions of CA1 revealed that NgRTKO−/− mice had a significant increase in
the density of excitatory synapses relative to heterozygous littermate controls (Figures 5C
and 5D). Furthermore, this effect was not limited to CA1 neurons, since analysis of CA3
neurons also revealed a clear increase in the number of PSDs in NgRTKO−/− animals
(Figure 5E). Thus, analysis by confocal and electron microscopy suggests that the NgR
family functions to limit the number of excitatory synapses in vivo.
To address whether the observed increase in synapse number reflects an increase in
functional synapses, we performed whole-cell patch-clamp electrophysiology on CA1
pyramidal neurons from acute hippocampal slices obtained from NgRTKO−/− mice and
control littermates to quantify the frequency and amplitude of miniature excitatory
postsynaptic currents (mEPSCs). This analysis revealed a significant increase in the
frequency of mEPSCs in NgRTKO−/− mice relative to littermate controls (Figure 5F and
S5C), suggesting that the NgR family restricts the development of functional excitatory
synapses. Interestingly, there was a small but significant decrease in the amplitude of
mEPSCs (Figure 5G and S5D), consistent with the immature spine types observed in NgR1
knockouts (Lee et al., 2008; Zagrebelsky et al., 2010). Thus, reducing the expression of the
NgR family results in an increase in functional synapses that are slightly reduced in strength.
The NgR Family Inhibits Dendritic Growth and Complexity
The question remained as to how NgRs work at a mechanistic level to restrict excitatory
synapse number. One possibility was that NgRs limit the formation of new synapses in part
by inhibiting dendritic growth, thereby reducing the possibility of contact between axons
and dendrites. Therefore, we asked whether loss of NgR family members affects dendritic
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branching. Specifically, we analyzed dendritic branch complexity in GFP-expressing
neurons by Sholl analysis, which quantifies the number of dendritic branches intersecting
concentric circles of increasing radii centered on the cell body (Sholl, 1953). We found that
neurons from mice lacking NgR1 showed a significant increase in dendritic complexity
relative to littermate controls, whereas overexpression of WTNgR1 resulted in a decrease in
complexity of the dendritic arbor (Figures 6A and 6B; all Sholl data are listed in Table S2).
Similarly, there was a significant increase in dendritic complexity and total dendritic length
in hippocampal slices upon knockdown of NgR1 (Figure S6). Moreover, this effect was also
observed in vivo, where analysis of GFP-expressing CA1 pyramidal neurons from
NgRTKO−/− animals revealed an increase in both the complexity of basal dendrites (Figures
6C–6E) and total dendritic length (Figure 6F). Taken together, these findings provide
evidence that NgR family members inhibit the growth and decrease the complexity of the
dendritic arbor and suggest that, in addition to decreasing synapse density, a second way that
NgR family members may restrict synapse number is by inhibiting dendritic growth,
reducing the overall area for potential synaptic inputs.
NgR1 Restricts Dendritic Growth and Synapse Number through Activation of RhoA
We asked if NgR/TROY limits dendrite and spine/synapse development by inhibiting the
polymerization of the actin cytoskeleton, a process that is essential for dendritic and spine
growth. Previous studies have shown that RhoA is a critical regulator of actin assembly
(Maekawa et al., 1999). To investigate the involvement of RhoA in the inhibition of
dendritic growth and synapse development by NgR1, we tested whether NgR1 activates
RhoA in hippocampal neurons during synaptic development. Hippocampal neurons were
infected with lentivirus expressing WTNgR1, and RhoA activity was assessed using a
Rhotekin-binding domain (RBD) assay, which utilizes the Rho-binding domain of
Rhoteckin as an affinity reagent to precipitate active Rho (Rho-GTP) from cells. We found
that the level of active RhoA was reduced by reduction of NgR1 and elevated upon NgR1
overexpression (Figures 7A and 7B). Thus, NgR1 signaling activates RhoA in hippocampal
neurons during synapse formation.
To test whether the inhibitory effect of NgR1 on synapse development is mediated by RhoA,
we blocked the activity of RhoA or one of its downstream effectors, ROCK, using selective
inhibitors. Treatment of hippocampal cultures with either the Rho inhibitor (C3 Transferase)
or the ROCK inhibitor (Y27632) led to a significant increase in synapse number (Figure
7C), suggesting that RhoA signaling acts downstream of NgR1 to restrict synapse number.
Further, Rho or ROCK inhibition entirely rescued WTNgR1 suppression of synapse
development (Figure 7C). These findings also extended to NgR2, NgR3, and TROY, all of
which require Rho and ROCK to suppress synaptic development (Figure S7A). Similarly,
inhibition of RhoA or ROCK blocked, albeit not completely, the effect of WTNgR1
overexpression on dendritic growth (Figures 7D, 7E, and S7B). Together, these findings
suggest that the NgR family regulates synapse number in part by activating RhoA,
potentially restricting actin polymerization that underlies the growth of dendrites and spines.
Neuronal Activity Downregulates the NgR family and TROY
The finding that the NgR family restricts dendritic and spine development raised the
possibility that NgR family members function together with TROY as a barrier that limits
neural connectivity during development. However, these receptors are highly expressed at a
time when neurons are beginning to form synapses, raising the question: what limits the
inhibitory effect of NgR family members to allow for synaptogenesis? We hypothesized that
stimuli such as neuronal activity that promote dendritic growth and synaptogenesis (Sin et
al., 2002; Peng et al., 2009) might trigger the downregulation of the NgR family and/or
TROY, thus relieving the barrier to excitatory synapse formation. To test this hypothesis, we
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analyzed the expression of NgR1, NgR2, NgR3, and TROY mRNA in response to changes
in neuronal activity. Increasing neuronal activity resulted in a significant decrease in the
mRNA level in all three NgR family members and TROY (Figures 8C–8F). To confirm
these observations at the level of NgR protein expression, GFP-expressing hippocampal
neurons were stained with anti-NgR1 antibodies and the total number of NgR1 puncta (cell
surface and intracellular) on dendrites was quantified. When neurons were depolarized,
either by elevation of levels of potassium chloride, addition of N-methyl-D-aspartic acid
(NMDA), or inhibition of GABA receptors with the antagonist bicuculline, the number of
NgR1 puncta along dendrites was significantly reduced relative to untreated neurons
(Figures 8A and 8B). A similar decrease in TROY and NgR1 protein levels was observed in
vivo in response to kainite-induced seizure (Figures 8H and 8I) or enriched environment
(Figures S8C and S8D). Conversely, blocking neuronal activity by treatment of neurons
with a combination of the NMDA receptor antagonist amino-5-phosphonovaleric acid
(APV) and the sodium channel blocker tetrodotoxin (TTX) had the opposite effect, causing
a significant increase in the number of dendritic NgR1 puncta (Figures 8A and 8B).
Importantly, cell-surface staining confirmed that modulation of neuronal activity altered
NgR1 levels present at the cell surface (Figure S8A). While significant levels of the NgR
family members persist throughout the period of synaptic development, TROY expression
was found to decrease upon the onset of pronounced synaptogenesis (Figure 8G). Thus,
neuronal activity and/or reduced expression of the coreceptor TROY may relieve the NgR-
dependent barrier to synaptic growth, facilitating synaptogenesis during development and
plasticity in the adult.
DISCUSSION
The formation of synaptic connections during development is a highly regulated process that
is mediated in part by cell-surface proteins that promote initial contact between developing
axons and dendrites. We hypothesized that neural connectivity might also be limited by cell-
surface proteins that function to restrict excitatory synapse development so that synapses
form at the right time and place and in the correct number. Here we show that the NgR
family of proteins serves this important function. Our study suggests that NgRs function
along the arbor of dendrites as a barrier that limits synapse formation. Loss of any one
member of the NgR family is sufficient to reveal their inhibitory influence in vitro, whereas
loss of all three NgRs is required for abnormally elevated excitatory synaptogenesis in vivo.
These findings broaden our understanding of NgR1’s function, since they identify a
dendritic role for receptors whose function was hitherto ascribed mainly to the axon.
At a mechanistic level, NgRs appear to work through the coordinated inhibition of synaptic
and dendritic growth. These findings are consistent with those of recent studies of more
mature neuronal circuits, demonstrating that both Nogo and the Nogo receptor constrain
dendritic growth (Zagrebelsky et al., 2010). The effects of NgR loss on synaptogenesis and
dendrogenesis are coupled. Unlike Neuropilin-2, which has a more selective role in
regulating the spatial distribution of synapses on a specific region of the dendrite, the
primary apical shaft (Tran et al., 2009), the NgR family functions broadly on the dendrite to
restrict dendritic growth and limit the number of excitatory synapses that form.
It will be important to identity the ligand or ligands that regulate the activity of the NgR
family members in this developmental context. Several ligands have been shown to regulate
NgR1 signaling. Recent work provides evidence that Nogo may promote synaptic
maturation in more established neuronal circuits (Zagrebelsky et al., 2010; Pradhan et al.,
2010). Consistent with these findings, we observe a significant increase in synapse density
following Nogo-Fc (Nogo-66) addition to cultured hippocampal neurons (Z. Wills and M.
Greenberg, unpublished observations), raising the possibility that Nogo may inhibit rather
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than activate NgR in this context. These findings suggest that NgR1 signaling may fulfill
multiple roles in synaptogenesis depending on its mechanism of activation and
developmental period. Given that Nogo is highly enriched in the PSD (Peng et al., 2004;
Raiker et al., 2010), a better understanding of how ligand binding to NgR1 affects its
downstream signaling may help to reveal how NgR1 regulates synapse number. It is
noteworthy that of the known NgR1 ligands, only MAG can activate NgR2 (Venkatesh et
al., 2005), and none have affinity for NgR3. These findings raise the possibility that NgR
family members may bind different ligands, allowing each receptor to be tuned to distinct
extracellular cues that function in parallel to inhibit synapse formation. Alternatively, these
receptors may share a common ligand that remains to be be identified.
NgR1 was originally discovered as a receptor that mediates the inhibition of axon regrowth
after injury in the adult (Fournier et al., 2001). More recent studies have also revealed
developmental functions of NgR1 in the closure of the critical period in adolescent mice
(McGee et al., 2005) and in regulating activity-dependent synaptic strengthening in the
hippocampus (Lee et al., 2008). However, robust expression of NgR family members begins
in newborn mice (Lee et al., 2008), and its function at this stage of growth was unknown.
Our study clarifies this issue by uncovering a role for the NgR family in the early postnatal
brain, where it functions in the dendrite to restrict synapse number. What might be the
purpose of synaptic restriction by NgR family members? Our live-imaging studies suggest
that the NgR family inhibits the formation of new synapses, possibly preventing premature
synaptogenesis so that synapses are established at the correct time and place. In addition, the
NgR family may provide inhibition to counterbalance prosynaptic factors. Therefore,
synapse formation might involve the concurrent activation of signaling pathways that
promote synaptogenesis and a relief of inhibition of synapse formation by the NgR family.
Consistent with these possibilities, we provide evidence that NgR1 mediates its effects
through the activation of RhoA, a GTPase that restricts actin polymerization and thereby
limits dendritic growth and spine development (Elia et al., 2006; Sin et al., 2002).
Signaling through RhoA to regulate actin assembly may be a common feature of NgR
signaling. Previous work has shown that NgR1 regulates actin dynamics in the axon through
TROY, RhoA, and ROCK (Yiu and He, 2006). In the present study, we provide evidence
that a similar signaling pathway mediates the effects of NgR1 in the dendrite. While we
have found that TROY can bind both NgR1 and NgR2 in heterologous cells (Figures S4E
and S4F), future work will be required to demonstrate the presence of a protein complex
comprised of these signaling components in developing dendrites. Further, the signals
promoting synaptic and dendritic growth may not be identical. Preliminary work suggests
that while TROY inhibits synapse development, it does not inhibit dendritic growth (Wills
and Greenberg, unpublished data). However, the finding that NgR1 regulates both dendritic
and synaptic growth suggests that NgR1 signaling may couple these processes to coordinate
neuronal development.
Though our studies were focused on elucidating the developmental function of the NgRs,
expression of this family of proteins continues into adulthood, and so it is interesting to
speculate that NgR may continue to limit dendritic growth and synapse number in the
mature brain. If so, NgR1’s dendritic function may be important to consider in the context of
neural damage caused by, e.g., injury or stroke, where, it has been suggested, NgR1-
mediated inhibition of axonal outgrowth impairs recovery of motor function (Lee et al.,
2004; Harvey et al., 2009). Our findings are notable because they raise the possibility that
enhanced functional connectivity observed upon blocking NgR1 may be due, at least in part,
to increased dendritic growth and elevated synapse formation in postsynaptic neurons.
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In addition to its role under pathological circumstances such as injury, it is now clear that
Nogo (Delekate et al., 2011) and NgR1 (Lee et al., 2008) have functions in the regulation of
neural plasticity. Neural activity causes the downregulation of NgR1, and expression of
ectopic NgR1 in the forebrain inhibits memory consolidation (Karlén et al., 2009). These
findings imply that NgR1 limits neural connectivity, and in keeping with this idea, mice
lacking NgR1 have an abnormal critical period in which ocular dominance plasticity
continues abnormally into adulthood (McGee et al., 2005). While these findings suggest that
NgR1 constrains plasticity in the brain, it was not known how NgR1 mediates these effects.
Results from our study raise the possibility that NgRs limit synaptic plasticity by restricting
excitatory synapse development. We speculate that the NgR family functions to limit
structural changes in circuitry, from initial circuit formation in the newborn mouse to the
closure of the critical period, as well as in the formation of long-term memories and the
ability to recover from neural injury. In so doing, the NgR family may ensure wiring fidelity
within neural circuits.
EXPERIMENTAL PROCEDURES
Animal Husbandry and Colony Management
NgR1−/− mice have been previously described (Zheng et al., 2005). NgR2−/− and NgR3−/−
mice were obtained from Lexicon Genetics. GFPM mice were obtained from Joshua Sanes
(Feng et al., 2000). For more details concerning mouse crosses, genotyping, and knockout
validation see Supplemental Information.
DNA Constructs
Details of DNA constructs can be found in the Supplemental Information.
Western Blotting and GEF Pull-Down Assays
For western blotting, hippocampal cultures were collected and homogenized in RIPA buffer.
Samples were boiled for 5 min in SDS sample buffer, resolved by SDS-PAGE, transferred
to nitrocellulose, and immunoblotted. RBD pull-down assays were conducted according to
the manufacturer’s suggestions (Upstate Cell Signaling Solutions). For details, see
Supplemental Information.
Immunocytochemistry
For immunocytochemistry, neurons were fixed and incubated with the indicated antibodies,
as previously described (Tolias et al., 2005). For cell-surface staining of NgR1, anti-NgR1
antibody (1 μg/ml) was added to 14 DIV cultured neurons for 1 hr at 37°C, washed, and
fixed as above. For details, see Supplemental Information.
Primary Neuron Cell Cultures
To obtain hippocampal neurons from mutant mice or littermate controls, single-embryo
dissections of E16 mouse embryos were performed as previously described (Tolias et al.,
2005). Rat hippocampal neurons were prepared from E18 Long-Evans rat embryos (Charles
River), as previously described (Xia et al., 1996). Dissociated hippocampal neurons were
transfected using the Lipofection method (Invitrogen) according to the manufacturer’s
suggestions. For details, see Supplemental Information.
Heterologous Cell Culture and Lentiviral Production
HEK293T cells were cultured in DMEM with10% fetal bovine serum and transfected using
the calcium phosphate method (Xia et al., 1996). Lentiviruses were produced by co-
transfection of HEK293T cells with pLenti-Lox plasmids together with the helper plasmids
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Δ8.9 and VSV-G, as previously described (Lois et al., 2002). For details, see Supplemental
Information. AP binding studies were carried out in COS cells transfected with GFP alone
(CON), WTNgR1, WTNgR2, or WTNgR3 expression constructs. TROY-fc (R&D Systems)
was conjugated with anti-fc-AP protein (Venkatesh et al., 2005), then incubated with COS
cells for 75 min, washed, fixed, and stained to identify AP activity using BCIP/NBT.
Organotypic Slice Culture
Transverse slices (350 μm) of P5-7 hippocampus were prepared and cultured essentially as
described in Stoppini et al. (1991). Slices prepared under sterile conditions were cultured on
nylon inserts (0.4 μm pore size, Millicell) in 6-well dishes containing 0.75 ml of antibiotic-
free medium (20% horse serum/MEM) and incubated in 5% CO2 at 37°C. Slice cultures
were transfected using a Helios Gene Gun (Biorad) at 8 DIV. Slices were fixed at 13 DIV in
2.5% para-formaldehyde and 4% sucrose and processed for immunohistochemistry.
Confocal Image Analysis and Quantification
All imaging analysis experiments were carried using a Zeiss LSM5 Pascal confocal
microscope. For details see Supplemental Information. For live imaging experiments,
organotypic rat hippocampal slice cultures were prepared at P5, biolistically transfected with
shCON or shNgR1 RNAi constructs at 4 DIV, and cultured for three days (7 DIV) before
imaging commenced. Spine-density measurements were carried out in Metamorph. For
details, see Supplemental Information.
Electron Microscopy and Analysis
EM analysis was carried out on P18 animals, as described in detail in the Supplemental
Information.
Electrophysiology
Electrophysiology was performed using standard methods (see Supplemental Information).
Immunohistochemistry
For immunohistochemistry, P18 mice were fixed with 4% paraformaldehyde in PBS by
intracardial perfusion. Brains were sectioned coronally with a vibratome at 100 μm.
Immunohistochemistry was performed on slice cultures directly on the nylon culture
membrane. See Supplemental Information for details.
RT-PCR
RT-PCR was carried out using standard methodologies. See Supplemental Information for
details.
Seizures and Enriched Environment
Seizures were induced for 3 hr in adult C57B6 mice by intraperitoneal injection of kainic
acid (Ocean Produce International) at a dose of 25 mg/kg before isolation of the
hippocampus. For enriched environment experiments, 6-week-old CD1 male mice were
either placed in standard laboratory cages or in cages containing a variety of rodent toys of
various shapes and colors (PETCO) for zero to six hours prior to isolation of the
hippocampus. Hippocampal tissue was lysed in RIPA lysis buffer and total protein was
quantified by BCA assay (Pierce).
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Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. NgR1 Is Expressed on Dendrites of Hippocampal Neurons during Synaptic
Development
(A) Specificity of NgR1 antibody in immunoblotting. Lysates from hippocampal neurons
(18 DIV) were analyzed by immunoblot using an antibody directed against NgR1. NgR1
protein is expressed in cultures derived from heterozygous NgR1+/− embryos (CON) and is
selectively lost in neurons derived from NgR1−/− embryos. Samples were blotted for actin as
a loading control.
(B) Time course of NgR1 expression. Immunoblot analysis of lysates from wild-type
hippocampal neurons using an NgR1 antibody demonstrates that NgR1 is highly expressed
from 7 to 18 DIV, a time of abundant synapse formation.
(C) Specificity of NgR1 antibody in immunostaining. Hippocampal neurons derived from
either heterozygous embryos (CON; NgR1+/−) or NgR1 mutant (NgR1−/−) embryos were
transfected with GFP and analyzed at 18 DIV by immunostaining for NgR1 (red) and
PSD95 (green). A representative dendrite is shown, revealing punctate NgR1 expression that
is specifically lost in neurons from NgR1−/−mice. Scale bar is 2.5 μm. Further validation is
shown in Figure S1A.
(D) NgR1 is broadly expressed in dendrites. Wild-type hippocampal neurons were analyzed
by immunostaining (18 DIV) for NgR1 (red) and PSD95 (green). NgR1 (red puncta in i and
iii) is expressed broadly along developing dendrites and axons but is largely excluded from
overlapping with the excitatory synaptic marker, PSD95 (green puncta in i and ii). Note that
apparent NgR1 staining in the soma is likely nonspecific, since this signal is also present in
neurons from NgR1−/− embryos. Scale bar is 10 μm. NgR1 cell-surface staining is shown in
Figure S1C.
(E) NgR1 is dendritic, but is excluded from synapses. Hippocampal neurons were
transfected with GFP (9 DIV) and then subsequently analyzed (18 DIV) by costaining for
Wills et al. Page 14
Neuron. Author manuscript; available in PMC 2013 February 09.
$w
aterm
ark-text
$w
aterm
ark-text
$w
aterm
ark-text
137
NgR1 (red) and the indicated markers (blue). Representative dendrites illustrate that NgR1
rarely colocalizes with synaptic markers, including PSD95 (i), GluR2 (ii), SV2 (iii), or
GAD67 (iv), though it frequently overlaps with broadly expressed proteins such as
filamentous actin (Phalloidin) (v). Scale bar is 1 μm. Quantification of NgR1 overlap with
synaptic proteins is presented in Figure S1B.
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Figure 2. The NgR Family Restricts Synapse Formation in Cultured Neurons
(A–C) Knockdown of NgR1 increases the density of PSD95/Syn1 puncta in cultured
hippocampal neurons. Cultured hippocampal neurons were cotransfected with GFP and
either shCON (white bar), shNgR1 (gray bar), siCON (green bar), or siNgR1 (black bar) and
subsequently immunostained with antibodies against the excitatory postsynaptic marker
PSD95 (red) and the presynaptic marker Syn1 (blue). (A) Representative examples of
control or shNgR1-transfected neurons. Scale bars represent 15 μm. (B) Representative
dendrites from control or shNgR1-transfected neurons. Scale bars represent 2 μm. (C)
Quantification of the density of colocalized PSD95 and Syn1 puncta along dendrites of
transfected neurons. Data are normalized to respective controls. * indicates p < 0.05, one-
way ANOVA with pairwise comparison by Bonferroni post hoc test. Data are mean ± SEM
from three to five experiments; total numbers of neurons analyzed (n) range from 28 to 54
cells per condition. Note that shNgR1 and siNgR1 were tested in heterologous cells and
neurons, where they were found to selectively and efficiently knock down NgR1 protein
(see Figure S2).
(D) RNAi-resistant NgR1 rescues the effect of shNgR1 on the density of PSD95/Syn1
puncta. Cultured hippocampal neurons were transfected with GFP and either shCON (white
bar), shNgR1 (black bar), shCON and ResNgR1 (blue bar), or shNgR1 and ResNgR1
(orange bar). Neurons were immunostained with antibodies against PSD95 and Syn1, and
the normalized density of apposed PSD95/Syn1 puncta along the dendrites of transfected
neurons was quantified. * indicates p < 0.05, one-way ANOVA with pairwise comparison
by Bonferroni post hoc test. Data are mean ± SEM from three experiments; total numbers of
neurons analyzed (n) range from 27 to 31cells per condition.
(E and F) A distinct set of synaptic markers (GluR2/Syt1) also reveals increased synapse
density upon knockdown of NgR1. Cultured hippocampal neurons were transfected with
GFP and either shCON (white bar), shNgR1 (gray bar), siCON (green bar), or siNgR1
(black bar), and subsequently immunostained with antibodies against the postsynaptic
marker GluR2 (red) and the presynaptic marker Syt1 (blue). (E) Representative dendrites.
Scale bars represent 2 μm. (F) Quantification of the density of colocalized GluR2 and Syt1
puncta along dendrites of transfected neurons. Data are normalized to respective controls. *
indicates p < 0.05, one-way ANOVA with pairwise comparison by Bonferroni post hoc test.
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Data are mean ± SEM from three experiments; total numbers of neurons analyzed (n) range
from 28 to 34 cells per condition. Note that knockdown of NgR1 was also found to increase
synapse intensity and size in vitro (see Figure S2).
(G) Hippocampal neurons from mice lacking any member of the NgR family (NgR1, NgR2,
or NgR3) show elevated synapse density. Cultured hippocampal neurons from littermates of
the indicated genotype were transfected with GFP and immunostained antibodies against
PSD95 and Syn1 to determine the normalized synapse density. Embryos that were
heterozygous for NgR1, NgR2, and NgR3 were used as a control (CON; white bar).
Neuronal cultures from NgR1−/− (black bar), NgR2−/−(blue bar), and NgR3−/− (green bar)
mutant embryos were heterozygous for the other respective NgR family members. *
indicates p < 0.05, one-way ANOVA with pairwise comparison by Bonferroni post hoc test.
Data are mean ± SEM from three experiments; total numbers of neurons analyzed (n) range
from 45 to 60 cells per condition. Note that acute knockdown of NgR1, NgR2, or NgR3 also
resulted in an increase in synapse density (see Figure S2I). Western blotting and quantitative
RT-PCR were used to confirm that NgR mutant mice were protein or mRNA nulls (see
Figure S5).
(H and I) Overexpression of WTNgR1 or WTNgR2 reduces synapse density. Cultured
hippocampal neurons were transfected with GFP alone (CON; white bar) or GFP and either
WTNgR1 (black bar) or WTNgR2 (blue bar). Neurons were subsequently immunostained
with antibodies against PSD95 (red) and Syn1 (blue). (H) Representative dendrites. Scale
bars represent 2 μm. (I) Quantification of the normalized density of colocalized PSD95 and
Syn1 puncta along dendrites of transfected neurons. * indicates p < 0.05, one-way ANOVA
with pairwise comparison by Bonferroni post hoc test. Data are mean ± SEM from three
experiments; total numbers of neurons analyzed (n) range from 21 to 49 cells per condition.
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Figure 3. NgR1 Restricts Spine Formation in a Hippocampal Circuit
(A–D) Effects of NgR expression on dendritic spine morphology. Organotypic hippocampal
slices were biolistically transfected with GFP alone (CON; green bar) or GFP along with
either a control shRNA construct (shCON, white bars), shNgR1 (black bars), siNgR1 (gray
bars), or WTNgR1 (red bars), as indicated, and fixed. (A) Representative images of
proximal secondary apical dendrites from GFP-labeled CA1 pyramidal neurons from CON,
shNgR1, and WTNgR1 are shown. Scale bar is 1 μm. Secondary apical dendrites were
analyzed following biolistic introduction of GFP together with the indicated constructs, and
the average dendritic spine density (B), spine length (C) and spine width (D) were
determined. Spine density is normalized to respective controls; spine length and width are
averages. * indicates p < 0.01, one-way ANOVA with pairwise comparison by Bonferroni
post hoc test. Data are means, with error bars representing ±SEM from three experiments;
total numbers of neurons analyzed (n) range from 20 to 30 cells per condition.
(E) Extended live imaging of spine density changes over time. Organotypic hippocampal
slices were biolistically transfected with GFP along with either a control shRNA construct
(shCON) or an shRNA construct targeting NgR1 (shNgR1). Representative images of
proximal secondary apical dendrites from GFP-labeled CA1 pyramidal neurons that were
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repeatedly imaged are shown. Top panels show the entire proximal dendritic region of
representative neurons at 7 DIV, while a higher magnification image of the boxed regions
(white dotted rectangles) is shown below following spine development over 7 days in vitro
(7–13 DIV). White numbers mark persistent spines (older than 48 hr), green numbers mark
newly formed spines (<48 hr old) and red numbers mark eliminated spines (lost within the
last 48 hr). Scale bars in top images indicate 10 μm, and those in the bottom images mark 1
μm.
(F) Quantification of spine density over time. The average spine density of dendritic regions
repeatedly imaged following the introduction of shCON (black line) or shNgR1 (red line) is
quantified at four time points (7, 9, 11, and 13 DIV). * indicates p < 0.01 with a Student’s t
test. Data are means, with error bars representing ±SEM from three experiments; total
number of neurons analyzed (n) was 26 per condition.
(G) Quantification of spine addition and elimination. The average number of spines added or
eliminated over all four time points was quantified on a per micron basis following biolistic
introduction of shCON (black) or shNgR1 (red). Data are presented as percent change
relative to control. * indicates p < 0.01 with a Student’s t test. Data are means, with error
bars representing ±SEM from three experiments. Quantification of spine addition and
elimination for each time point is illustrated in Figure S3.
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Figure 4. NgR1 Functions Postsynaptically through the Coreceptor TROY to Restrict Synapse
Formation
(A–C) Effect of NgR1 on the density of PSD95/Syn1 puncta is due to changes in the
postsynaptic protein PSD95. Cultured hippocampal neurons were transfected with GFP
alone (CON; white bar) or GFP and either shNgR1 (gray bar) or WTNgR1 (black bar), and
subsequently immunolabeled with antibodies against PSD95 and Syn1. (A) Synapse density
was quantified by assessing the number of colocalized PSD95/Syn1 puncta along the
dendrites of transfected neurons. These data were subsequently deconvolved to determine
the density of Syn1 (B) or PSD95 (C) puncta along the dendrites. Similar results were
observed upon de-convolution of the Syt1/GluR2 puncta (data not shown). * indicates p <
0.01, one-way ANOVA with pairwise comparison by Bonferroni post hoc test. Data are
means, with error bars representing ±SEM from three experiments; total numbers of neurons
analyzed (n) range from 32 to 49 cells per condition.
(D and E) Modulation of NgR1 expression throughout neuronal cultures affects total levels
of PSD95. Cultured hippocampal neurons (5 DIV) were infected with a control lentivirus
(CON), an shNgR1 lentivirus, or a WTNgR1 lentivirus. Neurons were lysed at 14 DIV and
analyzed by immunoblotting for NgR1, PSD95, Syn1 or actin (used as a loading control).
(D) Representative immunoblots. (E) Quantification of protein levels. Integrated intensities
were measured by infrared fluorescence detection of immunoblots. Syn1 (white bar) and
PSD95 (black bar) protein levels were normalized to actin and expressed as change relative
to CON. * indicates p < 0.01, one-way ANOVA with pairwise comparison by Bonferroni
post hoc test. Data are means, with error bars representing ±SEM from three to six
experiments. Note that knockdown of NgR1 also resulted in an increase in the total level of
a second postsynaptic protein, GluR2 (see Figure S4).
(F and G) Overexpression of a mutant form of NgR1 (DNNgR1) causes a significant
increase in synapse density. Cultured hippocampal neurons were transfected with GFP alone
(CON; white bar), or cotransfected with GFP and either WTNgR1 (black bar) or DNNgR1
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(gray bar). Samples were immunolabeled for PSD95 and Syn1. (F) Representative dendrites.
Scale bar is 1 μm. (G) Quantification of normalized synapse density. * indicates p < 0.05,
one-way ANOVA with pairwise comparison by Bonferroni post hoc test. Data are means,
with error bars representing ±SEM from three experiments; total numbers of neurons
analyzed (n) range from 32 to 49 cells per condition.
(H) Knockdown of the NgR1 coreceptor TROY causes a significant increase in synapse
density. Cultured hippocampal neurons were transfected with GFP and control RNAis
shCON (white bar) or siCON (green bar), or GFP and RNAis targeting TROY, shTROY
(black bar) or siTROY (gray bar), as indicated. Five days later, cells were fixed,
immunolabeled for PSD95 and Syn1, and quantified to determine the normalized synapse
density. * indicates p < 0.01, one-way ANOVA with pairwise comparison by Bonferroni
post hoc test. Data are means, with error bars representing ±SEM from three experiments;
total numbers of neurons analyzed (n) range from 24 to 51 cells per condition.
(I) Inhibition of synapse formation by NgR1 requires TROY. Cultured hippocampal neurons
were transfected with GFP alone (CON; white bar), or cotransfected with GFP and
WTNgR1 (blue bar), shTROY (black bar), or both (orange bar). Neurons were
immunolabeled with antibodies against PSD95 and Syn1 to determine the normalized
synapse density. * indicates p < 0.05, one-way ANOVA with pairwise comparison by
Bonferroni post hoc test. Data are means, with error bars representing ±SEM from three
experiments; total numbers of neurons analyzed (n) range from 25 to 67 cells per condition.
Note that TROY is highly expressed in cultured hippocampal neurons (data not shown) and
that knockdown of TROY significantly reduces its mRNA levels (see Figure S4).
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Figure 5. The NgR Family Restricts Synapse Formation in Vivo
(A and B) Mice lacking all three NgR family members have elevated spine density. Neurons
were labeled genetically by breeding the GFPM allele into triple NgR knockout or control
mice. Triple NgR knockout mice (NgRTKO−/− [red bar]) and triple heterozygous littermates
(CON; white bar) were perfused at P18, sectioned by vibratome and immunolabeled with an
anti-GFP antibody. (A) Representative images from proximal secondary apical dendrites.
Scale bar is 1 μm. (B) Quantification of spine features. Dendritic spine density, spine length,
and spine width from secondary apical dendrites of neurons expressing GFP were
determined. Spine density values are expressed as percentage of the control value. Spine
length and spine width values for the various genotypes are normalized to the mean value of
the triple heterozygotes. Data are mean ±SEM from three independent experiments; total
numbers of neurons analyzed (n) range from 30 to 60 cells per condition. * indicates p <
0.01, one-way ANOVA with pairwise comparison by Tukey’s post hoc test.
(C–E) Ultrastructural analysis reveals that triple NgR knockouts have an abnormally high
density of synaptic sites. (C) Representative transmission electron micrographs. Hippocampi
of either triple heterozygous (CON) or triple knockout (NgRTKO−/−) P18 littermates were
prepared for electron microscopy and apical CA1 regions were analyzed. Black arrows mark
examples of asymmetric excitatory postsynaptic densities (PSDs). White dashed boxes mark
example PSDs magnified in lower righthand corner, with white arrows highlighting
presynaptic vesicles. Scale bar represents 1 μm. (D and E) Quantification of asymmetric
PSDs. Asymmetric PSDs from either the CA1 (D) or CA3 (E) regions of the hippocampus
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were quantified, analyzing 5 × 5 μm regions. Data are mean ± SEM from two littermate
pairs, analyzing 30 regions per condition. * indicates p < 0.01, one-way ANOVA with
pairwise comparison by Bonferroni post hoc test.
(F and G) Acute slice recordings from triple NgR knockouts reveal an increase in the
frequency but decrease in the amplitude of mEPSCs. Mini-excitatory postsynaptic currents
(mEPSCs) were recorded from acute hippocampal slice preparations obtained from P15
triple heterozygous (CON) or triple knockout (NgRTKO−/−) animals. Mean interevent
intervals (IEI) or amplitudes are represented ± SEM from 10–14 animals. * indicates p <
0.05 using a KS test from analysis of cumulative probability plots of mEPSCs IEIs and
amplitudes (Figure S5).
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Figure 6. The NgR Family Restricts Dendritic Growth In Vitro and In Vivo
(A and B) NgR1 inhibits the dendritic complexity of hippocampal neurons in vitro. GFP was
expressed by transfection of cultured hippocampal neurons from wild-type mice (CON;
black bar), embryos lacking NgR1 (NgR1−/−; orange bar), or neurons in which WTNgR1
was cotransfected along with GFP (red bar). Subsequently, neurons were fixed and analyzed
by confocal microscopy. (A) Representative neurons. Scale bar is 15 μm. (B) Quantification
of dendritic complexity by Sholl analysis. Note that knockdown of NgR1 also increased
dendritic complexity and length in organotypic slice culture (see Figure S6). Data are mean
± SEM from three experiments; total numbers of neurons analyzed (n) are 23 cells per
genotype. * indicates p < 0.05, repeated-measures two-way ANOVA with pairwise
comparison by Bonferroni post hoc.
(C–F) The length and complexity of dendrites is significantly increased in NgR triple
knockout mice in vivo. Neurons were genetically labeled by breeding the GFPM allele
(Feng et al., 2000) into the background of mice lacking NgR family members. Triple NgR
knockout mice (NgRTKO−/−; red bar) and triple heterozygous littermates (CON; white bar)
were perfused at P18, sectioned by vibratome, and labeled with an anti-GFP antibody. (C)
Representative neurons from the CA1 region of the hippocampus. Scale bar is 10 μm. (D–F)
Quantification of dendritic complexity. Sholl analysis of apical (D) and basal (E) dendrites
was performed, and total dendritic length (F) was measured. Data are mean ± SEM from
three experiments; total numbers of neurons analyzed (n) range from 20 to 22 cells per
genotype. * indicates p < 0.05, repeated-measures two-way ANOVA with pairwise
comparison by Bonferroni post hoc.
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Figure 7. NgR1 Restricts Synaptic and Dendritic Growth through RhoA
(A) NgR1 regulates RhoA activity in hippocampal neurons. Cultured hippocampal neurons
were infected with lentivirus expressing a control shRNA (CON), shNgR1, or WTNgR1.
Alternatively, hippocampal cultures were treated with the Rho inhibitor C3 (200 ng/ml) or
vehicle (CON) for 12 hr. Active Rho was then isolated by performing rhoteckin-binding
domain (RBD) pull-downs and visualized by western blotting with antibodies to RhoA
(bottom). Total protein levels were also assessed by immunoblot, using antibodies against
NgR1 (top) and RhoA (middle).
(B) Quantification of active RhoA. Integrated intensities were measured by densitometry
measurements of immunoblots in ImageJ (see Methods). Protein levels were normalized to
actin and expressed as change relative to CON. * indicates p < 0.01–0.05, one-way ANOVA
with pairwise comparison by Bonferroni post hoc test. Data are means, with error bars
representing ±SEM from five independent experiments.
(C) Inhibition of synapse formation by NgR1 is reversed by blocking ROCK or Rho activity.
Cultured hippocampal neurons were transfected with GFP alone (CON; white bar) or
cotransfected with GFP and WTNgR1 (purple bar). Subsequently, transfected neurons were
either mock-treated (white and purple bars) or treated with the Rho inhibitor C3 (200 ng/ml,
black and green bars) or the ROCK inhibitor Y27632 (1 μM; red and orange bars) for 12 hr
prior to immunolabeling with antibodies against PSD95 and Syn1 to determine normalized
synapse density. Data are mean ± SEM from three experiments; total numbers of neurons
analyzed (n) range from 50 to 70 cells per condition. * indicates p < 0.05, repeated-measures
two-way ANOVA with pairwise comparison by Bonferroni post hoc.
(D and E) Inhibition of dendritic complexity by NgR1 is reversed by blocking Rho activity.
Cultured hippocampal neurons were transfected with GFP alone (black bar) or cotransfected
with GFP and WTNgR1 (red bar). Subsequently, neurons were mock-treated or treated with
the Rho inhibitor C3 (200 ng/ml, blue and gray bars) for 12 hr, fixed and subjected to Sholl
analysis. (D) Representative neurons. Scale bar is 15 μm. (E) Quantification of dendritic
complexity. Data are mean ± SEM from three experiments; 30 neurons were analyzed per
condition. * indicates p < 0.05, repeated-measures two-way ANOVA with pairwise
comparison by Bonferroni post hoc. Similar results were observed using the ROCK inhibitor
(see Figure S7).
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Figure 8. The NgR1 Family and Coreceptor TROY Are Downregulated by Neuronal Activity
(A and B) Expression of NgR1 protein on dendrites is downregulated by increased neuronal
activity. (A) Cultured hippocampal neurons were treated with vehicle (CON) or bicuculline
(5 μM, 12 hr). Subsequently, cells were fixed and immunolabeled with antibodies against
NgR1 and PSD95. Representative images are shown at top (i and ii). At bottom (iii and iv),
anti-NgR1 signal has been converted into a heat map (using Rainbow RGB setting in Image
J software). Scale bar is 10 μm. (B) Cultured hippocampal neurons were transfected with
GFP, treated with compounds for 12 hr and then immunolabeled with antibodies against
NgR1. Treatments were vehicle (CON; white bar), KCl (55 mM, red bar), NMDA (30 μM,
orange bar), bicuculline (5 μM, blue bar), BDNF (50 nM, green bar), or a combination of
tetrodotoxin (TTX, 1 μM) and APV (100 μM, black bar). Data are expressed as percentage
change in the number of NgR1 puncta expressed on the dendrites of GFP-transfected
neurons relative to mock treatment (CON). * indicates p < 0.05, one-way ANOVA with
pairwise comparison by Bonferroni post hoc test. Data are mean ± SEM from three
experiments; total numbers of neurons analyzed (n) range from 25 to 50 cells per condition.
Similar results were observed examining NgR1 protein on the cell surface (see Figure S8A).
(C–F) Neuronal activity causes a downregulation in the mRNA for NgR1, NgR2, NgR3 and
TROY. Cultures of hippocampal neurons were either mock-treated (CON) or treated with
KCl (55 mM, black bar) or NMDA (30 μM, red bar). RNA was collected at the indicated
times, and quantitative RT-PCR was performed for NgR1 (C), NgR2 (D), NgR3 (E), and
TROY (F). Message levels were normalized to actin and expressed as percent difference
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relative to control. Data represent mean ± SEM from four to five experiments. Changes in
the mRNA expression of NgR1 and NgR3 were significantly different from control at all
time points. NgR2 mRNA was significantly different from control at the 1 hr and 3 hr time
points. TROY mRNA was significantly different from control in all but the NMDA 6 hr
time point. * indicates p < 0.01, repeated-measures ANOVA with pairwise comparisons
Bonferroni post hoc test.
(G) TROY protein levels are developmentally downregulated. Protein lysates were prepared
from the hippocampi of mice from different developmental ages (E11.5 to P34) and
subjected to immunoblot analysis with antibodies directed against TROY, NgR1, PSD95, or
actin.
(H) TROY and NgR1 protein levels are downregulated by kainate-induced seizure. Protein
lysates were prepared from the hippocampi of two control and two kainite-seized mice.
Lysates were subjected to immnoblot analysis with antibodies directed against TROY,
NgR1, NPAS4, and actin.
(I) Quantification of TROY and NgR1 protein levels following kainate-induced seizure.
Integrated intensities of TROY and NgR1 were measured by infrared fluorescence detection.
Data represent mean ± SEM from two independent experiments and are expressed as change
relative to control. * indicates a p < 0.05 with a Student’s t test. Similar results were
observed when examining NgR1 and TROY protein levels following mouse exposure to an
enriched environment (see Figures S8C and S8D).
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